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Abstract 
Human, animal, and in vitro data indicate significant vasoprotective activity of anthocyanins.  
However, few studies have investigated the activity of anthocyanin degradation products and 
metabolites which are likely to mediate bioactivity in vivo.  The present thesis therefore examined 
the vascular bioactivity in vitro of anthocyanins, their phenolic degradants, and the potential for 
interactions between dietary bioactive compounds.  Seven treatment compounds (cyanidin-, 
peonidin-, petunidin- & malvidin-3-glucoside, and protocatechuic, vanillic, and syringic acid) and two 
treatment combinations (cyanidin-3-glucoside or protocatechuic acid with epicatechin, quercetin, 
and ascorbic acid) were screened in a human endothelial cell model for effects on endothelial nitric 
oxide synthase (eNOS) activity (via ELISA & colourimetric assay), and NADPH oxidase (NOX)-mediated 
superoxide production (by cytochrome c reduction assay, optimised in-house).  A bioactive treatment 
was then chosen to explore possible mechanisms of NOX inhibition, namely gene expression of 
NOX2, NOX4, p47phox, p67phox, p22phox, & haem oxygenase-1 (HO-1), and activation/expression of 
p47phox and HO-1 protein; using RT-qPCR and immunoblotting (optimised for cell stimulation 
conditions and qPCR reference genes).  Differential bioactivity of parent anthocyanins and their 
phenolic degradants was observed at physiologically relevant concentrations, as only anthocyanins 
upregulated eNOS expression (by 4- to 7-fold; p < 0.01), whereas both anthocyanins and degradants 
appeared to reduce endothelial superoxide levels (by 1- to 8-fold; p < 0.05).  The phenolic degradant 
vanillic acid significantly reduced (p < 0.05) superoxide by 2-fold at 1μM, and has been reported at 
low micromolar levels in human serum; therefore vanillic acid was selected to elucidate pathways 
potentially underlying observed bioactivity.  Vanillic acid did not significantly modulate expression of 
NOX isoforms/subunits, but an apparent induction of the cytoprotective enzyme HO-1 by vanillic acid 
(2-fold increase) was observed in human umbilical vein and coronary artery endothelial cells, 
although changes were non-significant (p ≥ 0.3).  In conclusion, anthocyanin phenolic degradants 
could enhance vascular function in vivo by decreasing superoxide production, and thus scavenging of 
the key mediator nitric oxide (NO).  Vanillic acid might inhibit endothelial superoxide production 
through modulation of HO-1, thereby preserving NO bioavailability and vascular homoeostasis, and 
this pathway should be the focus of future research. 
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1 Flavonoids: review of the scientific literature 
1.1 Introduction 
Fruits and vegetables consumed as part of the human diet contain a variety of phytochemicals, 
some of which may be beneficial to human health (Geleijnse and Hollman, 2008, Crozier et al., 
2009).  Phytochemicals can be classified into several groups, one of which is the class of phenolic 
compounds; covering over 8,000 aromatic structures occurring throughout the plant kingdom 
(Erdman et al., 2007, Crozier et al., 2009).  This compound class can be further subdivided, with 
the family of polyphenolic compounds termed flavonoids forming a large sub-group – over 5,000 
distinct flavonoids have been identified (Erdman et al., 2007).  Flavonoids are water-soluble 
compounds found in many plants, and thus in commonly consumed plant-derived foodstuffs 
(Erdman et al., 2007, Geleijnse and Hollman, 2008, Crozier et al., 2009).  They share a common 
structure of two aromatic rings linked through three carbons (Crozier et al., 2009), generally 
forming an oxygenated heterocycle nucleus (Grassi et al., 2009) (Figure 1.1). 
Figure 1.1 Basic structure of flavonoids showing two aromatic rings (labelled A &B) linked by 
heterocyclic (C) ring. 
 
Adapted from (Erdman et al., 2007). 
Flavonoids can be subdivided into several classes based on ring substituents and C-ring structure 
(Erdman et al., 2007).  A number of epidemiological studies have suggested a protective 
association between dietary components rich in flavonoids and cardiovascular mortality (Hertog 
et al., 1993, Geleijnse et al., 2002, Mink et al., 2007, McCullough et al., 2012, Cassidy et al., 2013), 
although not all studies concur (Huxley and Neil, 2003, Arts and Hollman, 2005, Curtis et al., 
2009).  Moreover, predominantly in vitro data indicate flavonoids may have anti-inflammatory 
and immunomodulatory activity (González-Gallego et al., 2010), whilst dietary intervention 
studies point to positive effects of flavonoid-rich foods on memory and cognition (Spencer, 2010). 
This review aims to provide an overview of the dietary occurrence, bioavailability and bioactivity 
of flavonoids, focusing primarily on the flavonoid sub-group anthocyanidins; which in plants are 
usually found as sugar conjugates termed anthocyanins (Crozier et al., 2009).  Epidemiological 
8
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7
6
2
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O
4
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data and in vitro studies indicate anthocyanins may act to reduce the risk of cardiovascular 
disease by modulating key vascular signalling pathways (Lazze et al., 2006, Bell and Gochenaur, 
2006, Cassidy et al., 2010); thus the pathophysiology of the chronic inflammatory disease 
atherosclerosis (Ross, 1999, Libby et al., 2002, Bonomini et al., 2008) and underlying endothelial 
dysfunction (Landmesser et al., 2004, Higashi et al., 2009) will also be considered.  Finally 
deficiencies in current knowledge of anthocyanin bioavailability and bioactivity are discussed, 
which it is hoped will be addressed in part by this thesis. 
1.2 Flavonoids 
1.2.1 Dietary occurrence and relevance to human health 
Flavonoids are phenolic phytochemicals, the latter defined as plant secondary metabolites which 
may accumulate in high concentrations in plants, but which are not essential nutritional 
components of the human diet (Crozier et al., 2009).  Flavonoids have important roles in plant 
physiology including modulation of transport of the plant hormone auxin, defence, and providing 
colour to flowers (Buer et al., 2010).  Over 5,000 flavonoids have been identified, of which some 
hundreds are present in common foodstuffs such as fruits, vegetables and beverages including tea 
and red wine (Aherne and O'Brien, 2002, Erdman et al., 2007); in fact flavonoids represent the 
most common plant polyphenolics derived from a typical plant-based diet (Chun et al., 2007).  
Dietary flavonoids can be grouped by structure into flavonols, flavones, flavanones, flavan-3-ols 
(and proanthocyanidin oligomers), isoflavones and anthocyanins (glycosylated anthocyanidins) 
(Erdman et al., 2007) (Figure 1.2).  Flavonoids, with the exception of flavan-3-ols, are usually 
found in plants and most foods as glycosides; conjugated to one or more sugar molecules 
(Erdman et al., 2007, Crozier et al., 2009). 
Flavonols, for example quercetin and kaempferol, represent the most widespread flavonoids in 
foods, with rich sources including onions, curly kale, broccoli and apples (Erdman et al., 2007); 
however, the dietary content of flavonols is comparatively low (Manach et al., 2005).  Flavones, 
such as luteolin and apigenin, are less common and occur in parsley and celery (Erdman et al., 
2007); whilst flavanones, for example glycosides of hesperetin and naringenin, are a small 
compound group found in citrus fruits, (Manach et al., 2005).  Flavan-3-ols, or flavanols, represent 
the subclass with most structural complexity; from simple monomers such as (+)-catechin and the 
isomer (-)-epicatechin to oligomeric and polymeric proanthocyanidins, including procyanidins 
[proanthocyanidins consisting of (epi)catechin units only] (Crozier et al., 2009).  Major dietary 
sources of flavanols are apples, grapes, red wine, chocolate, and tea (Manach et al., 2005); 
whereas isoflavones such as daidzein and genistein occur almost exclusively in leguminous plants 
(Crozier et al., 2009) and are derived from only soy bean based products in the diet (Manach et 
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al., 2005).  Finally anthocyanins, including glycosides of cyanidin and pelargonidin, are found in 
aubergines, berries, cherries and black grapes; and thus in derived products such as juices and red 
wine (Wu et al., 2006b, Zamora-Ros et al., 2011). 
Figure 1.2 Example chemical structures for flavonoid subclasses. 
   
 
   
 
   
Adapted from (Hooper et al., 2008). 
Regarding human dietary intake of flavonoids, it is apparent that a diet with substantial 
consumption of fruits and vegetables, and plant-derived beverages such as wines, tea and fruit 
juices, should contain significant flavonoid content.  However, estimation of human flavonoid 
intake has proved difficult, owing to a lack of information on food content of flavonoids and 
variations in methods of estimation and national dietary habits (Chun et al., 2007, Zamora-Ros et 
al., 2010).  Flavonoid content can also be influenced by factors such as plant species, cultivation, 
ripeness, and food preparation and processing (Aherne and O'Brien, 2002).  Zamora-Ros et al 
(2010) and Chun et al (2007) have estimated daily flavonoid intakes of 313.26 ± 213.75mg and 
189.7 ± 11.6mg for adult populations in Spain (Zamora-Ros et al., 2010) and the United States of 
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formed a small part of daily flavonoid intake, consideration must be given to the high 
concentrations of anthocyanins which may be achieved in some diets through consumption of 
berries and grapes and derived beverages (Manach et al., 2005, Wu et al., 2006b).  Equally, the 
paucity of nutrient databases with comprehensive quantitation of anthocyanin content (Curtis et 
al., 2009), and anthocyanin molecular stability and concomitant issues with detection 
methodology (section 1.3.2), could result in under-estimation of anthocyanin consumption. 
Table 1.1 Estimated daily flavonoid intake for Spanish and American adult populations. 
Flavonoid class 
Estimated intake in mg/day (mean ± SD)
1
 
(1) Spain (2) United States of America 
Flavonols 18.7 ± 11.06 12.9 ± 0.4 
Flavones 3.4 ± 2.92 1.6 ± 0.2 
Flavanones 50.55 ± 47.15 14.4 ± 0.6 
Flavan-3-ols 32.47 ± 51.8 156.5 ± 11.3 
Proanthocyanidin multimers 189.17 ± 164.07 - 
Anthocyanidins 18.88 ± 21.5 3.1 ± 0.5 
Isoflavones 0.08 ± 0.33 1.2 ± 0.2 
Total 313.26 ± 213.75 189.7 ± 11.6 
1
Estimated daily individual and total flavonoid intakes of (1) 40,683 Spanish adults (aged 35 - 64 years) 
included in the European Prospective Investigation into Cancer and Nutrition (EPIC) study Spanish 
cohort (recruited between 1992 - 1996) (Zamora-Ros et al., 2010); and (2) 8,809 adults (aged 19 years or 
over) in the United States of America (USA) derived from The National Centre for Health Statistics 
(NHANES) 24-hour dietary recall survey 1999-2002 (Chun et al., 2007). 
Whilst estimation of dietary flavonoid intake within and between populations may be 
problematic, there is considerable interest in the relevance of these non-essential nutrients to 
maintenance of human health.  An epidemiological study reported during the 1990s, the Zutphen 
Elderly Study, indicated a significant protective effect of several flavonols against mortality owing 
to coronary heart disease (Hertog et al., 1993).  Data from subsequent epidemiological studies, 
for example the Rotterdam study (Geleijnse et al., 2002) and Iowa Women’s Health Study (Mink 
et al., 2007), have indicated a protective effect of flavonoids for risk of cardiovascular mortality, 
though not all studies confirm this association (Huxley and Neil, 2003, Arts and Hollman, 2005).  A 
recent review covering 20 prospective studies (derived from 12 cohorts) of dietary flavonoid 
consumption and cardiovascular disease (CVD) occurrence/outcomes concluded that an 
association between flavonoid intake and reduced CVD incidence or mortality was observed in 
eight studies (Peterson et al., 2012).  Moreover, a systematic review and meta-analysis by Hooper 
et al (2008) examined 133 randomised controlled trials of flavonoid/flavonoid-rich food 
interventions and risk factors for CVD (Hooper et al., 2008).  Certain flavonoid-rich foods were 
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associated with beneficial effects on risk factors, such as a reduction in systolic and diastolic blood 
pressure (BP) with chocolate or cocoa consumption (Hooper et al., 2008).  However, it is worth 
noting that associations with foodstuffs, rather than discrete chemicals, could wholly or partly 
reflect bioactivity of other components of food/beverages (Halliwell, 2007, Hooper et al., 2008, 
Sies, 2010). 
1.2.2 Metabolism and bioactivity of flavonoids 
In order for flavonoids to elicit biological effects in vivo, bioactive forms must be present in the 
systemic circulation at sufficiently high concentrations, and for an adequate length of time, to 
elicit effects on putative molecular targets.  As with all ingested xenobiotics, to reach the systemic 
circulation flavonoids must pass through and be absorbed from the gastro-intestinal tract, during 
which molecules are subject to metabolism by intestinal and hepatic enzymes (Grassi et al., 2009, 
Wang and Ho, 2009).  Colonic microbes also play a key metabolic role, catabolising unabsorbed 
flavonoids into smaller molecules such as phenolic and aromatic acids, which can be absorbed 
(Williamson and Clifford, 2010). 
Following gastric digestion, absorption of flavonoids occurs in the small and large intestine, with a 
few reports suggesting anthocyanins can be absorbed in the stomach (Erdman et al., 2007, Wang 
and Ho, 2009, Grassi et al., 2009).  Absorption of flavonoid glycosides in the small intestine is 
usually associated with hydrolysis, to yield the more lipophilic aglycone form (Crozier et al., 2009).  
The enzyme lactase phloridzin hydrolase (LPH), located in the brush border of intestinal epithelial 
cells/enterocytes, demonstrates broad specificity for flavonoid-O-Β-D-glucosides; with the 
resulting aglycone penetrating epithelial cells by passive diffusion (Walle, 2004, Crozier et al., 
2009).  Alternatively, flavonoid glycosides could be hydrolysed within enterocytes by cytosolic Β-
glucosidase (CBG), although in this case the polar glycoside form must be transported into cells 
(Crozier et al., 2009).  The sodium-dependent glucose transporter 1 (SGLT1) protein may act as a 
mechanism for such uptake (Walle, 2004), though it has been questioned as to whether SGLT1 
actually transports flavonoid glycosides (Crozier et al., 2009). 
Absorbed aglycones are metabolised within enterocytes to generate predominantly sulphated, 
glucuronidated and/or methylated forms; catalysed by sulphotransferases (SULT), uridine-5’-
diphosphate glucuronosyltransferases (UGT) and catechol-O-methyltransferases (COMT) 
respectively (Walle, 2004, Crozier et al., 2009, Del Rio et al., 2010).  Other metabolites, such as 
flavonoid thiol conjugates (with glutathione or cysteine), have been less extensively studied 
(Wang and Ho, 2009).  Efflux of flavonoid glycosides and/or metabolites from enterocytes, either 
into the intestinal lumen or basolateral blood supply, may be mediated by transporter proteins 
such as multidrug resistance proteins (MRP) and P-glycoprotein (P-gp), which are members of the 
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ATP-binding cassette (ABC) family of transporters (Walle, 2004, Brand et al., 2006, Crozier et al., 
2009).  Compounds entering the bloodstream may be subject to further hepatic metabolism 
before reaching the systemic circulation (Del Rio et al., 2010). 
Thus, for flavonoids consumed as part of the diet, the parent compound(s) may not be 
responsible for perceived bioactivity post-absorption; instead this may be mediated by 
metabolites present in the systemic circulation (Wang and Ho, 2009).  Possible mechanisms of 
flavonoid bioactivity have been the subject of many in vitro studies; but the physiological 
relevance of doses used in such studies is of great significance, as is the duration of exposure to 
compounds tested.  Low levels of dietary flavonoids and derived molecules are present in the 
systemic circulation (generally the maximum concentration is < 10µmol/L in total), yet it is argued 
that for any such molecule to exert a biologically significant effect in vivo it must have sufficient 
potency to do so at 50% of its transient plasma Cmax (Crozier et al., 2009).  Crozier et al (2009) 
have summarised several possible molecular mechanisms of actions for phenolic compounds and 
metabolites, including flavonoids (Crozier et al., 2009, Del Rio et al., 2010). 
One signalling pathway which has been the subject of extensive study is that of NF-κB (nuclear 
factor kappa B); an ubiquitous redox sensitive transcription factor which regulates expression of 
pro-inflammatory cytokines, and other mediators of inflammation such as inducible nitric oxide 
synthase (iNOS) and cyclo-oxygenase 2 (COX-2) (Bremner and Heinrich, 2002, Crozier et al., 2009, 
González-Gallego et al., 2010, Wallace, 2011).  The flavonol quercetin has demonstrated inhibition 
of NF-κB activation in several cell types, including stimulated human umbilical vein endothelial 
cells (HUVECs) (González-Gallego et al., 2010), and similar activity has been reported for 
anthocyanins in both human monocytic cells (Karlsen et al., 2007) and human articular 
chondrocytes (Haseeb et al., 2013).  Flavonoids may also interact with the mitogen-activated 
protein kinase (MAPK) or extracellular signal regulated protein kinase (ERK) signalling pathways; 
which are highly conserved eukaryotic kinase signalling cascades involved in intracellular signal 
transduction (Robinson and Cobb, 1997, Crozier et al., 2009).  Moreover, methylated metabolites 
of (-)-epicatechin have been shown to inhibit the reactive-oxygen species generating NADPH 
oxidase (NOX) enzyme (Cai et al., 2003, Bedard and Krause, 2007) in HUVECs, leading to improved 
steady-state level of nitric oxide (NO) in endothelial cells (Steffen et al., 2007b, Steffen et al., 
2008).  NO exhibits vasodilatory, anti-coagulant and anti-inflammatory properties, and thereby 
serves a key role in protection of the vascular endothelium (Michel and Vanhoutte, 2010). 
1.2.3 Flavonoids and in vitro antioxidant activity 
Flavonoids, and other phenolic compounds in foodstuffs, have been the subject of increasing 
interest owing to epidemiological data suggesting an inverse correlation between consumption of 
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these compounds and incidence of diseases such as CVD (Geleijnse and Hollman, 2008, Crozier et 
al., 2009).  Initially, the putative beneficial effects of flavonoids were often attributed to 
antioxidant activity in vivo (Halliwell et al., 2005), owing to the ability of almost every group of 
flavonoids to function in this capacity in vitro (Rice-Evans et al., 1996, Nijveldt et al., 2001); and 
substantial evidence that oxidative stress is associated with, and contributes to development of, 
major age-related diseases such as CVD (Halliwell et al., 2005). 
Direct antioxidant activity arises from inactivation, or ‘scavenging’ of reactive radical species 
(Rice-Evans et al., 1996), which are molecules with an unpaired electron such as hydroxyl (˙OH), 
superoxide (O2˙
-), nitric oxide (NO˙), and peroxynitrite (-ONOO; formed by the reaction of nitric 
oxide and superoxide) (Forman et al., 2002, Naseem, 2005).  Such species can be extremely 
reactive, to the extent that free hydroxyl radical essentially does not exist (Forman et al., 2002), 
and reactions initiated by free radicals can have damaging consequences; for example lipid 
oxidation of cell membranes with potential membrane damage or alteration of function (Galleano 
et al., 2010).  Reactive oxygen species (ROS) are generated within the cell from sources such as 
the mitochondrial electron transport chain, and enzymes including NOX, myeloperoxidase (MPO) 
and xanthine oxidase (XO) which generate superoxide (Leopold and Loscalzo, 2009).  Superoxide 
reacts rapidly with protons to yield the non-radical hydrogen peroxide (H2O2) (dismutation), and 
this reaction is accelerated by the superoxide dismutase (SOD) family of enzymes (Forman et al., 
2002).  Reactive nitrogen species (RNS) include nitric oxide, synthesised by the nitric oxide 
synthase (NOS) family of enzymes (Forman et al., 2002), and derived species such as peroxynitrite, 
nitrite (NO2
-; terminal oxidation product of NO˙) and nitrogen dioxide (˙NO2; formed by reaction of 
NO˙ with oxygen) (Forman et al., 2002, Leopold and Loscalzo, 2009). 
More recently, the limited bioavailability of flavonoids in vivo, and extent of metabolism during 
absorption, have led to the recognition that direct antioxidant activity in vivo is very unlikely to 
form part of flavonoid bioactivity (Halliwell, 2007, Crozier et al., 2009, Sies, 2010, Galleano et al., 
2010, Hollman et al., 2011).  Flavonoids undergo extensive metabolism post-absorption, such as 
glucuronidation, sulphation and methylation reactions; which may block phenolic hydroxyl groups 
required for direct radical scavenging activity (Halliwell et al., 2005, Halliwell, 2007).  Moreover, 
endogenous enzymatic and molecular mechanisms exist to counter oxidative challenges to cells 
and tissues (Sies, 2007).  Key enzymes include SOD, which occurs in three different forms 
(mitochondrial, cytosolic and extracellular) and rapidly converts superoxide to hydrogen peroxide; 
and glutathione peroxidase, which utilises glutathione to reduce hydrogen peroxide and possibly 
peroxynitrite (Forman et al., 2002).  Hydrogen peroxide is also reduced to water by the activity of 
the catalase enzyme (Leopold and Loscalzo, 2009).  Small molecules, including vitamins and trace 
elements, form part of antioxidant defences by inclusion in larger molecules (for example cysteine 
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in glutathione, or selenium as part of the active site in glutathione peroxidase); or acting as 
antioxidants directly (such as ascorbate and urate circulating in plasma) (Sies, 2007).  Indeed, 
plasma total antioxidant capacity has been estimated as > 103µmol/L, therefore detection of a 
statistically significant increase in such assays would require a minimum of 20-50µmol/L 
additional antioxidant to be present – yet flavonoid/metabolite plasma concentrations are 
transient and unlikely to exceed very low micromolar levels (Halliwell et al., 2005, Crozier et al., 
2009, Galleano et al., 2010). 
1.3 Anthocyanins 
1.3.1 Dietary occurrence and consumption of anthocyanins 
Anthocyanins, from the Greek anthos (flower) and kyanos (blue), are plant pigments (Kong et al., 
2003).  Over 600 naturally-occurring anthocyanins have been reported (Wu et al., 2006b, Wallace, 
2011), and are present throughout the plant kingdom, particularly in fruits and vegetables where 
they provide red, blue and purple colouration (Crozier et al., 2009).  Anthocyanins are glycoside or 
acylglycoside conjugates of anthocyanidin aglycones (Wu et al., 2006b), and glycosides represent 
the form invariably present in planta (Crozier et al., 2009).  Approximately 17 anthocyanidins 
occur in plants, of which cyanidin (Cy), delphinidin (Dp), malvidin (Mv), pelargonidin (Pg), peonidin 
(Pe), and petunidin (Pt) are distributed ubiquitously (Wu et al., 2006b, Crozier et al., 2009). 
With regard to human dietary occurrence of anthocyanins, these compounds are found mainly in 
fresh berries, fruits, and certain vegetables (Manach et al., 2005, Wu et al., 2006b, Zamora-Ros et 
al., 2011).  Zamora-Ros et al (2011) have recently published estimates of dietary anthocyanin 
intake, and food sources, based upon 24 hour dietary recall data for 36,037 subjects (between 35 
- 74 years of age) participating in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) study (covering 27 centres in ten European countries) (Zamora-Ros et al., 2011).  
A food composition database was developed from scientific literature and internet-based sources, 
detailing anthocyanidin content for 1877 food items (Zamora-Ros et al., 2011) (Table 1.2).  
Cyanidin displays the widest distribution in foods examined, although with considerable variation 
in concentrations.  Raw elderberries contained the highest concentration of cyanidin, as opposed 
to blackcurrants for delphinidin, and blueberries for malvidin and petunidin (Zamora-Ros et al., 
2011).  The optimum sources of pelargonidin and peonidin were strawberries and bilberries 
respectively (Zamora-Ros et al., 2011). 
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Table 1.2 Anthocyanin composition of selected food sources estimated from food composition databases derived from scientific literature and internet-based 
sources (Zamora-Ros et al., 2011). 
Food Anthocyanidin aglycones (milligrammes) per 100 grammes fresh weight* 
Cy Dp Mv Pg Pe Pt Total 
Bilberry, raw 112.59 161.93 54.37 - 51.01 51.01 430.91 
Blackberries, raw 90.31 - - 0.15 - - 90.46 
Blueberries, wild raw 42.47 92.71 103.8 - 23.49 58.23 320.70 
Cranberries, raw 41.81 7.66 0.31 - 42.10 - 91.88 
Currants, European black, raw 85.63 181.11 - 1.17 0.66 3.87 272.44 
Eggplant (aubergine), raw 0.02 13.76 - 0.02 - - 13.80 
Elderberries, raw 758.48 - 61.35 1.13 - - 820.96 
Grapes, red, raw 1.46 3.67 34.71 0.02 2.89 2.11 44.86 
Pistachio nuts, raw 6.06 - - - - - 6.06 
Radishes, raw - - - 25.66 - - 25.66 
Raspberries, black 323.47 - - 0.15 0.55 - 324.17 
Raspberries, red, raw 35.84 0.29 0.70 1.85 - - 38.68 
Strawberries, raw 1.96 0.32 - 31.27 - 0.08 33.63 
 
Anthocyanin composition of selected items from food composition database (FCDB) developed using dietary recall data for 36,037 subjects participating in the European 
Prospective Investigation into Cancer and Nutrition (EPIC) study (covering 27 centres in ten European countries) (Zamora-Ros et al., 2011). The FCDB database was based 
on the United States Department of Agriculture database (USDA, 2007) and expanded with values from Phenol Explorer (Neveu et al., 2010). *Anthocyanidin aglycones 
per 100 g fresh weight, calculated as sum of available forms (glycosides and aglycones). Abbreviations used are Cy, cyanidin; Dp, delphinidin; Mv, malvidin; Pg, 
pelargonidin; Pe, peonidin; Pt, petunidin. 
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Anthocyanin intake in the United States of America has been estimated as 12.5mg/day/person (Wu 
et al., 2006b) (Table 1.3), although dietary intake estimates can vary within and between regions.  
For example, average daily intake of anthocyanins in Germany was reported as 2.7mg/person in 2002 
(Wu et al., 2006b), whilst mean dietary intake in Finland has been estimated as 82mg/day (Manach 
et al., 2005).  Zamora-Ros et al (2011) described total anthocyanidin intake for males ranging from 
19.8mg/day in The Netherlands (study centre at Bilthoven) to 64.9mg/day in Italy (Turin) (mean 
29.4mg/day), and for females from 18.7mg/day in Spain (Granada) to 44.1mg/day in Italy (Turin) 
(mean 33.5mg/day) (Zamora-Ros et al., 2011).  The high content of anthocyanins found in grapes and 
berries indicates that a substantial daily intake of anthocyanins may be achieved with regular 
consumption of these foods and derived beverages (Manach et al., 2005, Wu et al., 2006b), such that 
doses of 400 - 500mg anthocyanins could be consumed in a single serving (Kay et al., 2009).  This is of 
particular relevance for grape and berry juices, which could therefore serve as accessible dietary 
sources of anthocyanins. 
Table 1.3 Summary of estimates of daily anthocyanin consumption from beverages, fruits and 
vegetables in the United States of America. 
Food group Daily anthocyanin consumption (mg)* 
Beverages (grape juice & wine) 1.68 
Fruits (raw, 11 foods) 8.75 
Nuts (pistachio nut) 0.004 
Vegetables (raw, 6 foods) 2.19 
Total 12.53 
*Food intake data from the National Health and Nutrition Examination Survey (NHANES 2001-2002) 
[derived from (Wu et al., 2006b)]. 
A substantial body of epidemiological evidence suggests that consumption of flavonoid-rich food and 
beverages is inversely associated with the risk of CVD (Erdman et al., 2007, Mazza, 2007, Geleijnse 
and Hollman, 2008, Wallace, 2011), though it should be noted that not all such studies have 
supported this association (Geleijnse and Hollman, 2008, Curtis et al., 2009, Wallace, 2011).  
Moderate red wine consumption has been associated with decreased coronary heart disease (CHD) 
mortality in several epidemiological studies (Rimm et al., 1991, Gaziano et al., 1993), and may be 
partly ascribed to anthocyanin content of this beverage (Dell'Agli et al., 2004, Erdman et al., 2007).  
Furthermore, data from over 30,000 post-menopausal women enrolled in the Iowa Women’s Health 
Study suggested a significant inverse relationship between dietary anthocyanin consumption 
(median intake 0.2mg/day versus no intake) and mortality owing to CHD and CVD over a 16 year 
follow-up period (Mink et al., 2007).  Anthocyanin intake (highest versus lowest grouping) has also 
been associated with a reduced relative risk of hypertension in a prospective study (14 year follow-
up) of participants enrolled from the Nurse’s Health Study (NHS) I and II (46,672 and 87,242 women, 
respectively) and Health Professionals Follow-Up Study (HPFS; 23,043 men) (Cassidy et al., 2010). 
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More recently, anthocyanidin intake (top versus bottom quintile of intake) was associated with a 
lower risk of fatal CVD for subjects enrolled in the Cancer Prevention Study II Nutrition Cohort 
(38,180 men and 60,289 women) during seven years of follow-up (McCullough et al., 2012); and 
anthocyanin intake was inversely correlated with risk of myocardial infarction in a population of 
93,600 young- and middle-aged women from the NHS II over 18 years of follow-up (32% decrease in 
risk for highest versus lowest quintile of intake) (Cassidy et al., 2013).  Moreover, an inverse 
relationship between anthocyanin intake and measures of central blood pressure (specifically 
peripheral systolic blood pressure, central systolic blood pressure, & mean arterial pressure) and 
arterial stiffness (as assessed by pulse wave velocity) has been reported from a cross-sectional study 
of 1898 women drawn from the TwinsUK registry (Jennings et al., 2012).  Of particular interest, the 
observed decrease in pulse wave velocity between lowest and highest quintiles of anthocyanin 
intake corresponded to a mean difference in intake of 44mg, which the authors noted to be 
equivalent to one or two portions of certain berries (Jennings et al., 2012). 
Data from animal and in vitro studies have demonstrated a variety of potential cardiovascular 
activities of anthocyanins (Domitrovic, 2011), including vasodilatory and vasoprotective effects (Bell 
and Gochenaur, 2006, Ziberna et al., 2013), anti-thrombotic activity (Rechner and Kroner, 2005, de 
Pascual-Teresa et al., 2010, Yang et al., 2011, Yang et al., 2012), activation and/or upregulation of 
endothelial nitric oxide synthase (eNOS) (Xu et al., 2004b, Xu et al., 2004a, Lazze et al., 2006, 
Chalopin et al., 2010, Simoncini et al., 2011, Edirisinghe et al., 2011, Paixão et al., 2012), decreased 
production of the vasoconstrictor endothelin-1/ET-1 (Lazze et al., 2006), and inhibition of 
angiotensin-converting enzyme (Persson et al., 2009, Hidalgo et al., 2012).  Thus, dietary anthocyanin 
intake may elicit beneficial effects on cardiovascular health (Basu et al., 2010, Wallace, 2011, Tsuda, 
2011, Landberg et al., 2012), and to that end anthocyanin chemistry, bioavailability and bioactivity 
are considered in more detail within the following sections. 
1.3.2 Chemistry and stability of anthocyanin compounds 
Anthocyanins are glycosides of polyhydroxy, and polymethoxy, derivatives of flavylium (2-
phenylbenzopyrylium) salts (Kong et al., 2003).  In common with other flavonoids, the anthocyanin 
molecule contains two benzoyl rings (A and B), linked by a heterocyclic oxygen ring (C); giving the 
characteristic C6-C3-C6 structure (Kong et al., 2003, McGhie and Walton, 2007, Wallace, 2011).  
Anthocyanins are differentiated according to the number of hydroxyl groups attached to the 
molecule, and extent of methylation of these groups; together with the type, number and position of 
linked sugar moieties (Kong et al., 2003, McGhie and Walton, 2007) (Figure 1.3).  Commonly 
occurring glycosides are 3-monosides, 3-biosides (disaccharides), 3-triosides and 3,5-diglycosides; 
associated with the sugars glucose, galactose, rhamnose, arabinose and xylose (Kong et al., 2003, 
McGhie and Walton, 2007). 
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Figure 1.3 Chemical structure of an anthocyanin molecule. 
 
 
Flavylium cation form of anthocyanin and attached substituent groups.  R
1
, R
2
, are –H, -OH or –OCH3 (refer 
to inset table); R
3
 is –H or a sugar moiety; R
4
 is –OH or a sugar moiety [adapted from (Kong et al., 2003)]. 
Anthocyanins are responsible for the pigmentation of many fruits and vegetables (Keppler and 
Humpf, 2005), owing to a chromophore formed by eight conjugated double bonds and a positively 
charged oxygen in the heterocyclic C ring (Wallace, 2011).  However, the stability of this flavylium 
cation form is significantly influenced by pH, and within aqueous solutions several molecular forms of 
anthocyanins exist which are in a dynamic equilibrium (McGhie and Walton, 2007) (Figure 1.4).  At 
pH values of <2, the flavylium cation is the predominant form present, giving rise to a characteristic 
red colour (McGhie and Walton, 2007, Wallace, 2011).  However, rapid de-protonation occurs with 
increasing pH, to generate a quinonoidal structure (pH 6-8) and blue colouration (Fleschhut et al., 
2006, McGhie and Walton, 2007).  A concurrent but substantially slower hydration of the flavylium 
cation also ensues, to generate a colourless hemiketal form (pH 4-5), which then tautomerises 
through opening of the C-ring to yield colourless cis and trans chalcone forms (pH 7-8) (Fleschhut et 
al., 2006, McGhie and Walton, 2007). 
Aglycone anthocyanidins, formed by hydrolysis of the glycoside linkage, are stable under acidic 
conditions; but likewise undergo similar structural changes with increasing pH (Keppler and Humpf, 
2005, Fleschhut et al., 2006).  This results in the formation of a highly reactive α-diketone structure 
(pH >4) and decomposition into monomeric phenolic acid and aldehyde compounds (Keppler and 
Humpf, 2005) (Figure 1.5).  The presence of a sugar moiety confers a degree of stability on 
anthocyanin glycosides (Fleschhut et al., 2006), but degradation also occurs at more alkaline pH 
(Woodward et al., 2009, Kay et al., 2009). 
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Figure 1.4 Molecular structures of anthocyanin generated under varying pH conditions. 
 
Derived from (Fleschhut et al., 2006, McGhie and Walton, 2007, Del Rio et al., 2010). 
 
Figure 1.5 Monomeric phenolic acids and aldehyde formed by anthocyanidin degradation. 
 
 
 
 
 
 
 
 
Derived from (Keppler and Humpf, 2005, Fleschhut et al., 2006, Forester and Waterhouse, 2008, Williamson 
and Clifford, 2010). 
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A recent study demonstrated that in physiological buffer (pH 7.4), cyanidin, delphinidin and 
pelargonidin anthocyanidins undergo rapid degradation with generation of phenolic acid/aldehyde, 
to the extent that no anthocyanidin could be detected after two hours (Woodward et al., 2009).  
Decomposition of the 3-glucoside conjugates of these anthocyanins was also examined in 
physiological buffer, and total losses of 20%, 40% and 100% over the first 12 hours of study were 
recorded for pelargonidin-3-glucoside, cyanidin-3-glucoside and delphinidin-3-glucoside respectively; 
with phenolic acid/aldehyde formation (Woodward et al., 2009).  Moreover, Kay et al (2009) 
examined the stability of cyanidin and cyanidin-3-glucoside during incubation in phosphate buffer 
and cell culture media (Kay et al., 2009), and reported losses of 96% and 57% for cyanidin and its 3-
glucoside respectively after a four incubation period in cell-free Dulbecco’s Modified Eagle Medium 
(DMEM; pH 7).  No significant difference was observed in the level of cyanidin-3-glucoside during 
incubation in DMEM with cultured caco-2 (intestinal epithelial) cells, suggesting anthocyanin 
degradation was spontaneous; and degradation products were identified as protocatechuic acid 
(PCA) and phloroglucinol aldehyde (PGA) (Kay et al., 2009). 
Thus, and with regard to anthocyanin disposition in vivo, the flavylium cation is likely to be the 
predominant form in the acidic gastric environment (Crozier et al., 2009).  However, in the more 
neutral pH conditions of the small and large intestines (and subsequently plasma), other molecular 
forms will predominate (McGhie and Walton, 2007, Del Rio et al., 2010), with concomitant effects on 
anthocyanin and anthocyanidin stability.  Several in vitro studies have demonstrated deglycosylation 
of anthocyanins by intestinal microflora (Keppler and Humpf, 2005, Fleschhut et al., 2006), with 
subsequent degradation of liberated aglycones into phenolic acids and aldehydes; which may be 
subject to further microbial metabolism and/or absorption (Williamson and Clifford, 2010).  
Therefore anthocyanin bioactivity in vivo may be mediated by phenolic acid/aldehyde metabolites, as 
opposed to parent glycosides (Woodward et al., 2009, Williamson and Clifford, 2010, Del Rio et al., 
2013), and indeed these have been reported to be the predominant forms in the systemic circulation 
(Czank et al., 2013). 
1.3.3 Metabolism and bioavailability of anthocyanins 
Manach et al (2005), Kay (2006), McGhie & Walton (2007), and Del Rio et al (2010, 2013) have 
published summaries of human bioavailability of anthocyanins, based on previously reported studies 
(Manach et al., 2005, Kay, 2006, McGhie and Walton, 2007, Del Rio et al., 2010, Del Rio et al., 2013).  
Such studies usually involved ingestion of red wine, grape or berry juices, berries, or berry extracts or 
concentrates; with anthocyanin dose (in terms of total intake) ranging from 50mg to 2g (McGhie and 
Walton, 2007).  In terms of physiological relevance, a dose of several hundred milligrams of 
anthocyanin in a serving would not be deemed unreasonable (Manach et al., 2005); although 
anthocyanin bioavailability from extracts or concentrates may not be directly comparable to that 
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from normal dietary components (Wiczkowski et al., 2010, Wallace, 2011).  Moreover, bioavailability 
studies invariably involve fasted subjects [for example (Kay et al., 2004, Kay et al., 2005, Wiczkowski 
et al., 2010)] and ingestion of significant bolus doses (Manach et al., 2005); as opposed to 
consumption of anthocyanin-containing foodstuffs as part of a normal diet (and with potential 
influence of other dietary components). 
Low bioavailability of anthocyanin glycosides has been reported across many human studies (Table 
1.4), with rapid excretion (6-8 hours) and little of the ingested dose appearing in urine (McGhie and 
Walton, 2007).  Moreover, the time to maximal plasma concentration is relatively short, and has 
been suggested to reflect absorption of anthocyanins across the gastric mucosa (Passamonti et al., 
2002, Passamonti et al., 2003).  Recently, Czank et al (2013) have reported bioavailability data from 
an isotope tracer human study, wherein 500mg of 13C-labelled cyandin-3-glucoside was consumed as 
a single bolus by eight healthy male volunteers (Czank et al., 2013); and excretion of 13C-labelled 
anthocyanin and metabolites in urine, faeces, and breath was monitored over a 48 hour period.  In 
this study, Czank et al (2013) described a Cmax of 0.14µmol/L for 
13C-labelled cyanidin-3-glucoside at 
1.8 hours post ingestion (Czank et al., 2013). 
Anthocyanin glycosides are apparently absorbed and excreted intact (Manach et al., 2005), but 
glucuronidated, methylated and sulphated metabolites have been detected (Kay et al., 2004, Kay et 
al., 2005, Wiczkowski et al., 2010, Wallace, 2011) and phenolic acid/aldehyde degradation products 
and/or metabolites are reported at levels exceeding the parent glycoside (Vitaglione et al., 2007, de 
Pascual-Teresa et al., 2010, Azzini et al., 2010, Czank et al., 2013).  After ingestion of 500mg 13C-
labelled cyanidin-3-glucoside by fasted volunteers, the serum concentration of degradants of the 
parent anthocyanin (protocatechuic acid and phloroglucinol aldehyde) peaked at 0.72µmol/L (Tmax 6 
hours), whilst phase II conjugates of the degradant protocatechuic acid (including methylated, 
glucuronidated and sulphated metabolites) reached a collective Cmax of 2.35µmol/L (Tmax 13 hours) 
(Czank et al., 2013). 
Possible mechanisms of flavonoid absorption in the small intestine have been summarised 
previously; namely transport of intact glucoside through the active sodium-dependent glucose 
transporter (SGLT1) with subsequent hydrolysis by cytosolic Β-glucosidase; or hydrolysis by brush-
border lactase phloridzin hydrolase (LPH) and aglycone entry by passive diffusion (Kay, 2006, Crozier 
et al., 2009, Del Rio et al., 2013).  Similar mechanisms are thought to be involved in the absorption of 
the large, polar anthocyanin molecules (McGhie and Walton, 2007), although this has yet to be fully 
elucidated (Kay, 2006), and the instability of liberated aglycones (anthocyanidins) at alkaline 
(intestinal) pH must also be considered (Fleschhut et al., 2006, McGhie and Walton, 2007, Woodward 
et al., 2009).  Faria et al (2009) have reported transport of anthocyanins extracted from red grape 
skin through cultured caco-2 cells potentially involving the GLUT2 glucose transporter, though with 
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low efficiency (Faria et al., 2009).  Moreover, anthocyanins have been shown in vitro to interact with 
the organic anion membrane transporter bilitranslocase, which is expressed in gastric epithelium and 
the basolateral region of liver plasma membrane (Passamonti et al., 2002).  Gastric absorption of 
anthocyanins has been demonstrated from the stomach of anesthetised rats, potentially mediated 
by bilitranslocase (Passamonti et al., 2003), but direct evidence for a similar mechanism in humans is 
as yet unavailable (Kay, 2006). 
Table 1.4 Summary of key pharmacokinetic data derived from selected human bioavailability studies 
of anthocyanins. 
Material 
consumed 
Anthocyanin 
dose (total 
intake; mg) 
Maximal 
plasma 
concentration/
Cmax (nmol/L) 
Time to 
maximal 
plasma 
concentration/
Tmax (hours) 
Urinary 
excretion 
(% of 
intake) 
Reference 
Blackcurrant 236 115
a
 1.25 - 1.75 
0.11 
(8 hours) 
(Matsumoto et 
al., 2001) 
Blackcurrant juice 
(330 ml) 
1000 3.5 - 51
b
 1.0 
0.032 – 
0.046
b
 
(Rechner et al., 
2002) 
Blood orange 
juice 
~26.5 0.63
c
 0.96
c
 - 
(Giordano et al., 
2012) 
Blueberry powder 
(100 g) 
1200 29 4.0 - 
(Mazza et al., 
2002) 
Chokeberry 
extract 
(7.1 g) 
721 96 2.8 
0.15 
(24 hours) 
(Kay et al., 2004) 
Chokeberry juice 60
d
 32.7 1.3 
0.25 
(24 hours) 
(Wiczkowski et 
al., 2010) 
Elderberry extract 
(12 g) 
720 97 1.2 
0.06 
(24 hours) 
(Milbury et al., 
2002) 
Grape juice 238µM 1.0 - 2.0
e
 1.3 - 3.3
e
 
0.26 
(24 hours) 
(Stalmach et al., 
2012) 
Red grape juice 
(500 ml) 
117
f
 2.8 2.0 
0.02 
(6 hours) 
(Bub et al., 2001) 
Strawberries 
(fresh) 
~9.57 0.0
g
 - 
0.9 
(24 hours) 
(Azzini et al., 
2010) 
a
Total for four anthocyanin species. 
b
According to anthocyanin considered in mixture.  
c
Data tabulated for 
cyanidin-3-glucoside only.  
d
Dose of 0.8mg anthocyanins per kg, estimated for 75kg body weight.  
e
Range for 
four anthocyanin species detected in plasma.  
f
Malvidin-3-glucoside.  
g
No traces of parent anthocyanins or 
conjugated metabolites detected in plasma samples. 
Whilst uptake of nutrients is typically associated with the small intestine, the colon is also capable of 
absorption of compounds, and is likely to be of particular relevance to anthocyanins (McGhie and 
Walton, 2007, Williamson and Clifford, 2010).  Studies involving individuals who have undergone an 
ileostomy (where the colon has been excised and the ileum is drained into an affixed exterior pouch) 
suggest that a proportion of ingested anthocyanins transit the small intestine unchanged, and 
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therefore reach the colon (Williamson and Clifford, 2010, Gonzalez-Barrio et al., 2010, Stalmach et 
al., 2012).  Moreover, the colon contains an extensive microbial population, as the majority of 
microorganisms populating the gastrointestinal tract are located in the distal region (Williamson and 
Clifford, 2010).  Therefore unabsorbed anthocyanins may be degraded by colonic microflora to 
generate smaller aromatic molecules, which are then absorbed (Williamson and Clifford, 2010).  
Czank et al (2013) have estimated elimination half-lives of between 12.44 ± 4.22h and 51.62 ± 22.55h 
for 13C-labelled phenolic metabolites of cyanidin-3-glucoside, which could partly reflect prolonged 
colonic production and absorption of these species (Czank et al., 2013).  Potential enterocyte 
pathways of anthocyanin absorption are illustrated in Figure 1.6. 
Figure 1.6 Putative mechanisms for intestinal absorption of anthocyanins into portal circulation. 
 
Putative mechanisms of anthocyanin-3-glycoside (Anth-3-G) intestinal absorption, based on (Walle, 2004, 
Kay, 2006).  SGLT1, sodium-dependent glucose transporter; LPH, lactase phloridzin hydrolase; CBG, 
cytosolic-Β-glucosidase; MRP, multi-drug resistance protein; Anthocyanidin or degradants; aglycone or 
phenolic acid/aldehyde degradation products; Anth metabolites, sulphated, glucuronidated or methylated 
metabolites of parent glycoside or degradation products. 
Hepatic, and subsequently renal, biotransformation may further modify absorbed compounds, for 
example methylation or conjugation with glucuronic acid or sulphate (McGhie and Walton, 2007, 
Grassi et al., 2009).  Czank et al (2013) identified 24 isotope-labelled metabolites following ingestion 
of 13C-labelled cyanidin-3-glucoside by healthy volunteers; including phase II conjugates of cyanidin 
and cyanidin-3-glucoside, phenolic degradants of cyanidin (protocatechuic acid and phloroglucinol 
aldehyde), and phase II metabolites of protocatechuic acid (including vanillic acid, isovanillic acid, 
glucuronides & sulphates of protocatechuic acid, and glucuronides & sulphates of vanillic and 
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isovanillic acid) (Czank et al., 2013).  Phase II conjugates of cyanidin-3-glucoside were only detected 
in urine (Czank et al., 2013). 
Human elimination of anthocyanins has also been described by Czank et al (2013) as part of the 
aforementioned tracer study, with excretion of the 13C label detected in urine (~5% of 13C dose 
recovered), faeces (~32% of 13C dose recovered), and breath (~7% of 13C dose recovered) over a 48 
hour period (Czank et al., 2013).  A minimum relative bioavailability of ~12% for cyanidin-3-glucoside 
was calculated based upon these elimination data for breath and urine (Czank et al., 2013).  Urinary 
excretion of anthocyanins has been reported by a number of other human intervention studies, and 
as already noted low urinary recovery of ingested dose is documented (typically < 1%) (Perez-
Jimenez et al., 2010).  This may reflect substantial conversion of ingested anthocyanins to 
unmeasured phenolic or aromatic metabolites (Kay, 2006) as discussed above.  Any compounds 
subject to biliary excretion [more probable for large conjugates (Wang and Ho, 2009)] may be 
metabolised by intestinal microflora and subsequently reabsorbed, leading to enterohepatic 
recycling and continued presence within the body; as described for quercetin (Wang and Ho, 2009, 
Grassi et al., 2009) (Figure 1.7). 
Figure 1.7 Scheme of pathways for anthocyanin absorption, metabolism and excretion. 
 
Routes of anthocyanin absorption and biotransformation within the body, adapted from (Kay, 2006). ‘?’ 
denotes unconfirmed pathways in humans. 
In summary, low bioavailability of parent anthocyanin glycosides is likely to reflect in vivo 
degradation and/or colonic metabolism to previously unmeasured phenolic and aromatic 
metabolites; and these metabolites may be responsible for the perceived bioactivity of anthocyanins 
(Williamson and Clifford, 2010, Wallace, 2011, Czank et al., 2013). 
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1.4 Bioactivity of anthocyanins and metabolites 
1.4.1 Background and experimental data 
Whilst molecular species mediating potential anthocyanin bioactivity in vivo are not yet fully 
elucidated, epidemiological studies suggest dietary consumption of anthocyanins is associated with 
beneficial effects on cardiovascular function (Erdman et al., 2007, Mink et al., 2007, Cassidy et al., 
2010, Wallace, 2011, Jennings et al., 2012).  Indeed, a considerable body of epidemiological data 
indicates an inverse association between intake of flavonoid-rich dietary components and CVD risk 
(Hertog et al., 1993, Geleijnse et al., 2002, Erdman et al., 2007); and a substantial intake of 
anthocyanins might be achieved by daily consumption of grapes and berries, or derived beverages 
(Manach et al., 2005, Wu et al., 2006b).  Biological activity of anthocyanins has been investigated in a 
number of in vitro and animal studies with relevance to mechanisms of cardiovascular disease, such 
as effects on eNOS and endothelial function/reactivity (de Pascual-Teresa et al., 2010, Wallace, 
2011).  For example, Andriambeloson et al (1997, 1998) reported endothelium-dependent 
vasorelaxation of rat thoracic aortic rings elicited by red wine polyphenolic compounds 
(Andriambeloson et al., 1997), and anthocyanin-enriched fractions of red wine polyphenolic 
compounds (Andriambeloson et al., 1998).  A similar study was conducted by Fitzpatrick et al, which 
demonstrated endothelium-dependent vasorelaxant activity of grape skin extracts, grape juice, and 
several wines (Fitzpatrick et al., 1993). 
Experimental data in support of cardioprotective effects of anthocyanins is elucidated below; 
however, the physiological relevance of compounds and dose thereof utilised for in vitro 
investigations must always be considered (Crozier et al., 2009).  In particular, prolonged incubation of 
cultured cells with anthocyanin glycosides at physiological pH is likely to result in formation of 
degradation products (Kay et al., 2009, Woodward et al., 2009), which may mediate observed 
bioactivity.  Likewise, phenolic and aromatic metabolites may constitute the bioactive form of 
anthocyanins in vivo (de Pascual-Teresa et al., 2010, Czank et al., 2013, Del Rio et al., 2013).   
Endothelium-derived NO is a key mediator of vascular homeostasis, most significantly through its 
role as endothelium-derived relaxing (vasodilatation) factor (EDRF); impairment of which is a critical 
step in the development of atherosclerosis (Kawashima and Yokoyama, 2004, Higashi et al., 2009).  
Bell and Gochenaur reported dose-dependent relaxation of isolated porcine coronary arterial rings 
elicited by chokeberry and bilberry extracts (using concentrations of 0.005 - 5mg total 
anthocyanins/L), in an endothelium-dependent response which was ablated by inhibition of eNOS 
(Bell and Gochenaur, 2006).  Moreover, impairment of endothelium-dependent vasorelaxation, 
caused by pre-incubation with a superoxide-generating agent, was attenuated with concurrent pre-
incubation using chokeberry, bilberry and elderberry extracts (0.05mg total anthocyanins/L) (Bell and 
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Gochenaur, 2006).  More recently, Ziberna et al (2013) examined the importance of the 
bilitranslocase membrane transporter for anthocyanin-induced endothelium- and NO-dependent 
vasorelaxation (as confirmed by removal of endothelium or NOS inhibition) in excised rat thoracic 
aortic rings (Ziberna et al., 2013).  Pre-incubation of aortic rings with rabbit polyclonal anti-
bilitranslocase antibodies elicited a significant reduction in vasorelaxation induced by cyanidin-3-
glucoside (1nM - 10µM), and a bilberry anthocyanin extract (0.01 - 20mg/L as equivalents of 
cyanidin-3-glucoside) (Ziberna et al., 2013).  These data suggest a potential role for bilitranslocase-
mediated membrane transport in the mechanism of anthocyanin-induced NO-dependent 
vasorelaxation (Ziberna et al., 2013). 
Upregulation of eNOS by anthocyanins in bovine artery endothelial cells (BAECs) has also been 
described for malvidin-3-glucoside (Paixão et al., 2012) and cyanidin-3-glucoside (Xu et al., 2004b, Xu 
et al., 2004a).  Incubation of BAECs with 25µM malvidin-3-glucoside for 14 hours resulted in 
significantly increased eNOS mRNA levels (Paixão et al., 2012); whilst cyanidin-3-glucoside at 1 - 
100nM elicited a dose-dependent upregulation in eNOS protein expression, with the maximal 
increase measured after treatment with 100nM cyanidin-3-glucoside for eight hours (Xu et al., 
2004b).  Activation of cell signalling proteins Src kinase and ERK 1/2 kinase [ERK, extracellular signal 
regulated protein kinase (Robinson and Cobb, 1997)] was involved in eNOS upregulation, as 
measured by cyanidin-3-glucoside stimulated phosphorylation of these kinases and use of kinase 
inhibitors (Xu et al., 2004b).  Moreover, 500nM cyanidin-3-glucoside was shown to rapidly regulate 
eNOS activity through phosphorylation of eNOS at Serine 1179, and dephosphorylation at Serine 116, 
in BAECs (Xu et al., 2004a). 
With regard to anthocyanin bioactivity in human cells, Lazzѐ et al (2006) have described the effects 
of aglycone cyanidin and delphinidin on the expression of eNOS, and the vasoconstrictor protein ET-
1, in cultured HUVECs (Lazze et al., 2006).  Significant decreases in ET-1 secretion, and increases in 
eNOS protein level, were measured following 24 hour incubations with 100µM cyanidin, and 50µM 
or 100µM delphinidin (Lazze et al., 2006).  However, the instability of anthocyanidins at physiological 
pH must be noted (Woodward et al., 2009), in conjunction with the supraphysiological or 
pharmacological levels of anthocyanidins to which cells were exposed (Crozier et al., 2009).  Malvidin 
(at 0.1μM) (Quintieri et al., 2013), cyanidin-3-glucoside (2.3μg/ml; ~5μM), and delphinidin-3-
glucoside (5.8μg/ml; ~12μM) (Edirisinghe et al., 2011) have also been reported to activate eNOS in 
HUVECs, as determined by phosphorylation of Serine 1177.  Therefore anthocyanins, or their 
degradation products and/or metabolites in vivo, could increase both eNOS expression and activity; 
with enhanced endothelial function resulting from increased NO production (Wallace, 2011). 
It is interesting to note that for dietary flavanols, inhibition of NADPH oxidase activity, with reduced 
scavenging of NO by generated superoxide anion, has been suggested as a ‘short-term’ mechanism 
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for enhanced NO bioavailability (Schewe et al., 2008); based upon structure-activity studies of (-)-
epicatechin and its metabolites in a HUVEC model of angiotensin II-stimulated superoxide production 
(Steffen et al., 2007b, Steffen et al., 2008).  Mono-O-methylation of a flavonoid catechol B-ring, or 
presence of a 4’-OH group only at the B-ring (refer to Figure 1.1 and Figure 1.2), are reported to 
confer NADPH oxidase inhibitory activity (Steffen et al., 2008).  This is of structural significance for 
anthocyanins containing a catechol B-ring susceptible to methylation (cyanidin), or an existing mono-
methylated catechol B-ring (peonidin), or a 4’-OH B-ring (pelargonidin) (refer to Figure 1.3 and Figure 
1.5) (Cassidy et al., 2010).  Moreover, the vasoactive compound apocynin, which incorporates a 
mono-methylated catechol group, is reported to decrease NOX activity by inhibiting the association 
of the p47phox subunit (refer to section 1.4.5) with membrane-associated subunits (Stolk et al., 1994, 
Drummond et al., 2011).  Downregulation of p47phox by the flavonol quercetin, which contains a 
catechol B-ring, has been described in aortic rings from spontaneously hypertensive rats (Sanchez et 
al., 2006); and in rat aortic rings following stimulation with ET-1 (Romero et al., 2009), and 
angiotensin II (Sanchez et al., 2007).  It should also be noted that cyanidin-3-glucoside (at 6.25nM - 
6.25µM, and 62.5 - 250µM) upregulated expression of the enzyme haem oxygenase isoform 1 (HO-
1), which demonstrates protective activities against cellular oxidative stress [(Ryter et al., 2002), refer 
to section 1.4.6], in human iliac artery endothelial cells following a 24 hour incubation period with 
this anthocyanin (Sorrenti et al., 2007). 
Expression and/or activation of adhesion molecules on endothelial cells and circulating inflammatory 
cells is a key process in the recruitment of leucocytes to sites of inflammation (Granger et al., 2004); 
and anthocyanins may act to modulate this response to pro-inflammatory stimuli (Wallace, 2011, 
Chen et al., 2011a).  For example, blueberry and cranberry anthocyanins have been reported to 
reduce tumour necrosis factor-alpha (TNF-α)-induced expression of intercellular adhesion molecule 1 
(ICAM-1) by human microvascular endothelial cells (Youdim et al., 2002); whilst cyanidin-3-glucoside 
inhibited gene expression of endothelial cell adhesion molecules ICAM-1, vascular cell adhesion 
molecule 1 (VCAM-1), and E-selectin, in a TNF-α-stimulated HUVEC model (Speciale et al., 2010).  
Wang et al (2010) have also investigated the effects of protocatechuic acid on monocyte adhesion to 
murine endothelial cells, and atherosclerotic development in a mouse model (Wang et al., 2010a).  
Pre-treatment of mouse aortic endothelial cells (MAECs) with protocatechuic acid for 24 hours 
elicited a significant reduction in human monocyte adhesion to TNF-α activated MAECs.  In addition, 
protocatechuic acid partially inhibited TNF-α-stimulated expression of VCAM-1 and ICAM-1 
expression by MAECs (Wang et al., 2010a). 
Overall, data from both animal studies and cell culture experiments suggest a variety of biological 
mechanisms by which anthocyanins, or their degradation products/metabolites, could elicit 
cardioprotective effects in vivo; with effects on NO bioavailability of particular significance.  
38/185 
Anthocyanin bioactivity in vivo is likely to be mediated by derivatives of ingested parent compounds, 
and as noted in vitro studies may not reflect physiologically relevant doses - or exposures - to 
bioactive molecules. 
1.4.2 Anthocyanins and cardiovascular disease 
Cardiovascular disease arises from disorders of the heart and vasculature, as manifested in 
pathophysiologies such as peripheral arterial disease, cerebrovascular disease (stroke), and CHD (de 
Pascual-Teresa et al., 2010, WHO, 2013).  It is responsible for almost half of all deaths in Europe 
annually (Chong et al., 2010), and it is estimated that approximately 23.3 million people will die 
owing to CVDs by 2030 (WHO, 2013). Epidemiological data have associated consumption of 
flavonoid-rich foodstuffs with decreased risk of CVD (Vita, 2005, Wallace, 2011); and anthocyanin 
intake has been inversely related to mortality owing to CHD and CVD (Mink et al., 2007, McCullough 
et al., 2012, Cassidy et al., 2013) and relative risk of hypertension (Cassidy et al., 2010).  A review of 
human dietary intervention studies by Chong et al (2010) indicated that fruits such as berries and 
purple grapes (with relatively high content of anthocyanins, flavonols and procyanidins) appeared 
more effective, as compared to other fruits studied, at reducing CVD risk; particularly with regard to 
anti-hypertensive activity, elevation of endothelium-dependent vasodilatation, and inhibition of 
platelet aggregation (Chong et al., 2010).  In a recent study, consumption of a blueberry drink by 
healthy volunteers elicited increased endothelial-dependent vasodilation (measured as flow-
mediated dilatation) relative to control, in a biphasic and dose-dependent response (Rodriguez-
Mateos et al., 2013).  Moreover, ingestion of a daily supplement of 320mg anthocyanins over 12 
weeks by hypercholesterolaemic individuals was reported to significantly enhance endothelial 
function compared to placebo treatment, in a double-blind parallel group intervention (Zhu et al., 
2011).  However, not all studies support this protective association (Curtis et al., 2009, Jin et al., 
2011, Hassellund et al., 2012, Riso et al., 2013, Del Bo et al., 2013); for example, Del Bo et al (2013) 
found no improvement in peripheral vascular function one hour after consumption of a single 
portion of blueberries (~348mg anthocyanins) by healthy subjects in a randomised cross-over 
intervention; which the authors noted may be partly attributable to the population studied (Del Bo et 
al., 2013). 
In order to appreciate potential mechanisms of anthocyanin bioactivity in CVD, it is necessary to 
review briefly the pathophysiology of atherosclerosis, which underlies atherosclerotic cardiovascular 
disease and the concomitant morbidity and mortality arising from complications of this disease 
(Leopold and Loscalzo, 2009).  Endothelial dysfunction forms an early part of the development of 
atherosclerosis (Vita and Keaney, 2002, Widlansky et al., 2003, Higashi et al., 2009), and 
anthocyanins or their in vivo bioactive derivatives may act to modulate molecular mechanisms 
underlying this disordered function. 
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1.4.3 Atherosclerosis, endothelial dysfunction, and effects of anthocyanins 
Atherosclerosis is a chronic inflammatory disease (Libby et al., 2002), which occurs principally in 
medium and large-sized elastic and muscular arteries (Ross, 1999, Vita, 2005), and has been 
associated with areas of disturbed blood flow such as arterial bifurcations (Ross, 1999, Libby et al., 
2002, Leopold and Loscalzo, 2009).  The disease is characterised by localised thickening within the 
sub-intimal (endothelial) region of the arterial wall (Figure 1.8) (Ross, 1999, Bonomini et al., 2008) 
giving rise to progressive lesions termed plaques, which ultimately intrude into the arterial lumen 
(Bonomini et al., 2008).  Advanced lesions may be of sufficient size to impair blood flow; but rupture 
of the fibrous cap of such lesions, or ulceration of the plaque, can lead to platelet-rich thrombosis [as 
the thrombogenic sub-endothelium is exposed to circulating blood (Vita, 2005)] and partial or total 
arterial occlusion (Ross, 1999, Vita, 2005, Bonomini et al., 2008).  This is manifested clinically as 
infarction or ischaemia, such as myocardial infarction or stroke (Vita, 2005, Bonomini et al., 2008). 
Figure 1.8 Overview of structure of the arterial wall 
 
Structure of the arterial wall, and key cell types involved in the development of atherosclerosis [adapted 
from (Naseem, 2005)]. 
Dysfunction of the vascular endothelium is the initial process in the development of atherosclerosis 
(Landmesser et al., 2004, Higashi et al., 2009); in particular reduced bioavailability of NO from eNOS 
and impairment of endothelium-dependent relaxation (Kawashima and Yokoyama, 2004) through 
stimulation of soluble guanylate cyclase in vascular smooth muscle cells by NO (Hobbs et al., 1999, 
Michel and Vanhoutte, 2010).  Nitric oxide also inhibits expression of cell surface adhesion molecules 
VCAM-1 (located on endothelium), ICAM-1 (located on endothelium and leucocytes) and P-selectin 
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(located on endothelium and platelets) and monocyte chemoattractant protein-1 (derived from 
endothelial cells); thereby reducing leucocyte recruitment, adhesion and extravasation (Ross, 1999, 
Granger et al., 2004, Naseem, 2005, Michel and Vanhoutte, 2010).  Furthermore, NO acts to inhibit 
platelet activation and aggregation, proliferation of vascular smooth muscle cells (VSMC), and 
oxidation of low density lipoprotein (LDL; by scavenging of lipid radicals); all of which are important 
processes in atherogenesis (Kawashima and Yokoyama, 2004, Naseem, 2005, Michel and Vanhoutte, 
2010).  Experimental data suggest that loss of NO is linked to increased adhesion of leucocytes to 
vascular endothelium, and subsequent infiltration into the arterial wall; representing an essential 
step in the formation of atherosclerotic lesions (Wever et al., 1998, Landmesser et al., 2004, Granger 
et al., 2004).  Likewise, clinical data indicate an association between coronary endothelial dysfunction 
(as assessed by endothelium-dependent vasodilatation) and cardiovascular events in patients with 
coronary artery diseases (Vita and Keaney, 2002, Higashi et al., 2009). 
Endothelium-derived NO thus has anti-atherosclerotic activity (Wever et al., 1998, Naseem, 2005, 
Förstermann and Sessa, 2012), and any reduction in NO bioavailability can enhance inflammatory 
processes underlying atherosclerosis (Landmesser et al., 2004, Michel and Vanhoutte, 2010).  This 
may arise from decreased production of NO by eNOS (whether by down-regulation of enzyme 
expression or loss of activity); or increased reaction of NO with ROS leading to loss of NO signalling 
[(Landmesser et al., 2004, Naseem, 2005, Higashi et al., 2009), refer also to section 1.2.3].  The 
primary mechanism for loss of NO in many vascular pathologies is thought to be by reaction with O2˙
-, 
to form the potent oxidant –ONOO (Wever et al., 1998, Naseem, 2005).  The rate of this reaction is 
nearly diffusion-limited (6.7 x 10-9 M/s), and is approximately three times faster than the dismutation 
of O2˙
- by SOD (2.0 x 10-9 M/s) (Wever et al., 1998).  Under normal physiological conditions, the 
estimated concentration of O2˙
- (10-9 - 10-12 M) relative to NO (10 - 300nM) is insufficient to drive 
formation of –ONOO (Wever et al., 1998, Naseem, 2005); but increased vascular superoxide 
production has been associated with risk factors for atherogenesis (such as hypertension and 
hypercholesterolaemia) and cardiovascular disease states (Wever et al., 1998, Landmesser et al., 
2004, Kawashima and Yokoyama, 2004, Naseem, 2005, Higashi et al., 2009).  NADPH oxidase 
enzymes constitute a major source of ROS in the vasculature (Zalba et al., 2000, Touyz, 2004, Bedard 
and Krause, 2007, Bonomini et al., 2008), and inhibition of NOX may serve to enhance NO levels in an 
acute effect (Steffen et al., 2008, Schewe et al., 2008). 
The activity of eNOS and NOX is thus of great importance in the development of endothelial 
dysfunction (Kawashima and Yokoyama, 2004, Landmesser et al., 2004, Higashi et al., 2009); and 
modulation of these enzymes by anthocyanins, or their in vivo metabolites, may underlie reported 
cardioprotective activity (Wallace, 2011).  Given the importance of NO in maintenance of vascular 
homeostasis (Higashi et al., 2009), improving NO bioavailability should enhance vascular function 
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(Cassidy et al., 2010), and anthocyanins may act to upregulate eNOS expression and activity (Xu et 
al., 2004b, Xu et al., 2004a, Edirisinghe et al., 2011, Paixão et al., 2012).  Moreover, anthocyanins 
and/or metabolites could attenuate superoxide production by NOX; with reduced scavenging of NO 
by generated ROS (Schewe et al., 2008), based on structural similarities with other flavonoids 
demonstrating inhibition of NOX activity (Schewe et al., 2008, Cassidy et al., 2010). 
1.4.4 Activity of endothelial nitric oxide synthase & effects of anthocyanins 
Nitric oxide is generated by the family of haem-containing NOS enzymes, through the oxidation of L-
arginine (Arg) to produce NO and L-citrulline, in an oxygen- and NADPH-dependent reaction (Hobbs 
et al., 1999).  Three mammalian isoforms of NOS have been characterised, namely neuronal (nNOS or 
NOS I), inducible (iNOS or NOS II) and endothelial (eNOS or NOS III) (Michel and Vanhoutte, 2010, 
Förstermann and Sessa, 2012).  Endothelial NOS is constitutively expressed in most endothelial cells 
(particularly in conductance arteries) (Fleming and Busse, 2003) and a number of other cell types, 
including fibroblasts, lymphocytes and neutrophils (Villanueva and Giulivi, 2010).  Functional eNOS is 
a homodimer of approximately 260 kDa, and requires binding of Ca2+/calmodulin (CaM) [an allosteric 
effector (Michel and Vanhoutte, 2010)] for activation (Hobbs et al., 1999, Fleming and Busse, 2003), 
in addition to the essential cofactors tetrahydrobiopterin (BH4), flavin mononucleotide (FMN) and 
flavin adenine dinucleotide (FAD) (Fleming and Busse, 2003) (Figure 1.9).  An N-terminus consensus 
sequence for myristoylation/palmitoylation confers membrane association on eNOS, particularly 
with plasma membrane caveolae [lipid microenvironments or ‘rafts’ containing caveolin integral 
membrane proteins (Simons and Toomre, 2000)] (Hobbs et al., 1999, Fleming and Busse, 2003). 
Figure 1.9 Representation of eNOS homodimer and associated cofactors 
 
Structure of eNOS homodimer, with arrows indicating electron flow between monomers to haem (Fe) 
moiety [adapted from (Fleming and Busse, 2003)].  AL, auto-inhibitory loop; Arg, arginine; CBD, CaM binding 
domain; FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide; H4B, tetrahydrobiopterin; NADPH, 
reduced nicotinamide adenine dinucleotide phosphate. 
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Activity of eNOS is stimulated by agonists such as bradykinin or acetylcholine, which is coupled to 
increased intracellular Ca2+/[Ca2+]i (Shaul, 2002, Fleming and Busse, 2003); or by fluid shear stress 
resulting from the flow of blood over endothelial cells, which is apparently independent of a 
sustained increase in [Ca2+]i (Shaul, 2002, Fleming and Busse, 2003, Higashi et al., 2009, Förstermann 
and Sessa, 2012).  However, shear stress is reported to elicit differential effects on eNOS, according 
to the type of stress applied to blood vessels (Leopold and Loscalzo, 2009).  Laminar (unidirectional) 
shear stress, which predominates in straight vessel segments, induces elevated eNOS activity and 
upregulation of enzyme expression, thereby limiting oxidative stress (Boo and Jo, 2003, Leopold and 
Loscalzo, 2009).  In contrast, oscillatory shear stress, created by turbulent blood flow at arterial 
bifurcations, results in downregulation of eNOS; with upregulation and increased activation of NOX 
and xanthine oxidase (Hwang et al., 2003, McNally et al., 2003, Hsiai et al., 2007).  Many of the 
physiological effects of generated NO result from binding of NO to the haem moiety of the soluble 
guanylate cyclase enzyme, causing increased enzyme activity and formation of the intracellular 
second messenger molecule cyclic guanosine monophosphate (cGMP) (Hobbs et al., 1999, Michel 
and Vanhoutte, 2010). 
Two amino acid residues of the eNOS protein appear to be of particular importance as key regulatory 
sites through protein phosphorylation and/or dephosphorylation; specifically Ser (serine)1177 (human 
eNOS; Ser1179 bovine eNOS) in the C-terminal reductase domain [so called as this region of the 
protein closely resembles cytochrome P450 reductase (Hobbs et al., 1999)], and Thr (threonine)495 
(human eNOS; Thr497 bovine eNOS) within the CaM binding domain (Fleming and Busse, 2003).  
Phosphorylation at Ser1177 is mediated by kinases including Akt/protein kinase B (PKB), protein kinase 
A (PKA), and the AMP-activated protein kinase (AMPK), according to stimuli applied to endothelial 
cells (Shaul, 2002); and results in increased NO production (two to three-fold over basal) by 
enhanced electron flow through the reductase domain (Fleming and Busse, 2003).  By contrast, Thr495 
appears to be constitutively phosphorylated in endothelial cells [probably by protein kinase C (PKC)], 
and acts as a negative regulatory site; in that phosphorylation interferes with CaM binding, and 
dephosphorylation [possibly by protein phosphatase-1 (PP1)] results in a significantly increased NO 
generation over basal levels (Fleming and Busse, 2003).  Other sites of eNOS phosphorylation which 
may affect enzyme activity include Ser114/Ser116 and Ser633/Ser635 (human/bovine eNOS respectively) 
(Fleming and Busse, 2003). 
Production of NO may be attenuated by increased levels of ROS, owing to oxidative degradation of 
the essential eNOS cofactor BH4 (Landmesser et al., 2004), which leads to ‘uncoupling’ of eNOS, with 
reduced generation of NO and increased production of O2˙
- by the enzyme (Kawashima and 
Yokoyama, 2004, Naseem, 2005) (Figure 1.10).  Endothelial NOS activity could also be reduced by a 
local deficiency of L-arginine (Förstermann and Sessa, 2012); or elevated levels of the circulating 
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endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), owing to ROS-induced inhibition of 
the enzyme dimethylarginine dimethylaminohydrolase (DDAH) (Landmesser et al., 2004), which 
metabolises ADMA (Naseem, 2005).  Oxidised LDL (oxLDL) may act to reduce expression of eNOS, 
although a consensus has yet to be reached given contradictory in vivo and in vitro data (Wever et 
al., 1998, Naseem, 2005), but there is evidence for lipoprotein-induced disruption of eNOS associated 
with caveolae and subsequent attenuation of signalling (Shaul, 2002, Naseem, 2005).  Of interest, 
regenerated endothelial cells, which replace apoptotic endothelial cells following cell death, 
demonstrate diminished endothelium-dependent relaxations to agonists (such as thrombin and 
serotonin) which activate eNOS through a signalling cascade using the Gi G-protein [heterotrimeric 
GTP-dependent signal transduction protein (Tesmer, 2010)] (Michel and Vanhoutte, 2010).  
Regenerated endothelium may therefore exhibit selective dysfunction of eNOS signalling, which 
appears to be an initial step in the process of atherosclerosis (Michel and Vanhoutte, 2010). 
Figure 1.10 Putative scheme for eNOS ‘uncoupling’ in conditions of oxidative stress 
 
Possible mechanism for eNOS ‘uncoupling’ arising from increased oxidative stress.  (1) Under physiological 
conditions, NO generated by eNOS mediates endothelial protection and vascular homeostasis.  (2) When 
oxidative stress is increased, decreased tissue levels of the essential cofactor BH4 results in uncoupling of 
eNOS, with reduced generation of NO and increased production of O2˙
-
.  Superoxide, and peroxynitrite 
derived from scavenging of NO by O2˙
-
, can elicit deleterious effects on endothelial function [figure adapted 
from (Kawashima and Yokoyama, 2004)].  e
-
, electron flow to haem moiety of eNOS. 
With regard to anthocyanin modulation of eNOS activity, and as discussed in section 1.4.1, 
anthocyanins have demonstrated endothelium- and NO-dependent vasorelaxant activity in studies 
utilising excised porcine (Bell and Gochenaur, 2006) and rat (Ziberna et al., 2013) arterial rings.  
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Moreover, chokeberry, bilberry and elderberry extracts were able to attenuate impairment of 
endothelium-dependent vasorelaxation induced by a superoxide-generating agent (Bell and 
Gochenaur, 2006).  Xu et al (2004) reported upregulation of eNOS expression by cyanidin-3-
glucoside, involving activation of Src and ERK 1/2 kinases, in BAECs (Xu et al., 2004b); and stimulation 
of eNOS activity (through phosphorylation at Ser1179 and dephosphorylation at Ser116) by cyanidin-3-
glucoside in the same cell line (Xu et al., 2004a).  Increased expression of eNOS protein was also 
demonstrated in HUVECs following incubation with cyanidin and delphinidin aglycones (Lazze et al., 
2006), and both cyanidin-3-glucoside and delphinidin-3-glucoside elicited activation of eNOS in 
human vascular endothelial cells (Edirisinghe et al., 2011).  Therefore anthocyanins, or their 
degradation products and/or metabolites in vivo, could increase both eNOS expression and activity; 
with enhanced endothelial function resulting from increased NO bioavailability (Wallace, 2011). 
1.4.5 Activity of NADPH oxidase & effects of anthocyanins 
The predominant source of ROS in the vasculature is, as previously noted, generally identified as the 
family of NADPH oxidase or NOX enzymes (Cai et al., 2003, Sumimoto et al., 2005, Leopold and 
Loscalzo, 2009); of which the original member is the phagocyte NADPH oxidase [gp91phox/NOX2; 
‘phox’ denotes phagocyte oxidase (Lassegue and Clempus, 2003)] (Bedard and Krause, 2007).  
NADPH oxidase enzymes are transmembrane proteins which transfer electrons across biological 
membranes to an acceptor molecule, usually oxygen, thereby generating superoxide anion (Lassegue 
and Clempus, 2003, Bedard and Krause, 2007) although one NOX isoform produces mainly hydrogen 
peroxide (Altenhofer et al., 2012, Streeter et al., 2013) (Figure 1.11). 
Six mammalian isoforms of the NOX2 protein have been identified and cloned, namely NOX1 
(previously mox-1 or NOH-1), NOX3, NOX4, NOX5; and dual oxidases (DUOX) 1 and 2 (originally 
thyroid oxidases) (Sumimoto et al., 2005, Bedard and Krause, 2007).  Assembly of a functional 
enzyme complex may require, according to the NOX isoform, association of additional protein 
components; however, all NOX isoforms share several conserved structural features (Bedard and 
Krause, 2007).  These features comprise a cytoplasmic C-terminus with FAD and NADPH binding 
domains, six putative transmembrane domains (TMDs) (with an additional N-terminal TMD present 
in DUOX1 & 2), and two highly conserved histidine residues in both TMD III and TMD V (IV and VI for 
DUOX1 & 2) which bind two haem molecules between these domains (Bedard and Krause, 2007).  
The proposed topology of NOX subunits indicates that generated superoxide is released into 
intracellular vesicles or the extracellular space, although superoxide might pass into the cytoplasm 
through membrane organic anion channels (Lassegue and Clempus, 2003, Bedard and Krause, 2007). 
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Figure 1.11 Proposed transmembrane topology of NOX protein 
 
Proposed membrane topology for six transmembrane domain NOX protein, with C-terminal FAD and 
NADPH binding domains, and two haem (Fe) molecules bound between the third and fifth transmembrane 
domains (refer to text).  ‘•’ denotes electron transfer from electron donor (NADPH) to acceptor (O2/oxygen) 
molecule; ‘H
+
’ shows proton conductance to give electrical balance [adapted from (Lassegue and Clempus, 
2003)]. 
NADPH oxidase isoform 2 represents the prototype NADPH oxidase, and has been extensively 
investigated (Lassegue and Clempus, 2003, Bedard and Krause, 2007).  The relative molecular mass 
(RMM) for human NOX2 is ~ 70-90 kDa, and represents a highly glycosylated protein (Bedard and 
Krause, 2007).  NOX2 constitutively associates with the integral membrane protein p22phox, predicted 
to contain two TMDs, to form a stable complex termed cytochrome b558 (Sumimoto et al., 2005) 
(Figure 1.12).  p22phox also serves as a site of interaction with cytoplasmic regulatory proteins (Bedard 
and Krause, 2007); specifically the ‘organiser’ subunit p47phox (Sumimoto et al., 2005).  
Phosphorylation of p47phox [by a number of serine kinases, including protein kinase C (PKC) (Brandes 
et al., 2010) or the c-Src tyrosine kinase (Cai et al., 2003)] is thought to induce a conformational 
change permitting association with p22phox, and membrane localisation of p47phox elicits translocation 
of the cytoplasmic proteins p67phox (the NOX ‘activator’ subunit) and p40phox (an adaptor subunit 
which may not be essential for enzyme function) to the enzyme complex (Sumimoto et al., 2005, 
Bedard and Krause, 2007).  The small cytoplasmic G-protein Rac forms the final part of the complex, 
initially interacting with NOX2 and subsequently with p67phox, creating a functional enzyme 
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(Sumimoto et al., 2005, Bedard and Krause, 2007).  As noted, NOX2 is the phagocyte NADPH oxidase; 
responsible for the microbicidal ‘oxidative burst’ of superoxide (and derived ROS) during 
phagocytosis by cells such as neutrophils and monocytes/macrophages (Lassegue and Clempus, 
2003, Sumimoto et al., 2005).  In addition to high levels of expression in phagocytes, NOX2 is 
expressed at lower levels in cardiovascular tissues including cardiomyocytes, endothelium, and 
smooth muscle (notably resistance vessel smooth muscle) (Bedard and Krause, 2007). 
Figure 1.12 Proposed structure of NOX2 (gp91
phox
) in association with p22
phox
 
 
Proposed membrane topology of the glycosylated, haem-binding NOX2 protein (gp91
phox
), shown in 
association with the integral membrane protein p22phox.  ‘H’ denotes histidine residue, ‘N’ and ‘C’ refer to 
protein N- and C-termini respectively [adapted from (Sumimoto et al., 2005)]. 
Whilst NOX isoforms display a similar structure and function (Bedard and Krause, 2007), the 
mechanism of enzyme activation, and tissue distribution of protein, are distinct (Sumimoto et al., 
2005, Bedard and Krause, 2007).  Vascular ROS generation by NOX enzymes represents activity of 
several isoforms, and arterial expression of NOX1, NOX2, NOX4 and NOX5 has been reported; 
although relative abundance of isoforms varies according to cell type and location (Bedard and 
Krause, 2007).  In contrast to the large quantities of superoxide produced by phagocytes during the 
oxidative burst (Cai et al., 2003), the rate of superoxide production in vascular cells has been 
estimated as ~ 1 – 10% of leucocyte activity (Lassegue and Clempus, 2003). 
NOX1 is expressed at high levels in colon epithelial cells (Sumimoto et al., 2005); and at lower levels 
in both vascular endothelium, and smooth muscle cells (mainly in large conduit vessels) (Bedard and 
Krause, 2007).  Activity of NOX1 requires the p22phox subunit [though the enzyme may function in the 
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absence of this subunit (Sumimoto et al., 2005)], and the cytoplasmic proteins NOX organiser 1 
(NOXO1; a homologue of p47phox), NOX activator 1 (NOXA1; a homologue of p67phox) and Rac 
(Sumimoto et al., 2005, Bedard and Krause, 2007).  However, p47phox may act as a NOX1 subunit in 
the vasculature (Bedard and Krause, 2007).  By contrast NOX4, which is abundantly expressed in the 
kidney and vascular endothelium (Sumimoto et al., 2005), does not require cytosolic subunits for 
enzyme activity (Brown and Griendling, 2009); but is associated with p22phox (Bedard and Krause, 
2007) and may be regulated by polymerase δ-interacting protein 2 (POLDIP2) (Drummond et al., 
2011).  NOX4 appears to be constitutively active (Brandes et al., 2010), generating predominantly 
hydrogen peroxide (Sumimoto et al., 2005, Bedard and Krause, 2007, Brown and Griendling, 2009, 
Brewer et al., 2011); and immunoblotting has detected two bands for NOX4 protein at 75-80 kDa and 
65 kDa, perhaps indicating protein glycosylation (Bedard and Krause, 2007).  Finally, NOX5 [~ 85 kDa 
protein by immunoblotting (Bedard and Krause, 2007)] appears to form a functional enzyme without 
additional subunits, and is activated by Ca2+; possibly by association with Ca2+-binding sites (‘EF-
hands’) present in an extended N-terminal region [though several variants of NOX5 have been 
described, one of which lacks this motif (Bedard and Krause, 2007)] (Sumimoto et al., 2005).  NOX5 is 
highly expressed in lymphocytes, and to a lesser extent in vascular endothelium (Sumimoto et al., 
2005, Bedard and Krause, 2007).  Figure 1.13 illustrates the formation of a functional enzyme 
complex for NOX1, NOX2, NOX4 and NOX5 [adapted from (Drummond et al., 2011)]. 
In summary, NOX isoforms 1, 2, 4 and 5 are reported to be expressed in vascular endothelium 
(Leopold and Loscalzo, 2009), with NOX4 apparently the predominant isoform (Ago et al., 2004); by 
contrast, NOX1 and NOX4 are the principal isoforms in vascular smooth muscle cells (Bedard and 
Krause, 2007).  Activity of NOX can be induced by a variety of stimuli, including mechanical forces and 
hormones (Cai et al., 2003), several of which may have relevance in the development of 
atherosclerosis; such as vascular oscillatory shear stress, inflammatory cytokines, and angiotensin II 
(Ang II) (Leopold and Loscalzo, 2009).  Angiotensin II, an octapeptide hormone, is an important 
stimulus for activation of vascular NOXs (Cai et al., 2003); and subsequent oxidative stress with loss 
of NO activity (Dzau, 2001).  The Ang II receptor [AT1 receptor (Cai et al., 2003)] and Ang II are 
localised in regions of inflammation in human atherosclerotic lesions (Dzau, 2001); and Ang II 
induced NOX activity is one of the major sources of ROS in atherosclerosis (Higashi et al., 2009).  
Furthermore, increased expression of NOX subunits (p22phox, p47phox, and p67phox) and NOX5 has been 
described in isolated coronary arteries from patients with established atherosclerosis (Guzik et al., 
2006, Guzik et al., 2008). 
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Figure 1.13 Proposed transmembrane structure, and associated proteins forming enzyme complex, for 
NOX isoforms 1, 2 4 and 5 
 
Proposed membrane topology, and associated proteins forming enzyme complex, for NOX isoforms 1, 2, 4 
and 5.  Both NOX1 and NOX2 associate with p22
phox
 and cytoplasmic proteins, as detailed in text, to produce 
a functional enzyme complex; phosphorylation of the ‘organiser’ subunit p47
phox
 is required for NOX2 
activity.  NOX4 associates with p22
phox
 and may be regulated by POLDIP2; whereas NOX5 appears to be 
functional without additional subunits and is activated by Ca
2+
 [figure adapted from (Drummond et al., 
2011)]. 
However, it should be noted that NOX isoforms may have distinct functions in vivo (Anilkumar et al., 
2008, Schroder, 2010, Brandes et al., 2011, Touyz and Montezano, 2012); in that overexpression of 
endothelium-targeted NOX4 in transgenic mice resulted in enhanced histamine and acetylcholine-
induced vasodilatation, through increased production and activity of H2O2 (Ray et al., 2011).  Indeed, 
a recent study has suggested a key role for NOX4-derived hydrogen peroxide in eliciting eNOS 
activation in response to laminar shear stress in bovine aortic endothelial cells (Breton-Romero et al., 
2012).  Furthermore, Brewer et al (2011) have reported that overexpression of NOX4 in 
cardiomyocytes (using a transgenic mouse model) elicited activation of the transcription factor Nrf2 
[nuclear factor-erythroid 2-related factor 2 (Pendyala et al., 2011), refer also to section 1.4.6], and 
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subsequent upregulation of transcription of a number of antioxidant/detoxification enzymes (Brewer 
et al., 2011).  By contrast, superoxide anions generated through the activity of NOX1 and NOX2 in 
vascular pathophysiologies can react with NO to form peroxynitrite [a reaction which cannot occur 
with H2O2 (Brandes et al., 2011)], reducing NO bioavailability and leading to uncoupling of eNOS 
through oxidation of BH4 by peroxynitrite [(Schroder, 2010, Brandes et al., 2011), refer also to section 
1.4.4].  Elevated NOX2 activation, in association with impaired endothelial function (as measured by 
flow-mediated dilatation), has been reported for patients with peripheral artery disease as compared 
to control subjects (Loffredo et al., 2013); whereas inherited mutations in the CYBB gene encoding 
NOX2, which underlie most cases of the immunodeficiency pathology termed chronic granulomatous 
disease/CGD (Drummond et al., 2011), have been associated with enhanced flow-mediated dilatation 
in a multi-centre study involving 25 CGD patients (Violi et al., 2009). 
As discussed in section 1.4.1, inhibition of NOX activity, with decreased scavenging of NO by 
generated O2˙
-, has been proposed as a ‘short-term’ mechanism by which dietary flavanols may 
enhance NO bioavailability and thereby improve vascular function (Schewe et al., 2008).  Structure-
activity studies of (-)-epicatechin, and its metabolites, in a HUVEC model of angiotensin II-stimulated 
superoxide production (Steffen et al., 2007b, Steffen et al., 2008) identified a mono-O-methylated 
flavonoid catechol B-ring (refer to section 1.2.2), or a B-ring with a 4’-OH group only, as structural 
configurations conferring NOX inhibitory activity [(Steffen et al., 2008, Cassidy et al., 2010), Figure 1.1 
and Figure 1.2].  This is of particular significance for anthocyanins, or their B-ring phenolic acid 
degradation products (refer to Figure 1.5), which contain a catechol B-ring subject to methylation by 
COMT (such as cyanidin) or an existing mono-methylated catechol B-ring (peonidin); or a 4’-OH B-
ring (pelargonidin) [(Cassidy et al., 2010), Figure 1.3 and Figure 1.5].  Thus, anthocyanins could 
potentially act to increase NO bioavailability in vivo by both direct (upregulation/activation of eNOS) 
and indirect [NOX inhibition with reduced scavenging of NO by O2˙
-, and possibly decreased oxidative 
degradation of eNOS cofactor BH4 (Kawashima and Yokoyama, 2004)] mechanisms; thus improving 
vascular endothelium function (refer to sections 1.4.3 and 1.4.4).  It is interesting to note that 
methylation of protocatechuic acid (the B-ring degradation product of cyanidin-3-glucoside) by 
COMT has also been reported as a key process for perceived bioactivity, in a study of potential anti-
anginal mechanisms in the rat heart (Cao et al., 2009).  Moreover, downregulation of the key p47phox 
subunit, as elicited by quercetin (containing a catechol B-ring) and its mono-methylated metabolite 
(Sanchez et al., 2006, Sanchez et al., 2007, Romero et al., 2009, Davalos et al., 2009), may represent a 
potential mechanism by which anthocyanins or their phenolic degradants could inhibit NOX activity.  
Indeed, a recent report by Lim et al (2013) has described inhibition of ultraviolet light (UV) subtype B-
induced p47phox membrane translocation by the anthocyanidin delphinidin (at 10 or 20μM) in human 
dermal fibroblasts (Lim et al., 2013). 
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1.4.6 Activity of haem oxygenase & effects of anthocyanins 
Haem oxygenase (HO) catalyses the oxidative catabolism of haem in an oxygen- and NADPH-
dependent reaction (Ryter et al., 2002, Ryter et al., 2006), and constitutes the rate-limiting enzyme in 
the haem degradation pathway (Abraham and Kappas, 2008).  Activity of HO generates equimolar 
quantities of the bile pigment biliverdin-IXα (rapidly reduced to bilirubin-IXα by cytosolic biliverdin 
reductase), free ferrous (Fe2+) iron (immediately bound by the protein ferritin), and carbon monoxide 
(CO) (Siow et al., 1999, Ryter et al., 2002, Ryter et al., 2006, Abraham and Kappas, 2008) (Figure 
1.14).  Haem oxygenase is expressed as inducible (HO-1) and constitutive (HO-2) isoenzymes, with 
molecular masses of 32 kDa and 34 kDa respectively (Abraham and Kappas, 2008).  With regard to 
subcellular localisation, HO-1 is known to associate with the endoplasmic reticulum, and both 
isoenzymes may be localised to the rough endoplasmic reticulum and membrane caveolae (Ryter et 
al., 2006). 
Figure 1.14 Oxidative catabolism of haem by haem oxygenase 
 
Degradation of haem by haem oxygenase (inducible and constitutive isoforms) yielding biliverdin 
(converted to bilirubin), ferrous iron (sequestered by ferritin) and CO gas [figure adapted from (Abraham 
and Kappas, 2008)]. 
Expression of HO-1 is activated by binding of the transcription factor Nrf2 to antioxidant response 
elements (AREs) or electrophile response elements (EpREs) located in the promoter regions of genes 
encoding antioxidant or detoxification enzymes such as HO-1, in response to oxidative stress (Pi et 
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al., 2010, Maher and Yamamoto, 2010).  HO-1 demonstrates protective activity against cellular 
oxidative stress (Siow et al., 1999, He et al., 2010), which may be mediated in part by activity of 
generated CO (Chan et al., 2011).  Moreover, biliverdin and bilirubin display potent antioxidant 
activity in vitro (Ryter et al., 2002).  Induction of HO-1 can be stimulated in both animal tissues, for 
example vascular endothelium and smooth muscle (Siow et al., 1999), and many types of cells in 
culture (including endothelial cells), by exposure to haem and factors such as metals, pro-
inflammatory cytokines and growth factors, xenobiotics, NO, oxidised lipids and oxidative stress 
(Ryter et al., 2002, Abraham and Kappas, 2008).  Agents capable of inducing HO-1 expression may 
modulate intracellular redox balance, and/or elicit formation of ROS, by direct or indirect 
mechanisms; thus elevated HO-1 levels could serve as a marker of cellular oxidative stress (Ryter et 
al., 2002). 
Carbon monoxide derived from HO activity [representing approximately 80% of CO produced in vivo 
(Abraham and Kappas, 2008)] is reported to have anti-inflammatory, anti-apoptotic, and anti-
proliferative effects (Ryter et al., 2002, Abraham and Kappas, 2008, Chan et al., 2011).  Akin to NO, 
CO can interact with soluble guanylate cyclase, resulting in enhanced generation of the intracellular 
second messenger cGMP (Siow et al., 1999); though CO is considerably less potent relative to NO 
(Chan et al., 2011).  This signalling pathway may underlie subsequent vasodilatory (Idriss et al., 2008, 
Chan et al., 2011) and anti-thrombotic activity attributed to HO-derived CO (Ryter et al., 2006).  
Vasodilatation might also be effected by CO through stimulation of K+ channel activity (Chan et al., 
2011).  Furthermore, CO can inhibit lipopolysaccharide (LPS)-induced expression of inflammatory 
cytokines such as TNF-α, by activation of p38 MAPK (Ryter et al., 2002), and may influence the 
activity of haemoproteins such as NOX and iNOS (Ryter et al., 2002, Abraham and Kappas, 2008).  
Bilirubin generated from haem degradation, by reduction of HO-1 derived biliverdin, is reported to 
inhibit NOX activity (Jiang et al., 2006, Datla et al., 2007) possibly by interruption of enzyme assembly 
and activation (refer also to section 1.4.5); and to preserve eNOS expression in human aortic 
endothelial cells following stimulation with oxLDL or TNF-α (Kawamura et al., 2005).  In addition, 
bilirubin can act to inhibit expression of cell adhesion molecules and adhesion of neutrophils (Ryter 
et al., 2006, Abraham and Kappas, 2008), of significance with regard to the development of 
atherosclerosis (Granger et al., 2004).  It should be noted that pro-atherogenic stimuli (such as 
angiotensin II and oxidised LDL) can induce HO-1 in endothelial and vascular smooth muscle cells 
(Ryter et al., 2006); and evidence from both animal models and clinical studies indicates that HO-1 
activity may have protective effects on the cardiovascular system (Idriss et al., 2008, Chan et al., 
2011).  For example, Yet et al (2003) examined the formation of hypercholesterolaemia-induced 
atherosclerotic lesions in HO-1 and apolipoprotein E (ApoE)-deficient mice, and observed increased 
size and severity of lesions compared with those induced in ApoE-deficient mice expressing HO-1 (Yet 
et al., 2003).  Additionally, in a cross-sectional study of 91 healthy subjects, Erdogan et al (2006) 
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reported an association between reduced serum bilirubin levels, and decreased flow-mediated 
dilatation (indicating impaired endothelial function) and increased carotid artery intima-media 
thickness (an index of atherosclerosis); suggesting lower bilirubin concentrations were inversely 
associated with an elevated risk of atherosclerosis (Erdogan et al., 2006). 
Regarding activity of anthocyanins on HO expression, cyanidin-3-glucoside has been reported to 
upregulate expression of HO-1 in human iliac artery endothelial cells (Sorrenti et al., 2007), and 
serum samples obtained from healthy subjects following ingestion of 160mg purified anthocyanins 
elicited Nrf2 nuclear translocation and HO-1 expression in cultured HUVECs (Cimino et al., 2013).  
Moreover, delphindin-3-glucoside has previously been reported to enhance survival of murine 
hepatocytes exposed to a cytotoxic concentration of epigallocatechin-3-gallate through upregulation 
of HO-1 mRNA levels (Inoue et al., 2012); and Hwang et al (2011) have described protection against 
dimethylnitrosamine-induced hepatic fibrosis in rats elicited by an anthocyanin fraction purified from 
purple sweet potato, mediated in part through expression of Nrf2-regulated genes including HO-1 
(Hwang et al., 2011).  Therefore, activation of Nrf2-mediated expression of HO-1 and other 
antioxidant enzymes by anthocyanins could enhance protection against oxidative stress in 
endothelial cells. 
1.5 Summary and concluding remarks 
It is hoped that the foregoing review has illustrated not only current knowledge regarding 
anthocyanin availability in foodstuffs, dietary intake, and bioavailability/bioactivity; but also areas 
where, to date, limited or no data are available.  As discussed in section 1.3.1, the high content of 
anthocyanins found in berries and grapes suggests a substantial daily intake of anthocyanins might 
be achieved by consumption of these foods, and derived beverages (such as fruit juices) (Manach et 
al., 2005, Zamora-Ros et al., 2011).  Indeed, 400 - 500mg of anthocyanins could be consumed in one 
serving (Kay et al., 2009).  Moreover, epidemiological data indicate consumption of flavonoid-rich 
foodstuffs is inversely associated with CVD risk (Erdman et al., 2007, Geleijnse and Hollman, 2008, 
Wallace, 2011); whilst dietary intake of anthocyanins has been inversely related to arterial stiffness 
(Jennings et al., 2012), hypertension (Cassidy et al., 2010), and CHD & CVD morbidity and mortality 
[(Mink et al., 2007, McCullough et al., 2012, Cassidy et al., 2013), refer also to section 1.4.2].  Data 
from animal and in vitro studies, as discussed in sections 1.4.1 and 1.4.2 - 1.4.5, suggest anthocyanins 
may act to increase NO bioavailability; for example as measured by endothelium- and NO-dependent 
vasorelaxation (Bell and Gochenaur, 2006, Ziberna et al., 2013).  This could be effected directly by 
upregulation/stimulation of eNOS (Xu et al., 2004b, Xu et al., 2004a, Lazze et al., 2006, Edirisinghe et 
al., 2011, Paixão et al., 2012), or potentially indirectly by inhibition of endothelial NOX and reduced 
scavenging of NO by generated superoxide [(Cassidy et al., 2010), refer also to sections 1.4.4 & 1.4.5]; 
with beneficial effects on vascular endothelial (and thus cardiovascular) function, given the role of 
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endothelium-derived NO as a key mediator of vascular homeostasis (Kawashima and Yokoyama, 
2004).  Anthocyanins, or derived species, might also act to increase expression of haem oxygenase-1 
(Sorrenti et al., 2007, Cimino et al., 2013) with resultant protection against cellular oxidative stress 
(He et al., 2010). 
However, and as noted previously, the physiological relevance of compounds and doses examined in 
animal and in vitro studies must always be considered (Crozier et al., 2009, Wallace, 2011).  Phenolic 
acid/aldehyde degradation products and/or metabolites have been reported in human 
plasma/serum at higher levels than parent glycoside(s) following ingestion of anthocyanins 
(Vitaglione et al., 2007, Azzini et al., 2010, Czank et al., 2013), and are likely to mediate the observed 
bioactivity (Wallace, 2011).  Indeed, Czank et al (2013) have reported a 42-fold greater abundance of 
metabolites in the systemic circulation relative to the parent anthocyanin in a human tracer study 
(Czank et al., 2013). 
In conclusion, future research into vascular bioactivity of anthocyanins must use not only parent 
glycosides, but also identified in vivo degradants and metabolites, and all species should be assayed 
at physiologically relevant concentrations.  The capacity of anthocyanins and derived species to 
inhibit NOX activity and upregulate eNOS at physiologically relevant levels should be examined in a 
vascular endothelial cell model (as described in Chapters 2 & 3 respectively), as structurally similar 
compounds have demonstrated NOX inhibitory activity (Steffen et al., 2008, Cassidy et al., 2010).  
Investigating the molecular mechanisms by which anthocyanins, or their bioactive derivatives, may 
modulate key vascular enzymes is essential in understanding the potential cardioprotective effects of 
anthocyanins, as increased consumption of dietary anthocyanins might represent a simple measure 
to reduce the relative risk of CVD. 
1.6 Hypothesis and aims of present thesis 
It is hypothesised that the reported vasoprotective properties of anthocyanins may be elicited by 
their in vivo degradation products and metabolites, which act by directly stimulating eNOS 
expression and activity, and/or indirectly through inhibiting NOX function and reducing scavenging of 
NO by generated ROS; ultimately elevating NO levels and enhancing vascular function.  The aims of 
the current thesis were therefore as follows: firstly, to compare the in vitro vascular bioactivity of 
selected parent anthocyanins with their phenolic acid degradation products, by screening 
physiologically relevant concentrations (0.1, 1, 10µM) for effects on eNOS expression and activity, 
and angiotensin II-stimulated superoxide production by NOX, in human vascular endothelial cells 
(Chapters 2 & 3); secondly, to explore the potential for interactions between a parent anthocyanin, 
or its phenolic acid degradation product, with other dietary bioactive compounds often present in 
sources of anthocyanins such as berries and berry-derived juices, by screening treatment 
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combinations (at cumulative concentrations of 0.1, 1, 10µM) for effects on eNOS expression and 
activity, and angiotensin II-stimulated superoxide production by NOX, in human vascular endothelial 
cells (Chapters 2 & 3); thirdly, to investigate cellular and molecular mechanisms potentially 
underlying observed reductions in stimulated endothelial superoxide production (Chapter 2) by using 
a selected degradation product (vanillic acid, at 0.1, 1, 10µM) to explore modulation of stimulated 
expression of NOX isoforms and subunits, and expression of HO-1 (as a possible indirect mechanism 
of NOX inhibition), in human venous and arterial endothelial cells (Chapters 4 - 6). 
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2 Modulation of angiotensin II-induced superoxide production 
by anthocyanin glucosides and phenolic acid degradants 
2.1 Background 
Impairment of vascular endothelial function, in particular reduced bioavailability of nitric oxide (NO), 
is a critical stage in the development of atherosclerosis (Kawashima and Yokoyama, 2004, Higashi et 
al., 2009).  Loss of NO in vascular pathologies may be primarily mediated by reaction with superoxide 
anion (O2
.-) (Wever et al., 1998, Naseem, 2005), an important source of which is vascular NADPH 
oxidase or NOX enzymes (Bonomini et al., 2008, Higashi et al., 2009).  NOX4 is reported to be the 
predominant isoform expressed in the vascular endothelium (Bedard and Krause, 2007) and appears 
to generate hydrogen peroxide (Brown and Griendling, 2009); whilst NOX2 generates superoxide 
anion (Brandes et al., 2010), and is thought to be of considerable importance in the regulation of 
human vascular function by reducing NO bioavailability (Brown and Griendling, 2009, Schroder, 
2010).  Inhibition of NOX activity has been proposed as a mechanism by which specific flavonoids 
may increase NO bioavailability, thereby improving vascular function (Schewe et al., 2008). 
Anthocyanins, or their phenolic acid degradants, which contain a catechol or mono-O-methylated B-
ring (Figure 2.1) might demonstrate NOX inhibitory activity; based upon structural similarities with 
the vasoactive compound apocynin (Cassidy et al., 2010), and structure-activity studies of the 
flavanol (-)-epicatechin (Steffen et al., 2007b, Steffen et al., 2008).  In the current investigation, 
selected anthocyanin glucosides and their phenolic acid degradants (Figure 2.1 A) were screened to 
examine their effect on angiotensin II-stimulated superoxide production by endothelial NOX, using a 
previously reported assay (Rueckschloss et al., 2002, Steffen et al., 2007a, Steffen et al., 2007b, 
Steffen et al., 2008) which was optimised as detailed herein.  Anthocyanins which contained a 3’, 4’-
catechol B-ring susceptible to methylation [cyanidin, Figure 2.1 A (1), and its B-ring degradant 
protocatechuic acid, (2)], or an existing 3’-mono-methylated catechol B-ring [peonidin, (3) and its B-
ring degradant vanillic acid, (4)], or a modified methylated catechol B-ring structure [petunidin, (5), 
malvidin, (6), and the B-ring degradant of malvidin, syringic acid, (7)] were selected for bioactivity 
screening.  Two combination treatments of cyanidin-3-glucoside, or protocatechuic acid, in 
combination with the flavonol quercetin [Figure 2.1 B (8)], epicatechin (9), and ascorbic acid [vitamin 
C, (10)] were also examined; representing commonly occurring bioactive compounds in foods and 
derived juices (Levine et al., 1999, Manach et al., 2005) and thus reflecting dietary intake of a range 
of flavonoids. 
Cytotoxicity of the selected treatment compounds was assessed prior to bioactivity screening, to 
confirm that these compounds were not cytotoxic at the concentrations utilised.  The production of 
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superoxide anion by endothelial NOX was stimulated using angiotensin II, and quantified by 
concomitant one electron reduction of ferricytochrome c reagent; in the absence and presence of 
superoxide dismutase [which catalyses dismutation of superoxide to hydrogen peroxide (Forman et 
al., 2002)] to determine the level of cytochrome c reduced by generated superoxide.  Finally, 
endothelial cell lysates generated during bioactivity screening were analysed by immunoblotting to 
investigate possible modulation of expression of NOX2 and NOX4 isoforms by anthocyanin phenolic 
acid degradants; as degradants or metabolites may mediate at least part of anthocyanin bioactivity in 
vivo (Williamson and Clifford, 2010). 
Figure 2.1 Treatment compounds for vascular bioactivity screening. 
 
    
 
 
    
 
 
        
B  Treatment combinations:  C3G (1) OR PCA (2) in combination with 
 
      
2.2 Materials and methods 
Standards and reagents.  Cyanidin-3-glucoside, peonidin-3-glucoside and malvidin-3-glucoside were 
purchased from Extrasynthese (Genay Cedex, France); petunidin-3-glucoside from Polyphenols 
Laboratories AS (Sandnes, Norway); VAS2870 from Enzo Life Sciences [Exeter, United Kingdom (UK)]; 
and protocatechuic acid, vanillic acid, syringic acid, (-)-epicatechin, quercetin and L-ascorbic acid 
from Sigma-Aldrich [Poole, United Kingdom (UK)].  Standard solutions were prepared in 100% 
dimethylsulphoxide (DMSO) from Sigma-Aldrich (molecular biology grade) at concentrations of 
40mM for anthocyanins and 200mM for all other treatment compounds.  Cell proliferation reagent 
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WST-1 was obtained from Roche Applied Science (Burgess Hill, UK).  Human angiotensin II (synthetic), 
bovine serum albumin (BSA), (octylphenoxy)polyethoxyethanol (IGEPAL® CA-630), bovine erythrocyte 
superoxide dismutase (SOD), bovine heart cytochrome c, fibronectin, and Medium 199 were 
purchased from Sigma-Aldrich, and Medium 199 phenol-red free from Sigma-Aldrich and Invitrogen 
(Paisley, UK).  Foetal bovine serum (FBS, heat-inactivated) was purchased from Biosera (Ringmer, 
UK), safe-lock microcentrifuge tubes from Qiagen (Crawley, UK), and acid-washed glass beads 
(~0.5mm diameter) from Sigma-Aldrich.  All water utilised was of Milli-Q grade (18.2 MΩ cm-1). 
NuPAGE sample reducing agent and LDS sample buffer were purchased from Invitrogen, and 
Precision Plus Protein Dual Colour standards from Bio-Rad Laboratories, Inc (Hemel Hempstead, UK).  
Protein-Free T20 (TBS) blocking buffer was obtained from Fisher Scientific (Loughborough, UK); 
Immobilon-FL PVDF membrane from Millipore (Watford, UK), and InstantBlue protein gel stain from 
Expedeon Protein Solutions (Harston, UK).  Tween® 20 was purchased from Sigma-Aldrich.  Chicken 
polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; AB2302) and rabbit polyclonal 
anti-gp91phox (NOX2; 07-024) were obtained from Millipore; goat polyclonal anti-actin (sc-1615) 
from Santa Cruz Biotechnology, Inc. (California, USA), and rabbit polyclonal anti-NOX4 (ab81967) 
from Abcam (Cambridge, UK).  Donkey anti-chicken IgG (IR dye 680 LT), donkey anti-goat IgG (IR dye 
680), goat anti-rabbit IgG (IR dye 800 CW) and donkey anti-rabbit IgG (IR dye 800 CW) were supplied 
by Li-Cor (Cambridge, UK).  Antibodies were prepared in a diluent of 50% T20 blocking buffer:50% 
phosphate-buffered saline (PBS) with 0.5% Tween® 20; and including 0.02% sodium dodecyl sulphate 
for solutions of IR dye 680 LT anti-IgG antibodies. 
Cell culture.  Cryo-preserved, early passage, pooled human umbilical vein endothelial cells (HUVECs) 
were purchased from TCS CellWorks (Buckingham, UK) and used between passages two to four.  Cells 
were routinely cultured in Nunclon™ ∆ 75cm2 flasks in large vessel endothelial cell growth medium 
[TCS CellWorks; proprietary basal medium formulation supplemented with growth factor and 
antibiotic (gentamicin & amphotericin B) supplements, final concentration of 2% v/v foetal bovine 
serum] at 37°C and 5% CO2.  HUVECs were sub-cultured using 0.025% trypsin and 0.01% EDTA (TCS 
CellWorks). 
Cytotoxicity assay.  Cell viability was determined using cell proliferation reagent WST-1 [(4-[3-(4-
Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate)] (Berridge et al., 1996); 
whereby metabolically active cells cleave this tetrazolium salt to a water-soluble formazan dye, 
through the activity of mitochondrial succinate-tetrazolium reductase (Ngamwongsatit et al., 2008).  
Cytotoxicity assay method development was conducted as detailed in Appendix 9.1.  The optimised 
cytotoxicity assay was conducted using 96-well microplates (BD Falcon®) coated with fibronectin 
(0.42µg/cm2), which were seeded with HUVECs at a density of ~10,000 cells/well.  Cells were 
subsequently grown to confluence (~24-48 hours at 37°C and 5% CO2).  Culture medium was then 
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aspirated, and solutions of the treatment compounds (0.5, 1, 10, 50 or 100µM; maximum 0.25% 
DMSO) prepared in supplemented large vessel endothelial cell growth medium were added to 
relevant wells at a volume of 100µl/well.  The assay controls consisted of wells with media only 
(control), wells with DMSO in media (vehicle control), and blank wells (vehicle control only, no cells).  
Four replicate wells were used for each control and treatment solution.  The microplates were 
incubated for 24 hours at 37°C and 5% CO2; after which 10µl WST-1 reagent was added to each well, 
and plates were incubated for a further four hours prior to brief agitation.  Absorbance was then 
measured at 440-450nm using a microplate reader [Fluostar Omega or Polarstar Optima, BMG 
Labtech (Aylesbury, UK)]. 
2.2.1 Method development: stimulated superoxide production assay 
Preliminary experiments conducted in 6-well plates, using a cell seeding density of 47,500-57,000 
cells/well, yielded inconsistent results and indicated a need for further method development.  Ten 
key research papers selected for review were analysed, and data were summarised for nine method 
parameters; including cell seeding density, assay medium utilised, percentage of serum in the assay 
medium, stress agent and incubation time with the stress agent (Appendix Table 9.2.2).  Figure 2.2 
summarises the method development process. 
Figure 2.2 Stimulated superoxide production assay method development flow chart. 
 
 
 
 
 
Cell seeding density (A).  Whilst not all reports reviewed provided full details of assay methodology, 
the previously utilised cell seeding density was below that used in several other studies.  Therefore, 
the effect of an elevated cell seeding density (100,000 cells/well for 6-well plate) was evaluated with 
basal (treatment media only), angiotensin II and vanillic acid (phenolic acid degradant of peonidin 
glycoside) treatments (Figure 2.2 A).  A substantial increase in superoxide levels following 
angiotensin II stimulation was observed at a seeding density of 100,000 cells/well, as compared with 
unstimulated cells (~718% of basal superoxide levels) (Figure 2.3).  Superoxide levels were reduced 
following exposure of cells to vanillic acid in conjunction with angiotensin II (~536% of basal 
superoxide levels).  Therefore, a cell seeding density of 100,000 cells/well was utilised for subsequent 
method development. 
Fibronectin Agitation 
with beads 
24-well 
plate 
65U SOD 
 
2% FBS 100,000 
cells/well 
A. Cell 
seeding 
density 
50-100,000 
cells/well 
B. Serum 
conditions 
0.5% vs. 
2% 
FBS 
 
C. Super-
oxide 
dismutase 
400U vs. 
65U 
 
D. Assay 
format 
6-well or 
24-well 
plate 
E. Cell 
disruption 
Sonication/ 
agitation 
with beads 
F. Plate 
coating 
Uncoated 
vs. 
fibronectin 
59/185 
Figure 2.3 Modulation of superoxide production by HUVECs after treatment with angiotensin II/Ang II 
(0.1µM), and Ang II (0.1µM) with vanillic acid/VA (1µM). 
 
SOD-corrected mean absorbance (OD) ratio (550/620nm) normalised to protein, expressed as percentage of control 
(basal; designated as 100%) in stimulated superoxide production assay (6-well plate format).  Data are graphed as 
mean ± SD (n=2). 
Serum (B) and superoxide dismutase (C) conditions.  Experiments were performed to investigate the 
use of low-serum (0.5%) conditions during the six-hour incubation with angiotensin II and treatment 
compounds (‘serum starved’; Figure 2.2 B), or an elevated level of superoxide dismutase (400U, with 
20 µM cytochrome c; Figure 2.2 C).  However, poor cell viability was observed during these 
experiments, and therefore no changes were made to the assay methodology. 
Assay format (D).  In order to establish if screening efficiency could be increased, treatment 
compounds were tested in a 24-well plate format (Figure 2.2 D) as opposed to a 6-well plate format.  
HUVEC seeding density was adjusted in accordance with reduced well surface area (~20,000 
cells/well for 2cm2 surface area).  It was determined that screening could be conducted in 24-well 
plates, and therefore this format was utilised in subsequent method development. 
Cell disruption (E).  Optimisation was conducted for cell disruption methodology following harvesting 
of cells from culture plates (Figure 2.2 E), for protein quantitation and normalisation of the 
absorbance data.  Initially cell solutions were subject to probe sonication, but in order to improve 
efficiency cell disruption was performed by rapid agitation with acid-washed glass beads (~0.5mm 
diameter).  Aliquots of a sample HUVEC lysate were subject to cell disruption by each method, and 
the total protein was measured to confirm comparable recovery from each method.  No significant 
difference was observed between the two methods based on calculated protein concentration (1.11 
± 0.19 mg/ml with sonication versus 1.04 ± 0.03 mg/ml after agitation with beads; mean ± SD, n=3 
for protein assay).  As such, cell disruption was performed by rapid agitation with glass beads in the 
subsequent stages of method development. 
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Plate coating (F).  Initial screening data for treatment compounds, generated using the parameters 
identified above, demonstrated considerable variance in corrected absorbance measurements; 
particularly for phenolic acid degradants.  In order to improve assay reliability and reproducibility, 
the use of a fibronectin-coated surface for HUVEC culture (Baudin et al., 2007) was investigated as 
described previously (Figure 2.2 F). 
24-well plates were washed with warm PBS, and incubated with 100µl/well of 5µg/ml fibronectin (in 
PBS) for 60 minutes at room temperature.  Plates were then rinsed with PBS, dried, and stored at 4°C 
until use.  Syringic acid was screened for bioactivity using HUVECs cultured on fibronectin-coated 
plates, as opposed to uncoated plates, which resulted in reduced variation in assay data (Figure 2.4); 
particularly for 0.1µM syringic acid (coefficient of variation 110% with uncoated plate versus 19% 
with fibronectin coating).  Thus, the use of fibronectin-coated plates enhanced the reliability of the 
stimulated superoxide production assay, and was incorporated into the optimised methodology. 
Figure 2.4 Effect of uncoated (A) and fibronectin-coated (B) 24-well plates upon variation in corrected 
mean absorbance for syringic acid screened in stimulated superoxide production assay. 
 
SOD-corrected mean absorbance (OD) ratio (550/620nm), expressed as percentage of reference (angiotensin II; 
designated as 100% and denoted by dashed line), for syringic acid (structure inset) screened in stimulated superoxide 
production assay (24-well plate format) at 0.1, 1 and 10µM; using uncoated (A) and fibronectin-coated (B) 24-well 
plates.  Data are graphed as mean ± SD (n=3).  *Significant difference versus angiotensin II reference (*p < 0.05 and **p 
< 0.01 respectively); columns with different superscript letters are significantly different (p < 0.05). 
2.2.2 Method development: endothelial NOX expression 
Seven research reports detailing immunoblot analysis of cell lysates for the expression of NOX 
isoforms and/or endothelial nitric oxide synthase (eNOS) were reviewed (Appendix Table 9.2.3); as 
modulation of eNOS expression by anthocyanins & phenolic acid degradants was to be examined in 
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related studies (refer to Chapter 3).  Data were extracted for eleven key parameters, including 
amount of protein loaded for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), primary antibody utilised and concentration, and loading control antibody used and 
concentration (Figure 2.5).  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and actin served 
as ubiquitously expressed loading control proteins (Appendix Table 9.2.3). 
Figure 2.5 Immunoblotting method optimisation flow chart. 
 
 
 
 
 
*based on manufacturer’s recommendations 
Protein loading (A).  Expression of two loading controls, GAPDH and actin, was examined in lysates 
from unstimulated HUVECs using 10, 15 and 20µg of total protein (Figure 2.5 A).  Distinct bands were 
visualised at all protein loading levels (Figure 2.6); however, 20µg of protein was selected as the 
optimum amount of cell lysate to load for gel electrophoresis and immunoblotting owing to the 
reported low expression of NOX proteins (Brandes et al., 2010). 
Loading control antibody dilution (B).  Two concentrations of each antibody (Figure 2.5 B) were used 
to detect the loading control protein (1/2,000 & 1/10,000 for anti-GAPDH; 1/5,000 & 1/10,000 for 
anti-actin).  Clear bands were visualised in all cases (Figure 2.6); thus the loading control antibodies 
were used at a dilution of 1/10,000, since a more concentrated solution was not required for 
detection of protein. 
Figure 2.6 Effect of protein loading and primary antibody concentration on detection of loading controls 
by Western blotting. 
(A) 1/2,000 anti-GAPDH 1/10,000 anti-GAPDH 
 
  
       
(B) 1/5,000 anti-actin 1/10,000 anti-actin 
 
  
       
Protein:   10µg 15µg  20µg     10µg 15µg  20µg 
Detection of GAPDH (A) and actin (B) in lysates from unstimulated HUVECs by immunoblotting, at varying primary 
antibody concentrations and amount of total protein loaded for electrophoresis. 
Anti-NOX antibody dilution (C).  Endothelial expression of NOX2 and NOX4 was examined using 
lysates from unstimulated HUVECs, and from cells harvested following a six hour incubation with 
0.1µM angiotensin II; using anti-NOX antibodies at dilutions based on manufacturer’s 
A. Protein loading 
10µg, 15µg, 20µg 
B. Loading control 
antibody dilution 
1/2,000 – 1/10,000 
C. Anti-NOX antibody 
dilution* 
1/500 (NOX4) 
1/1,000 (NOX2) 
20µg 1/10,000 No change 
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recommendations (1/1,000 for anti-NOX2, 1/500 for anti-NOX4; Figure 2.5 C).  NOX4 expression was 
detected after angiotensin II stimulation, in accordance with previous reports (Bedard and Krause, 
2007, Brown and Griendling, 2009); whilst a band identified as NOX2 (Jiang et al., 2006) was 
visualised more faintly following angiotensin II treatment (Figure 2.7).  However, imaged NOX bands 
were of diminished intensity relative to the loading control (actin), and no signal was detected when 
anti-NOX4 was used at a concentration of 1/1,000 (data not shown).  Therefore, anti-NOX antibodies 
were used at initially selected concentrations. 
Figure 2.7 Detection of NOX2 and NOX4 protein in HUVEC lysates. 
 1/1,000 anti-NOX2  1/500 anti-NOX4  
  
  NOX2 
 
NOX4 
     
 
  
 
 
 
 Basal Angiotensin II 
(0.1µM) 
 Basal Angiotensin II 
(0.1µM) 
 
Detection of NOX2 and NOX4 protein (with actin loading control) in cell lysates from unstimulated HUVECs (basal) and 
following 6h incubation with angiotensin II. 
2.2.3 Final methodology 
Stimulated superoxide production assay: optimised parameters.  The optimised angiotensin II 
stimulated superoxide production assay utilised 24-well plates (Nunclon™ ∆) coated with fibronectin 
(0.25µg/cm2), which were seeded with HUVECs at a density of ~50,000 cells/well, and the cells grown 
to confluence (~48 hours at 37°C and 5% CO2).  Culture medium was then aspirated, and the cells 
were washed once with warm Medium 199 (supplemented with 2% FBS), prior to a 16 - 18 hour 
incubation in this medium (at 37°C and 5% CO2).  Thereafter, the cells were washed once with warm 
PBS, and incubated for six hours in Medium 199 (2% FBS) with 0.1µM angiotensin II, 30µM 
ferricytochrome c, and 0.1, 1 or 10µM of the treatment compounds or 5µM VAS2870 [selective NOX 
inhibitor (Stielow et al., 2006, Altenhofer et al., 2012)]; in the presence or absence of 65U superoxide 
dismutase.  Four replicate wells were plated for each treatment.  After incubation, aliquots of the cell 
supernatants from each well were transferred to a 96-well microplate, for measurement of 
absorbance at 550nm (reference wavelength 620nm) using a microplate reader (Fluostar Omega, 
BMG Labtech). 
After aspiration of the remaining supernatant, 24-well plates were subsequently frozen at -80°C for 
protein extraction.  Cells were harvested and lysed in 1% (octylphenoxy)polyethoxyethanol, 150mM 
NaCl, 20mM Tris and 10% glycerol (pH 8.0), supplemented with protease inhibitors (Complete 
Protease Inhibitor Cocktail).  Briefly, 24-well plates were incubated with lysis buffer (120µl/well) for 
30 minutes at 4°C, prior to removal of cells by scraping.  Recovered solutions were subject to cell 
Actin 
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disruption by rapid agitation (50Hz for 5 minutes using Qiagen TissueLyser LT) with acid-washed glass 
beads in safe-lock microcentrifuge tubes.  After centrifugation at 13,000 rpm (15 minutes at 4°C), the 
protein content of the supernatants was assayed using the Pierce BCA Protein Assay Kit according to 
manufacturer’s instructions. 
Immunoblot analysis of endothelial NOX expression: optimised parameters.  Cell lysates from the 
superoxide production assay were generated as described above.  Briefly, 6-well plates (Nunclon™ ∆) 
were seeded with HUVECs at a density of 100,000 cells/well and cells grown to confluence, prior to a 
16 - 18 hour incubation in Medium 199 (2% FBS) at 37°C and 5% CO2.  Thereafter, cells were 
incubated for six hours in Medium 199 (2% FBS) with 0.1µM angiotensin II, 30µM ferricytochrome c, 
and 0.1, 1 or 10µM of the treatment compounds; in the presence or absence of 65U superoxide 
dismutase.  Cells were harvested and lysed, and recovered solutions were then subject to cell 
disruption by rapid agitation with glass beads.  After centrifugation at 13,000 rpm (15 minutes at 
4°C), the protein content of the supernatants was assayed using the Pierce BCA Protein Assay kit. 
For gel electrophoresis, samples were reduced using NuPAGE sample reducing agent (50 mM 
dithiothreitol) prior to gel loading in NuPAGE LDS sample buffer.  Precision Plus Protein Dual Colour 
standards were loaded as comparative molecular weight markers.  Normally 20µg of protein was 
loaded onto a 4% polyacrylamide stacking gel, and separated across a 10% resolving gel (at 25mA for 
approximately one hour) prior to semi-dry transfer to Immobilon-FL PVDF membrane (at 200mA for 
approximately 90 minutes).  Equal protein transfer was confirmed by InstantBlue staining of the gels.  
Membranes were blocked with T20 blocking buffer for one hour at room temperature, and 
incubated overnight (at 4°C) in the appropriate concentration of primary and loading control 
antibody.  Membranes were washed using PBS with 0.1% Tween® 20 (PBST 0.1%), after which 
secondary antibody incubations were performed for one hour at room temperature, using IR dye-
conjugated (680 and 800) secondary antibodies at a concentration of 1 in 10,000.  Membranes were 
washed with PBST 0.1%, and subsequently imaged using an Odyssey Infrared Imaging System (Li-
Cor).  Immunoblots were quantified by densitometry using Odyssey Infrared Imaging System 
Application Software (Li-Cor, version 3.0.21). 
Statistical analysis.  Analysis of variance (ANOVA) with Tukey post-hoc test, or independent samples 
t-test as appropriate, was performed using SPSS software (IBM, New York, USA) version 18 for 
Windows.  Significance was determined at the 5% level, and expressed relative to control (culture 
medium only) or angiotensin II (positive control).  Three biological replicates for each 
control/treatment were utilised for analysis unless otherwise noted. 
For each control or treatment in the stimulated superoxide production assay, mean absorbance ratio 
(550nm/620nm) in the presence of superoxide dismutase (n=3) was subtracted from individual 
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absorbance ratio values in the absence of superoxide dismutase (n=3); to correct for cytochrome c 
reduction owing to generated superoxide anion.  Mean SOD-corrected absorbance ratio was then 
represented graphically; error bars in figures denote one standard deviation (SD) from the mean.  
Data for mean reduction of cytochrome c measured at 550nm (with and without SOD correction), 
and expressed as mM [molar extinction coefficient/ɛ = 21.1mM-1 cm-1 (Steffen et al., 2007b, Steffen 
et al., 2008)], for controls and treatment compounds/combinations are provided in Appendix 9.3 
(Figure 9.3.1 - Figure 9.3.4). 
2.3 Results 
Cytotoxicity assay.  Seven unique treatments and two treatment combinations (Figure 2.1) were 
screened for cytotoxicity at a concentration of 10µM, representing the highest concentration used in 
subsequent bioactivity investigations, using optimised methodology.  For the two treatment 
combinations, a cumulative concentration of 10µM was utilised, consisting of an equimolar ratio of 
all compounds.  No significant effects (p > 0.05) on endothelial cell viability were observed following 
a 24h incubation of HUVECs with 10µM of any treatment, or with the vehicle control (0.25% DMSO) 
(Figure 2.8). 
Figure 2.8 Assessment of cytotoxicity of anthocyanins, phenolic degradants and treatment combinations 
following 24h incubation with cultured HUVECs. 
 
Cell viability (mean absorbance as percentage of mean control absorbance) for control (supplemented culture 
medium), vehicle control (culture medium with 0.25% DMSO), and 10µM cyanidin-3-glucoside (C3G), malvidin-3-
glucoside (M3G), peonidin-3-glucoside (Peo3G), petunidin-3-glucoside (Pet3G), protocatechuic acid (PCA), vanillic acid 
(VA), syringic acid (SA), cyanidin-3-glucoside combination (C3G + epicatechin + quercetin + ascorbic acid) or 
protocatechuic acid combination (PCA + epicatechin + quercetin + ascorbic acid).  Data are graphed as mean ± SD 
(n=3). 
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Stimulated superoxide production assay.  Incubation of HUVECs with 0.1μM angiotensin II for six 
hours resulted in increased superoxide levels relative to basal (unstimulated) cells (Figure 2.9); 
moreover this increase was abolished by co-incubation with superoxide dismutase (Ang II + SOD), 
such that superoxide levels were not significantly different from basal (p > 0.05) but significantly 
lower than angiotensin II alone (p < 0.05). 
Figure 2.9 Elevation of superoxide levels by angiotensin II (0.1μM) following 6h incubation in HUVEC 
model. 
 
Mean absorbance (OD) ratio (550nm/620nm), for basal (unstimulated) cells, angiotensin II control (Ang II, 0.1μM) and 
Ang II with superoxide dismutase (SOD) correction in stimulated superoxide production assay (24-well plate format).  
Data are graphed as mean ± SD (n=8).  †Significant difference versus angiotensin II (p < 0.05). 
The generation of superoxide anion by endothelial NOX following angiotensin II stimulation was 
confirmed using an established NOX inhibitor, VAS2870 (Stielow et al., 2006, Altenhofer et al., 2012), 
at 5µM in the presence and absence of angiotensin II.  Following co-incubation of HUVECs with 
angiotensin II and VAS2870, superoxide levels were significantly reduced relative to incubation with 
angiotensin II alone (p < 0.05); moreover 5µM VAS2870 was without effect on basal superoxide levels 
(Figure 2.10). 
With regard to bioactivity of treatment compounds, significantly elevated superoxide levels were 
observed following incubation of cells with 0.1µM and 1µM cyanidin-3-glucoside (catechol B-ring; 
Figure 2.11 A), as compared with angiotensin II alone.  In contrast, statistically significant reductions 
in superoxide were elicited by the anthocyanins peonidin-3-glucoside (mono-O-methylated catechol 
B-ring; Figure 2.11 B) at 0.1µM and 10µM; malvidin-3-glucoside (methylated catechol B-ring with 5’-
methoxy group; Figure 2.11 C) at 10µM; and petunidin-3-glucoside (methylated catechol B-ring with 
5’-hydroxy group; Figure 2.11 D) at 1µM and 10µM.  In addition, decreased superoxide levels with 
10µM peonidin-3-glucoside were significantly different from those following 0.1µM exposure levels 
(Figure 2.11 B). 
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Figure 2.10 Modulation of angiotensin II-stimulated endothelial superoxide production by NOX 
inhibitor VAS2870. 
 
SOD-corrected mean absorbance (OD) ratio (550nm/620nm), for basal (unstimulated) cells, angiotensin II control (Ang 
II, 0.1μM), 5µM VAS2870 (NOX inhibitor) with 0.1µM Ang II (VAS2870 + Ang II), and 5µM VAS2870 in stimulated 
superoxide production assay (24-well plate format).  Data are graphed as mean ± SD (n=3).  †Significant difference 
versus angiotensin II (p < 0.05). 
 
Statistically significant reductions in superoxide levels were also elicited by anthocyanin B-ring 
degradants.  In contrast to the parent anthocyanin cyanidin-3-glucoside, a substantial decrease in 
superoxide was observed with the B-ring degradant protocatechuic acid at 10μM (Figure 2.11 E); to 
levels significantly below those measured for basal (unstimulated) HUVECs in the same assay (data 
not shown).  Vanillic acid (B-ring degradant of peonidin-3-glucoside) elicited reductions in superoxide 
levels at all concentrations examined, with a statistically significant decrease observed at 1µM 
(Figure 2.11 F).  Moreover, following treatment with angiotensin II and vanillic acid, superoxide levels 
were not significantly different from basal cells (data not shown).  Finally, a significant decrease in 
superoxide was elicited by 1µM syringic acid (Figure 2.11 G); and after treatment with angiotensin II 
and 1µM or 10µM syringic acid, superoxide levels were not significantly different from basal cells 
(data not shown). 
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Figure 2.11 Modulation of superoxide levels by cyanidin-3-glucoside (A), peonidin-3-glucoside (B), malvidin-3-glucoside (C), petunidin-3-glucoside (D), protocatechuic acid (E), 
vanillic acid (F), and syringic acid (G) following 6h incubation in angiotensin II-stimulated HUVEC model. 
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SOD-corrected mean absorbance (OD) ratio 
(550nm/620nm), for angiotensin II control (Ang II, 
0.1μM) and cyanidin-3-glucoside (A), peonidin-3-
glucoside (B), malvidin-3-glucoside (C), petunidin-3-
glucoside (D), protocatechuic acid (E), vanillic acid 
(F) and syringic acid (G; structures inset) screened in 
stimulated superoxide production assay (24-well 
plate format) at 0.1, 1 and 10µM.  Data are graphed 
as mean ± SD (n=3).  *Significant difference versus 
angiotensin II control (*p < 0.05 and **p < 0.01 
respectively); columns for treatment concentrations 
with different superscript letters are significantly 
different (p < 0.05); †Significant difference versus 
basal (unstimulated) cells (p < 0.05). 
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No significant changes in superoxide levels were elicited with cyanidin-3-glucoside in combination 
with epicatechin, quercetin and ascorbic acid (Figure 2.12 A); whereas a statistically significant 
reduction was observed with protocatechuic acid in combination with these compounds, at a 
cumulative concentration of 10µM (Figure 2.12 B). 
Figure 2.12 Modulation of superoxide levels by cyanidin-3-glucoside (A) or protocatechuic acid (B) in 
combination with epicatechin, quercetin and ascorbic acid following 6h incubation in 
angiotensin II-stimulated HUVEC model. 
 
SOD-corrected mean absorbance (OD) ratio (550nm/620nm), for angiotensin II control (Ang II, 0.1μM) and equimolar 
ratio of cyanidin-3-glucoside (A) or protocatechuic acid (B) with epicatechin, quercetin and ascorbic acid, screened in 
stimulated superoxide production assay (24-well plate format) at 0.1, 1 and 10µM.  Data are graphed as mean ± SD 
(n=3).  *Significant difference versus angiotensin II control (p < 0.05). 
 
Immunoblot analysis of endothelial NOX expression.  Following angiotensin II stimulation, weak 
immunoreactive bands corresponding to NOX2 were visualised by immunoblotting of endothelial 
lysates, although no substantial modulation of NOX2 expression was observed after incubation with 
angiotensin II and either protocatechuic acid (Figure 2.13 A) or syringic acid (Figure 2.13 C).  NOX2 
protein was poorly detected following incubation of cells with angiotensin II and vanillic acid (Figure 
2.13 B), such that quantification of bands by densitometry was not possible.  Statistical analysis of 
densitometric data from replicate immunoblots was also precluded by poor detection of NOX2 
protein. 
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Figure 2.13 Effect of protocatechuic acid (A), vanillic acid (B) and syringic acid (C) on NOX2 expression by 
HUVECs following angiotensin II stimulation. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Expression of NOX2 protein (with actin or GAPDH loading control) in cell lysates from unstimulated HUVECs (basal) and 
following 6h incubation with angiotensin II 0.1µM (Ang II), or angiotensin II with 0.1µM, 1µM or 10µM protocatechuic 
acid/PCA (A), vanillic acid/VA (B) or syringic acid/SA (C).  Relative molecular weight markers (kDa) are indicated at right-
hand side of immunoblots.  Inset graphs show fold increase in NOX2 expression relative to basal (designated as 1), 
after quantification by densitometry and normalisation to corresponding loading control (n=1; statistical analysis across 
replicate immunoblots was precluded by poor detection of NOX2 protein). 
 
By contrast, upregulation of NOX4 expression after incubation of HUVECs with angiotensin II was 
clearly visualised by immunoblotting (Figure 2.14).  However, the observed increase in NOX4 protein 
levels was not significantly modulated (p > 0.05) by co-incubation of cells with angiotensin II and 
either protocatechuic acid (Figure 2.14 A), vanillic acid (Figure 2.14 B) or syringic acid (Figure 2.14 C) 
at any concentration examined (0.1 - 10µM). 
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Figure 2.14 Effect of protocatechuic acid (A), vanillic acid (B) and syringic acid (C) on NOX4 expression by 
HUVECs following angiotensin II stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of NOX4 protein (with GAPDH loading control) in cell lysates from unstimulated HUVECs (basal) and 
following 6h incubation with angiotensin II 0.1µM (Ang II), or angiotensin II with 0.1µM, 1µM or 10µM protocatechuic 
acid/PCA (A), vanillic acid/VA (B) or syringic acid/SA (C).  Relative molecular weight markers (kDa) are indicated at right-
hand side of immunoblots.  Inset graphs show fold increase in NOX4 expression relative to basal (designated as 1), 
after quantification by densitometry and normalisation to corresponding loading control (mean ± SD, n=5). 
2.4 Discussion 
Cytotoxicity assessment of selected treatment compounds was necessary to ensure endothelial cell 
viability was not affected by these compounds at levels utilised in subsequent vascular bioactivity 
investigations; specifically 0.1, 1, & 10µM.  The maximal level of total dietary flavonoids and related 
compounds reported in the systemic circulation is generally below 10µM (Crozier et al., 2009), thus 
this concentration was used to represent the maximum in vivo concentration.  By contrast, 
~0.1µM/100nM of anthocyanins in plasma has been described in some human bioavailability studies, 
and phenolic acid/aldehyde degradation products or metabolites may be present at levels in excess 
of the parent compound(s) (Vitaglione et al., 2007, Williamson and Clifford, 2010, Azzini et al., 2010).  
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For example, Czank et al (2013) recently reported a serum Cmax of 0.14µM for cyanidin-3-glucoside 
following consumption of 500mg 13C-labelled cyanidin-3-glucoside by healthy volunteers; whereas 
Cmax values for 
13C-labelled phenolic degradants (protocatechuic acid and phloroglucinol aldehyde) 
and phase II conjugates of protocatechuic acid (including vanillic acid) were 0.72µM and 2.35µM 
respectively (Czank et al., 2013). 
Initial cytotoxicity data indicated all treatment compounds tested were cytotoxic between 
concentrations of 0.5µM and 100µM; but no dose-response relationship was evident.  In contrast, 
method development data (Appendix 9.1) indicated a cytotoxic effect of the phenolic degradant 
protocatechuic acid at 100µM but not 1µM in cultured HUVECs.  Cytotoxicity of anthocyanins in vitro, 
at micromolar concentrations, has previously been reported using human vascular endothelial cells; 
for example cyanidin-3-glucoside at ≥62.5µM (Sorrenti et al., 2007), but cytotoxicity at low 
micromolar levels has not been indicated.  Subsequent screening of all treatment compounds at a 
concentration of 10µM (the highest concentration used in bioactivity investigations) using optimised 
methodology revealed no significant reductions in endothelial cell viability with any treatment.  
Therefore no cytotoxicity was observed for the proposed treatment compounds at low micromolar 
levels, which is in accordance with both prior laboratory work, and previously published data 
(Sorrenti et al., 2007). 
Overall, physiologically relevant doses (≤ 10µM) of selected anthocyanin glucosides, and phenolic 
acid degradants, are not cytotoxic to human vascular endothelial cells over a 24 hour period; and 
thus these concentrations were utilised during subsequent assessment of vascular biological activity 
in a HUVEC model of angiotensin II-stimulated superoxide production.  Screening of treatment 
compounds in this model suggested several might act as NOX inhibitors, since significantly reduced 
superoxide levels were observed with 0.1µM & 10µM peonidin-3-glucoside (mono-O-methylated 
catechol B-ring), 10µM malvidin-3-glucoside (methylated catechol B-ring with 5’-methoxy group), 
and 1µM & 10µM petunidin-3-glucoside (methylated catechol B-ring with 5’-hydroxy group).  In 
contrast, a significant elevation in superoxide levels was elicited by 0.1µM and 1µM cyanidin-3-
glucoside (catechol B-ring susceptible to methylation), as compared with angiotensin II alone; 
although this may reflect a low angiotensin II reference within the cyanidin-3-glucoside screen 
(Figure 9.3.3 A).  Interestingly, no significant changes in levels of superoxide were elicited in the 
experiments where cyanidin-3-glucoside was added in combination with epicatechin, quercetin and 
ascorbic acid, though data suggested a possible trend for decreasing superoxide with increasing 
treatment concentration (Figure 2.12). 
Anthocyanin bioactivity in vivo may be mediated by phenolic and aromatic metabolites as opposed 
to parent glycosides (Williamson and Clifford, 2010, Wallace, 2011); moreover, low micromolar levels 
of phenolic degradants/metabolites in human plasma have been reported following ingestion of 
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anthocyanin glucosides (Vitaglione et al., 2007, Azzini et al., 2010, Czank et al., 2013).  Significant 
decreases in superoxide levels were elicited by 10µM protocatechuic acid (B-ring degradant of 
cyanidin-3-glucoside), and 1µM vanillic acid or syringic acid (B-ring degradants of peonidin- and 
malvidin-3-glucosides respectively).  Furthermore, following incubation with vanillic acid at 0.1-
10µM, or syringic acid at 1 & 10µM, superoxide levels were not significantly different from basal 
(unstimulated) HUVECs; and were significantly below basal after treatment with 10µM 
protocatechuic acid.  Superoxide levels were also significantly reduced by a cumulative concentration 
of 10µM of protocatechuic acid, epicatechin, quercetin and ascorbic acid; though the reduction 
observed with this combination treatment was smaller than that for protocatechuic acid alone. 
A limitation of the stimulated superoxide production assay was the variable response in superoxide 
generation observed following angiotensin II stimulation of the cultured HUVEC.  Previous studies 
using this methodology generally do not report induction of superoxide production by angiotensin II 
relative to basal levels, possibly for this reason (Steffen et al., 2007b, Steffen et al., 2008).  Alvarez et 
al (2010) have described limited induction of superoxide production by angiotensin II relative to the 
control in HUVEC cultures (Alvarez et al., 2010).  A limited and variable response has also been 
observed for upregulation of NOX4 mRNA following exposure of HUVEC to 0.1µM angiotensin II 
[(Yamagishi et al., 2005, Alvarez et al., 2010); refer also to Chapter 4], again suggesting inherent 
variability in the response of HUVEC to angiotensin II, and representing a possible limitation of this 
cell type.  Whilst HUVEC are an established in vitro research model for human endothelial cells 
(Baudin et al., 2007), an arterial cell type may be more relevant for investigating potential 
modulation of NOX activity (as explored in Chapter 5). 
In summary, anthocyanin-3-glucosides, and their phenolic acid degradants, appeared to reduce 
superoxide levels following stimulation of HUVECs by angiotensin II.  Screening of three phenolic 
degradants suggested reductions with a catechol B-ring at 10µM (protocatechuic acid), a mono-O-
methylated catechol B-ring at 1µM (vanillic acid), and a methylated catechol B-ring with 5’-methoxy 
group at 1µM (syringic acid); although methylation of a catechol B-ring by endothelial catechol-O-
methyltransferase has been described previously for the flavonoid (-)-epicatechin (Steffen et al., 
2008), yielding monomethyl metabolites which display NOX inhibitory activity [at a concentration 
range around 10µM (Steffen et al., 2007b, Steffen et al., 2008)].  Inhibition of NOX by anthocyanin 
glycosides or derived molecules in vivo, with decreased scavenging of NO by generated superoxide, 
could potentially enhance the function of the vascular endothelium.  Therefore, phenolic degradants 
which appeared to be bioactive in the current investigation were further examined for effects on 
endothelial expression of NOX protein; which represents a potential mechanism by which NOX 
activity, and thus superoxide production, could be reduced. 
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No significant modulation of angiotensin II-induced NOX4 expression was discerned after incubation 
of HUVECs with angiotensin II and protocatechuic acid, vanillic acid or syringic acid; indicating that 
these phenolic acids do not affect enzyme activity at the level of protein expression.  By contrast, 
NOX2 expression was more difficult to discern by immunoblotting of cell lysates, which may reflect 
low protein expression in vascular cells, and/or poor antibody specificity (Brandes et al., 2010), 
although upregulation of NOX2 in HUVECs following angiotensin II stimulation has been reported 
previously (Rueckschloss et al., 2002).  Quantification of immunoblots indicated no consistent effect 
of anthocyanin degradants on NOX2 expression, although owing to poor detection statistical analysis 
was not possible.  The use of a monoclonal anti-NOX2 antiserum, in conjunction with increased 
protein loading for SDS-PAGE, may resolve these issues. 
In conclusion, the anthocyanin degradants protocatechuic acid, vanillic acid, and syringic acid do not 
appear to alter expression of endothelial NOX2 or NOX4 proteins following stimulation of HUVECs 
with angiotensin II.  Therefore, any modulation of NOX activity elicited by these compounds may 
occur at the post-translational level.  NOX2, unlike NOX4, requires additional cytosolic subunits for 
enzyme activity (Schroder, 2010), and the putative NOX inhibitor apocynin is reported to act by 
inhibiting assembly of these subunits (Drummond et al., 2011).  Moreover, vanillic acid contains a 
mono-O-methylated catechol B-ring structure, which is similar to that of apocynin, and might 
therefore affect post-translational regulation of the superoxide-generating NOX2 isoform as 
discussed in Chapters 3 & 5. 
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3 Effect of anthocyanin glucosides and phenolic degradants on 
endothelial nitric oxide synthase expression and nitric oxide 
production 
3.1 Background 
Nitric oxide (NO) is a key mediator of vascular homeostasis, notably through its vasodilatory activity 
as the endothelium-derived relaxing factor (Michel and Vanhoutte, 2010); in addition to inhibiting 
platelet aggregation, oxidation of low density lipoprotein, and expression of cell surface adhesion 
molecules (Wever et al., 1998, Granger et al., 2004, Naseem, 2005).  Most vascular endothelial cells 
constitutively express endothelial nitric oxide synthase (eNOS) (Fleming and Busse, 2003), which 
generates NO in response to fluid shear stress (arising from blood flow over endothelial cells) or 
agonists including bradykinin and oestradiol (Shaul, 2002, Fleming and Busse, 2003). 
A number of in vitro studies have previously reported bioactivity of anthocyanins, or anthocyanin-
rich berry extracts, on endothelium-dependent vasorelaxation; or directly on eNOS 
expression/activation.  Chokeberry and bilberry extracts elicited endothelial- and NOS-dependent 
relaxation of porcine coronary arterial rings (Bell and Gochenaur, 2006); whilst bilberry extract, and 
cyanidin-3-glucoside (1nM - 10μM), induced NO- and endothelium-dependent relaxation of rat 
thoracic aortic rings (Ziberna et al., 2013).  Moreover, 0.1μM cyanidin-3-glucoside upregulated 
expression of eNOS in bovine artery endothelial cells (BAECs) (Xu et al., 2004b), and 0.5μM of this 
anthocyanin elicited regulation of eNOS in BAECs through phosphorylation and dephosphorylation at 
residues Serine 1179 and Serine 116 respectively (Xu et al., 2004a).  Upregulation of eNOS has also 
been reported following incubation of human umbilical vein endothelial cells (HUVECs) with the 
anthocyanidins cyanidin (at 100μM) and delphinidin (at 50 and 100μM) (Lazze et al., 2006); 
furthermore cyanidin-3-glucoside (2.3μg/ml; ~5μM) and delphinidin-3-glucoside (5.8μg/ml; ~12μM) 
activated eNOS in HUVECs, as determined by phosphorylation of Serine 1177 (Edirisinghe et al., 
2011).  Thus upregulation and/or activation of eNOS, and increased endothelial NO production, 
represent mechanisms by which anthocyanins, or their degradants/metabolites in vivo, could 
enhance vascular function through elevated NO bioavailability (Erdman et al., 2007, Wallace, 2011) 
In the current investigation, selected anthocyanin glucosides and their phenolic acid degradants 
(Figure 3.1 A) were screened for their effect on expression of eNOS in cultured HUVECs, and 
endothelial nitric oxide production, to assess relative vascular bioactivity of these compounds.  Two 
combination treatments of cyanidin-3-glucoside or protocatechuic acid, in an equimolar ratio with 
epicatechin, quercetin and ascorbic acid (Figure 3.1 B) were also examined; to represent 
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consumption of a mixture of flavonoids and other bioactive compounds which would be present in 
the habitual diet. 
Figure 3.1 Treatment compounds for vascular bioactivity screening. 
 
    
 
 
    
 
 
        
B  Treatment combinations:  C3G (1) OR PCA (2) in combination with 
 
      
3.2 Materials and methods 
Standards and reagents.  Cyanidin-3-glucoside, peonidin-3-glucoside and malvidin-3-glucoside were 
purchased from Extrasynthese (Genay Cedex, France); petunidin-3-glucoside from Polyphenols 
Laboratories AS (Sandnes, Norway); and protocatechuic acid, vanillic acid, syringic acid, (-)-
epicatechin, quercetin and L-ascorbic acid from Sigma-Aldrich [Poole, United Kingdom (UK)].  
Standard solutions were prepared in 100% dimethylsulphoxide (DMSO) from Sigma-Aldrich 
(molecular biology grade) at concentrations of 40mM for anthocyanins and 200mM for all other 
treatment compounds.  Quantikine Human eNOS Immunoassay was purchased from R&D Systems 
(Abingdon, UK) and Nitrate/Nitrite Colourimetric Assay Kit from Cambridge Bioscience (Cambridge, 
UK).  Resveratrol, tumour necrosis factor-α (TNF-α), and fibronectin were purchased from Sigma-
Aldrich.  All water utilised was of Milli-Q grade (18.2 MΩ cm-1). 
Cell culture.  Cryo-preserved, early passage, pooled human umbilical vein endothelial cells (HUVECs) 
were purchased from TCS CellWorks (Buckingham, UK) and used between passages two to four.  Cells 
were routinely cultured in 75cm2 flasks (SPL Life Sciences) with fibronectin coating (0.27µg/cm2) in 
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large vessel endothelial cell growth medium [TCS CellWorks; proprietary basal medium formulation 
supplemented with growth factor and antibiotic (gentamicin & amphotericin B) supplements, final 
concentration of 2% v/v foetal bovine serum] at 37°C and 5% CO2.  HUVECs were sub-cultured using 
0.025% trypsin and 0.01% EDTA (TCS CellWorks). 
Cell treatments.  24-well plates (SPL Life Sciences) were coated with fibronectin (0.25µg/cm2), and 
seeded with HUVECs at a density of ~30,000 cells/well.  Cells were subsequently grown to confluence 
(~24 - 48 hours at 37°C and 5% CO2).  Culture medium was then aspirated, and solutions of the 
treatment compounds (0.1, 1, or 10µM) prepared in supplemented large vessel endothelial cell 
growth medium (phenol-red free) were added to relevant wells at a volume of 500µl/well.  The assay 
controls included wells with media only (basal), and wells with DMSO in media (vehicle control).  
Three replicate wells were used for each control and treatment solution.  The plates were incubated 
for 24 hours at 37°C and 5% CO2; after which supernatants were removed and stored at -80°C.  Cells 
were washed once with warm phosphate-buffered saline (PBS), and then harvested in 250μl 
trypsin/EDTA and 250μl trypsin-blocking solution (TCS CellWorks).  Cell suspensions were stored at -
80°C until analysis. 
eNOS enzyme-linked immunosorbent assay (ELISA).  Quantification of eNOS in HUVEC lysates was 
performed with a commercially available ELISA (Quantikine, R&D Systems), using a microplate pre-
coated with monoclonal anti-eNOS.  Briefly, cell suspensions were thawed, prior to centrifugation at 
10,000rpm for 10 minutes and supernatant removal.  Cells were then lysed at 2-8°C using assay lysis 
buffer, and centrifuged at 5000rpm for five minutes; the resultant supernatants were subsequently 
assayed in duplicate (100μl per well).  One hundred microlitres of assay diluent was added to each 
well, and the microplate incubated for two hours at room temperature with agitation (500rpm).  
After washing with assay wash buffer, 200μl polyclonal anti-eNOS (conjugated to horseradish 
peroxidase) was added to each well, and the microplate incubated for a further two hours.  Unbound 
antibody was removed by washing; and 200μl/well substrate solution added prior to a 30 minute 
incubation.  After addition of 50μl/well stop solution, end-point absorbance was measured at 450nm 
(reference 540nm) with a microplate reader [Fluostar Omega, BMG Labtech (Aylesbury, UK)]; and 
eNOS quantified based upon a standard curve generated using recombinant human eNOS standard.  
Tumour necrosis factor-α (20ng/ml) was screened as a negative control for eNOS expression 
(Anderson et al., 2004).  The intra-assay coefficient of variation (CV) was 4.67% ± 1.86% [mean ± 
standard deviation (SD), n=3] and the inter-assay CV was 6.10% (n=3). 
Nitrate/nitrite assay.  Nitric oxide production was assessed by quantification of the levels of nitrite 
(NO2
-) and nitrate (NO3
-) decomposition products (Tsikas, 2007) in cell supernatants using a 
colourimetric microplate assay (Nitrate/Nitrite Colourimetric Assay Kit, Cayman Chemical Company).  
Briefly, cell supernatants were thawed, and particulate matter removed by centrifugation at 
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10,000rpm for 10 minutes.  The supernatants were then assayed in duplicate (50μl per well).  Thirty 
microlitres of assay buffer was added to each well, followed by 10μl/well enzyme cofactor mixture 
and 10μl/well nitrate reductase mixture.  The microplate was incubated for two hours at room 
temperature, prior to addition of Griess Reagents R1 and R2 (both at 50μl/well).  End-point 
absorbance was measured at 540nm (reference 690nm) with a microplate reader (Fluostar Omega, 
BMG Labtech) and total NO decomposition products quantified based upon a nitrate standard curve 
generated using nitrate standard.  Resveratrol (100μM) was screened as a positive control for 
endothelial NO production (Wallerath et al., 2002).  The intra-assay CV was 6.63% ± 1.10% (mean ± 
SD, n=3) and the inter-assay CV was 2.38% (n=3). 
Statistical analysis.  Analysis of variance (ANOVA) with Tukey post-hoc test was performed using 
SPSS software (IBM, New York, USA) version 18 for Windows.  Significance was determined at the 5% 
level, and expressed relative to DMSO (vehicle control).  Three biological replicates for each control 
or treatment were utilised for analysis unless otherwise noted, and means of replicates represented 
graphically.  Error bars in figures represent one SD from the mean. 
3.3 Results 
Significant upregulation of eNOS, as compared with vehicle control (p < 0.05), was observed 
following a 24h incubation of HUVECs with 0.1-10µM cyanidin-3-glucoside (Figure 3.2 A), 10μM 
peonidin-3-glucoside (Figure 3.2 B) and 0.1μM petunidin-3-glucoside (Figure 3.2 C).  However, no 
significant alteration in eNOS levels was observed with any concentration of malvidin-3-glucoside 
(Figure 3.2 D). 
No significant modulation of eNOS levels was elicited by the phenolic degradants protocatechuic acid 
(Figure 3.3 A), vanillic acid (Figure 3.3 B) and syringic acid (Figure 3.3 C); although a trend towards 
elevated eNOS relative to vehicle control was observed with 1μM syringic acid (p = 0.177).  
Incubation of HUVECs with cyanidin-3-glucoside, or protocatechuic acid, in combination with 
epicatechin, quercetin and ascorbic acid (in an equimolar ratio) did not significantly alter eNOS 
expression (Figure 3.4).  Tumour necrosis factor-α (negative control) elicited reduced eNOS 
expression relative to basal (220.2 ± 89.3pg/ml versus 419.4 ± 88.0pg/ml respectively; mean ± SD), 
although the reduction was not significant (p > 0.05).  Normalisation of measured eNOS protein 
levels to the total protein concentration of cell lysates assayed may help to reduce variability 
between biological replicates, and should be incorporated into future analyses. 
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Figure 3.2 Modulation of HUVEC eNOS expression by cyanidin-3-glucoside (A), peonidin-3-glucoside (B), 
petunidin-3-glucoside (C) and malvidin-3-glucoside (D) following 24h incubation. 
 
 
 
 
 
 
 
eNOS expression (pg/ml) following 24h incubation of HUVECs with vehicle control (0.05% DMSO in supplemented 
culture medium) or 0.1-10μM of cyanidin-3-glucoside (A), peonidin-3-glucoside (B), petunidin-3-glucoside (C), or 
malvidin-3-glucoside (D; structures inset).  Data are graphed as mean ± SD, n=3.  *Significant difference versus vehicle 
control (p < 0.05). 
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Figure 3.3 Modulation of HUVEC eNOS expression by protocatechuic acid (A), vanillic acid (B), and syringic acid (C) following 24h incubation. 
 
 
   
eNOS expression (pg/ml) following 24h incubation of HUVECs with vehicle control (0.05% DMSO in supplemented culture medium) or 0.1-10μM of protocatechuic acid (A), vanillic acid (B), or syringic acid 
(C, structures inset).  Data are graphed as mean ± SD, n=3. 
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Figure 3.4 Modulation of HUVEC eNOS expression by cyanidin-3-glucoside (A) or protocatechuic acid 
(B) in combination with epicatechin, quercetin and ascorbic acid following 24h incubation. 
 
 
 
eNOS expression (pg/ml) following 24h incubation of HUVECs with vehicle control (0.05% DMSO in supplemented 
culture medium) or 0.1-10μM of equimolar ratio of cyanidin-3-glucoside (A) or protocatechuic acid (B) with epicatechin, 
quercetin and ascorbic acid.  Data are graphed as mean ± SD, n=3. 
 
With regard to effects of treatment compounds on endothelial NO production, anthocyanin-3-
glucosides did not significantly alter levels of NO decomposition products in HUVEC supernatants 
(Figure 3.5), although an apparent elevation in nitrite & nitrate concentrations (p = 0.082) was 
elicited by 1μM malvidin-3-glucoside (Figure 3.5 D). 
No significant modulation of endothelial NO production was observed with 0.1-10μM anthocyanin 
phenolic degradants (Figure 3.6), though all degradants appeared to reduce nitrite and nitrate levels 
relative to vehicle control.  Equally, no significant changes in NO production were detected following 
incubation of HUVECs with cyanidin-3-glucoside, or protocatechuic acid, in combination with 
epicatechin, quercetin and ascorbic acid (Figure 3.7).  Resveratrol (positive control) elicited increased 
levels of NO decomposition products relative to basal (6.39 ± 0.39μM versus 5.34 ± 2.22μM), 
although this increase was not significant (p > 0.05). 
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Figure 3.5 Modulation of endothelial NO production by cyanidin-3-glucoside (A), peonidin-3-glucoside (B), 
petunidin-3-glucoside (C) and malvidin-3-glucoside (D) following 24h incubation. 
 
 
 
 
 
 
 
Concentration of nitrite & nitrate (μM) in cell supernatant following 24h incubation of HUVECs with vehicle control 
(0.05% DMSO in supplemented culture medium) or 0.1-10μM of cyanidin-3-glucoside (A), peonidin-3-glucoside (B), 
petunidin-3-glucoside (C), or malvidin-3-glucoside (D; structures inset).  Data are graphed as mean ± SD, n=3. 
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Figure 3.6 Modulation of endothelial NO production by protocatechuic acid (A), vanillic acid (B), and syringic acid (C) following 24h incubation. 
 
 
   
Concentration of nitrite & nitrate (μM) in cell supernatant following 24h incubation of HUVECs with vehicle control (0.05% DMSO in supplemented culture medium) or 0.1-10μM of protocatechuic acid 
(A), vanillic acid (B), or syringic acid (C, structures inset).  Data are graphed as mean ± SD, n=3. 
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Figure 3.7 Modulation of endothelial NO production by cyanidin-3-glucoside (A) or protocatechuic acid 
(B) in combination with epicatechin, quercetin and ascorbic acid following 24h incubation. 
 
  
Concentration of nitrite & nitrate (μM) in cell supernatant following 24h incubation of HUVECs with vehicle control 
(0.05% DMSO in supplemented culture medium) or 0.1-10μM of equimolar ratio of cyanidin-3-glucoside (A) or 
protocatechuic acid (B) with epicatechin, quercetin and ascorbic acid.  Data are graphed as mean ± SD, n=3. 
3.4 Discussion 
Bioactivity screening of selected anthocyanins and B-ring degradants, for effects upon HUVEC eNOS 
expression and endothelial NO production, indicates differential bioactivity of parent anthocyanins as 
compared to their phenolic degradants.  Cyanidin-3-glucoside has been reported to upregulate eNOS 
in BAECs at 1 - 100nM (Xu et al., 2004b), although not in human iliac artery endothelial cells (HIAEC) 
at ≤ 10μM (Sorrenti et al., 2007); and in the current investigation cyanidin-3-glucoside (at 0.1 - 
10μM), peonidin-3-glucoside (at 10μM) and petunidin-3-glucoside (at 0.1μM), but not malvidin-3-
glucoside, elicited significant upregulation of eNOS protein in HUVECs.  By contrast, the phenolic 
degradants protocatechuic acid (B-ring degradant of cyanidin-3-glucoside), vanillic acid (B-ring 
degradant of peonidin-3-glucoside) and syringic acid (B-ring degradant of malvidin-3-glucoside) did 
not significantly modulate eNOS expression.  Moreover, no significant changes in eNOS levels were 
induced by cyanidin-3-glucoside or protocatechuic acid in combination with quercetin, epicatechin 
and ascorbic acid (at 1 - 10μM in an equimolar ratio).  It should be noted that Steffen et al (2005) 
previously reported no modulation of basal eNOS levels by 40μM epicatechin in both BAECs and the 
endothelial cell line Ea.hy926 (Steffen et al., 2005).  In contrast to eNOS expression, no treatment 
compounds or combinations significantly modulated endothelial NO production, as assessed by 
levels of nitrite and nitrate decomposition products (Tsikas, 2007) in cell supernatants. 
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A limitation of the current investigation was the use of HUVECs, which are extensively used for 
general research concerning human endothelial cells; however, an arterial cell type may be more 
relevant for assessing the potential modulation of endothelial function predisposing to development 
of atherosclerosis (Baudin et al., 2007).  Moreover, no significant effects of treatment compounds 
upon endothelial NO production were detected in this study, yet activation of eNOS by cyanidin-3-
glucoside (through alteration of phosphorylation status at key serine residues) has been described in 
BAECs (Xu et al., 2004a) and HUVECs (Edirisinghe et al., 2011).  Furthermore, significant increases in 
nitrite levels were reported following incubation of HUVECs with malvidin and syringic acid 
(Simoncini et al., 2011), and epicatechin (Persson et al., 2006, Brossette et al., 2011, Simoncini et al., 
2011).  However, in the current investigation nitrite and nitrate decomposition products were 
detected within a range of 3 - 17μM, and it is possible that the modified Griess reaction utilised to 
quantify these products was not sufficiently sensitive to detect submicromolar changes in eNOS 
activity (Granger et al., 1996).  The use of an alternative detection methodology such as reductive 
chemiluminescence (MacArthur et al., 2007), possibly in combination with nitrite- and nitrate-free 
culture medium (Brossette et al., 2011), might address this issue.  In addition, extra time points could 
be included in both eNOS expression and NO production screening assays (for example six, 18 and 36 
hour incubations with treatment compounds or combinations) to ensure detection of bioactivity. 
Overall, only parent anthocyanin glucosides, as opposed to their phenolic degradants or 
combinations of flavonoids with other bioactive compounds, significantly upregulated endothelial 
expression of eNOS.  Bioactivity of anthocyanins was observed in the concentration range 0.1 - 
10μM; and whilst anthocyanin plasma concentrations of ~0.1μM/100nM have been reported in 
some human bioavailability studies, Cmax values are often below 100nM (Manach et al., 2005, McGhie 
and Walton, 2007, Milbury et al., 2010, Wiczkowski et al., 2010).  Indeed, following ingestion of 71mg 
of cyanidin glucosides, Cmax values for cyanidin-3-glucoside and protocatechuic acid in human serum 
were 1.9nM and 492nM (0.5μM) respectively (Vitaglione et al., 2007); and a plasma Cmax of 2.5μM for 
the B-ring degradant 4-hydroxybenzoic acid was reported after ingestion of the parent anthocyanin 
pelargonidin-3-glucoside in 300g fresh strawberries, whilst no anthocyanins were detectable (Azzini 
et al., 2010).  More recently, Czank et al (2013) described a serum Cmax of 0.14µM for cyanidin-3-
glucoside following consumption of 500mg 13C-labelled cyanidin-3-glucoside by healthy volunteers, 
as compared with Cmax values of 0.72µM and 2.35µM for 
13C-labelled phenolic degradants 
(protocatechuic acid and phloroglucinol aldehyde) and phase II conjugates of protocatechuic acid 
(including vanillic acid) respectively (Czank et al., 2013).  Therefore, the observed upregulation of 
eNOS in HUVECs by anthocyanins at ≥ 0.1μM may not be biologically relevant in vivo; but as detailed 
in Chapter 2, anthocyanin phenolic degradants appeared to reduce superoxide levels in a HUVEC 
stimulated superoxide production model, with significant decreases (p < 0.05) elicited by vanillic acid 
and syringic acid at 1μM.  Moreover, degradants which contain a catechol (protocatechuic acid) or 
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mono-O-methylated (vanillic acid) B-ring might act as inhibitors of NADPH oxidase/NOX (Steffen et 
al., 2007b, Steffen et al., 2008); thereby reducing superoxide production and scavenging of NO in 
vivo, and indirectly enhancing vascular endothelial function (Schewe et al., 2008, Cassidy et al., 
2010), as opposed to direct stimulation of NO production.  Vanillic acid elicited an apparent decrease 
in superoxide levels at all concentrations examined, such that these levels were not significantly 
different from basal (unstimulated) cells in the same assay. 
Given the observed bioactivity of vanillic acid at a physiologically relevant concentration for phenolic 
degradants, and the structural relationship between vanillic acid and reported NOX inhibitors, this 
compound was selected to investigate the mechanisms by which anthocyanin degradants could 
inhibit NOX activity and therefore reduce vascular superoxide production.  Modulation of endothelial 
NOX2 and NOX4 protein expression by anthocyanin degradants (at 0.1 - 10μM), following angiotensin 
II stimulation, has been assessed previously (as detailed in Chapter 2).  NOX4 is reported to be the 
predominant vascular endothelial isoform (Bedard and Krause, 2007); whilst NOX2, which requires 
additional cytosolic proteins for enzyme activity (Lassegue and Griendling, 2010), is thought to play a 
key role in regulating vascular function through reduction of bioavailable NO (Brown and Griendling, 
2009, Schroder, 2010).  Vanillic acid did not appear to alter expression of either of these isoforms; 
suggesting any modulation of NOX activity may occur at the post-translational level, or through 
effects on expression of other subunits of the NOX enzyme complex. 
In conclusion, inhibition of NOX activity and thus superoxide production by vanillic acid, with reduced 
scavenging of endothelial NO, could indirectly elevate NO levels and therefore enhance vascular 
function in vivo; and the cellular mechanisms potentially underlying this activity should be further 
investigated (as detailed in Chapters 4, 5 and 6). 
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4 Regulation of stimulated endothelial NOX gene expression by 
the anthocyanin phenolic acid degradation product vanillic 
acid 
4.1 Background 
Endothelium-derived nitric oxide (NO) is a mediator of vascular homeostasis (Higashi et al., 2009, 
Förstermann and Sessa, 2012), eliciting vasodilation through activation of soluble guanylate cyclase 
in vascular smooth muscle cells (Hobbs et al., 1999).  In addition, NO acts to inhibit activation and 
aggregation of platelets, expression of cell surface adhesion molecules, and oxidation of low density 
lipoprotein; which are all important processes in atherogenesis (Kawashima and Yokoyama, 2004, 
Naseem, 2005, Michel and Vanhoutte, 2010).  Nitric oxide therefore has anti-atherosclerotic activity 
(Wever et al., 1998), and decreased NO bioavailability can impair endothelial function (Higashi et al., 
2009), which is a critical process in atherosclerotic development (Kawashima and Yokoyama, 2004).  
Reduced NO bioavailability may result from inactivation of NO by reactive oxygen species (ROS) 
(Landmesser et al., 2004), and the NADPH oxidase, or NOX, family of transmembrane enzymes 
constitute a major source of ROS in the vasculature (Touyz, 2004, Bedard and Krause, 2007, Leopold 
and Loscalzo, 2009).  Structure-activity studies of (-)-epicatechin and its metabolites (Steffen et al., 
2007b, Steffen et al., 2008) have suggested inhibition of NOX activity may be a mechanism by which 
certain flavonoids could increase NO levels and improve vascular function (Schewe et al., 2008). 
NADPH oxidase proteins transfer electrons across biological membranes to an acceptor molecule, 
usually oxygen (Lassegue and Clempus, 2003, Bedard and Krause, 2007); and of seven identified 
mammalian isoforms (Sumimoto et al., 2005, Bedard and Krause, 2007), NOX1, 2, 4 and 5 are 
expressed in the cardiovascular system (Brandes et al., 2010, Takac et al., 2011).  With regard to the 
vascular endothelium, expression of NOX2, NOX4 and NOX5 has been described previously (Bedard 
and Krause, 2007, Brandes and Schröder, 2008).  NOX4 appears to be the major vascular endothelial 
isoform (Bedard and Krause, 2007, Takac et al., 2011) producing predominantly hydrogen peroxide 
(Brown and Griendling, 2009), whereas NOX2 generates superoxide (Brandes et al., 2010) and may 
have a key role in regulating vascular function by limiting NO bioavailability (Brown and Griendling, 
2009, Schroder, 2010).  Assembly of a functional enzyme complex can require additional protein 
components depending upon the NOX isoform (Brown and Griendling, 2009), and both NOX2 and 4 
associate with the integral membrane protein p22phox (Sumimoto et al., 2005).  However, whereas 
NOX4 is reported to be constitutively active (Takac et al., 2011), activation of NOX2 follows 
recruitment of additional cytosolic proteins including p47phox (‘organiser’ subunit), p67phox (‘activator’ 
subunit), p40phox, and the small G-protein Rac1/2 (Sumimoto et al., 2005, Drummond et al., 2011). 
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During an earlier investigation (Chapter 2), selected anthocyanin glucosides and phenolic acid 
degradants were screened for their effect on angiotensin II-stimulated superoxide production by 
endothelial NOX.  Based upon the generated bioactivity screening data, and structural similarities 
with reported NOX inhibitors such as apocynin, the anthocyanin B-ring degradant vanillic acid (Figure 
4.1) was selected to elucidate cellular mechanisms potentially underlying previously observed 
reductions in superoxide levels elicited by anthocyanins and their degradants (Chapter 2).  As noted 
above, inhibition of superoxide production by endothelial NOX may result in enhanced NO 
availability, with beneficial effects on vascular endothelial function in vivo (Schewe et al., 2008, 
Förstermann, 2010). 
Figure 4.1 Anthocyanin degradant vanillic acid selected for investigation of the potential mechanisms 
of NOX inhibition by anthocyanins. 
   
 
In the current investigation, the effect of vanillic acid at physiologically relevant concentrations 
(Czank et al., 2013) on endothelial mRNA levels of selected NOX isoforms and associated proteins 
following cell stimulation was examined by reverse transcription – quantitative polymerase chain 
reaction (RT-qPCR), to assess whether NOX function was affected by vanillic acid at the 
transcriptional level.  Both NOX2 and NOX4 isoforms were chosen for analysis, in addition to their 
common membrane partner p22phox, and the cytosolic subunits p47phox and p67phox required for NOX2 
activity. 
4.2 Materials and methods 
Standards and reagents.  Vanillic acid was purchased from Sigma-Aldrich [Poole, United Kingdom 
(UK)] and a 200mM standard solution prepared in 100% dimethylsulphoxide (DMSO; Sigma-Aldrich 
molecular biology grade).  All water utilised was of Milli-Q grade (18.2 MΩ cm-1). 
Recombinant human transforming growth factor-beta 1 (TGF-β1) was purchased from R&D Systems 
(Abingdon, UK).  Tumour necrosis factor-alpha (TNF-α), TRIzol® reagent, RNase-free water, oligo (dT) 
primer (50μM), SuperScript® II Reverse Transcriptase (with 5x first strand buffer and 100mM 
dithiothreitol/DTT), and MicroAmp™ optical microplates were obtained from Life Technologies 
(Paisley, UK).  RiboLock RNase inhibitor, DNase I (with 10x reaction buffer with MgCl2, and 50mM 
EDTA), dNTP PCR mix (10mM), oligo (dT) primer (100μM), chloroform (molecular biology grade), and 
isopropanol were purchased from Thermo Fisher Scientific (Fisher Scientific, Loughborough, UK); and 
OH O
OH
OCH3
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ethanol (molecular biology grade), human angiotensin II (synthetic), fibronectin, and Medium 199  
from Sigma-Aldrich.  Foetal bovine serum (FBS; heat-inactivated) was purchased from Biosera 
(Ringmer, UK).  Precision 2x real-time PCR MasterMix with SYBR®Green was obtained from 
PrimerDesign Ltd (Southampton, UK), and custom primer sets for human NOX2, NOX4, p22phox, 
p47phox and p67phox were designed, pre-validated and supplied by PrimerDesign Ltd.  Primer 
sequences are tabulated below. 
Table 4.1 Sense/anti-sense primers sequences (5’ to 3’) for qPCR (real time). 
Gene 
Symbol/accession 
number 
Sense Primer Anti-sense Primer 
NOX2 CYBB/NM_000397 AAGAAGAAGGGGTTCAAAATGGA GGGGCGGATGTCAGTGTAA 
NOX4 NOX4/NM_016931 CACAGACTTGGCTTTGGATTTC GGATGACTTATGACCGAAATGATG 
p22
phox
 CYBA/NM_000101 GTTTGTGTGCCTGCTGGAG CCGAACATAGTAATTCCTGGTAAAG 
p47
phox
 NCF1/NM_000265 GCGGTTGGTGGTTCTGTCAG TAGTTGGGCTCAGGGTCTTCC 
p67
phox
 NCF2/NM_000433 CCTCCACCCAGACCGAAAA TCTCAGGCACAAACCCAAATAG 
CYBA/CYBB, cytochrome b-245 alpha/beta polypeptide; NCF1/NCF2, neutrophil cytosolic factor 1/2; NOX2/4, NADPH 
oxidase isoform 2/4. 
Cell culture.  Cryo-preserved, early passage, pooled human umbilical vein endothelial cells (HUVEC) 
were purchased from TCS CellWorks (Buckingham, UK) and used between passages two to four.  Cells 
were routinely cultured in 75cm2 flasks (SPL Life Sciences) coated with fibronectin (0.27µg/cm2), 
using large vessel endothelial cell growth medium [TCS CellWorks; proprietary basal medium 
formulation supplemented with growth factor and antibiotic (gentamicin & amphotericin B) 
supplements, final concentration of 2% v/v foetal bovine serum] at 37°C and 5% CO2.  HUVECs were 
sub-cultured using 0.025% trypsin and 0.01% EDTA (TCS CellWorks). 
4.2.1 Method development – RT-qPCR 
Reverse-transcription – quantitative polymerase chain reaction: method development (Figure 4.2).  
Method development was conducted to confirm specificity of PCR products generated using custom 
primer sets for NOX isoforms and subunits (Figure 4.2 A), and to select optimal endogenous 
reference genes for normalisation of Ct data for genes of interest (Figure 4.2 B).  A time course 
experiment was also conducted to identify the optimum incubation time with angiotensin II for 
stimulated gene expression (Figure 4.2 C), as based upon reviewed reports (Appendix Table 9.2.4) 
and previous investigations (Chapters 2 & 3), 0.1μM angiotensin II (or 10ng/ml TGF-β1; Figure 4.2 D) 
was utilised to stimulate endothelial cells. 
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Figure 4.2 RT-qPCR analysis of stimulated endothelial NOX isoform/subunit expression: method 
development flow chart. 
 
 
 
 
 
 
 
 
Specificity of PCR products (Figure 4.2 A).  Analysis of melt curve data for NOX custom primer sets, 
to confirm specificity of PCR product prior to relative quantification of gene expression levels, 
indicated non-specific amplification for NOX2 (Appendix Figure 9.4.1 A), p47phox (Appendix Figure 
9.4.1 B), and p67phox (Appendix Figure 9.4.1 C) primer sets generating multiple Tm peaks.  
Amplification of multiple amplicons for NOX2, p47phox and p67phox was not resolved by either redesign 
of custom primers by the supplier, or conducting gene-specific reverse transcription to select for 
specific mRNA transcripts.  Melt curve analysis for NOX4 and p22phox primer sets indicated specific 
amplification of a single PCR product (Appendix Figure 9.4.2 A & B), permitting relative quantification 
of gene expression levels for these transcripts. 
Reference/housekeeping genes (Figure 4.2 B).  Identification of optimal reference genes for 
normalisation of Ct data was conducted using a geNorm
PLUS kit (PrimerDesign Ltd).  Primer sets for six 
stably expressed human reference genes (Table 4.2) were designed, pre-validated and supplied by 
PrimerDesign Ltd, and used to evaluate expression of these genes in both unstimulated and 
stimulated HUVEC.  Real-time PCR data were analysed using the geNorm function in qbasePLUS 
software (version 2.3, Biogazelle NV, Zwijnaarde, Belgium) to assess reference gene stability across 
samples, and optimal number of reference genes (Vandesompele et al., 2002). 
Table 4.2 Reference/housekeeping genes evaluated during method development. 
Gene Description 
PPIA Peptidylprolyl isomerase A (cyclophilin A) 
PRDM4 PR domain containing 4 
UBE2D2 Ubiquitin-conjugating enzyme E2D 2 
UBE4A Ubiquitination factor E4A 
TYW1 tRNA-yW synthesizing protein 1 homologue (S. cerevisiae) 
VIPAR/C14orf133/VIPAS39 VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 
homologue 
No change 4 hours 
NOX4, 
p22
phox
 
A. Specificity of 
PCR products 
NOX2, NOX4, 
p47
phox
, p67
phox
, 
p22
phox
 
C. Incubation 
time with 
angiotensin II 
1, 2, 3, 4, or 5 
hours 
D. Alternate cell 
stimulant 
TGF-β1 
B. Reference 
genes 
PPIA, PRDM4, 
UBE2D2, UBE4A, 
TYW1, VIPAR 
 
UBE4A, 
VIPAR 
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Cultured HUVEC were incubated for five hours with culture medium only (basal), 0.1μM angiotensin 
II, or 0.1μM angiotensin II with 10μM vanillic acid.  A five hour time point was selected as 
approximating to the mid-point of the range of four to seven hours used in previous studies with 
HUVEC reporting upregulation of NOX4 and p22phox mRNA induced by 0.1µM angiotensin II 
(Rueckschloss et al., 2002, Yamagishi et al., 2005, Alvarez et al., 2010).  Following RNA extraction and 
first strand cDNA synthesis, reference gene expression was assessed by real-time PCR, and the 
generated Ct data were analysed using qbase
PLUS.  The average expression stability of reference 
targets across treatment conditions (geNorm M value) was investigated by geNorm analysis (Figure 
4.3; targets plotted in order of increasing stability from left to right); and optimal number of targets 
was also confirmed (Figure 4.4).  UBE4A and VIPAR were identified as the optimum reference genes, 
and their geometric mean used as the normalisation factor in the final assay. 
Figure 4.3 Average reference gene expression stability (geNorm M graph) for untreated HUVEC and 
following 5h incubation with 0.1μM angiotensin II and 10μM vanillic acid. 
 
geNorm M graph demonstrating average reference gene expression stability (geNorm M value, y-axis) across 
experimental conditions (ie untreated, 0.1μM angiotensin II, & 10μM vanillic acid).  Reference genes (x-axis) are 
arranged in order of increasing stability from left to right (refer to Table 4.2. for gene descriptions). 
Incubation time with angiotensin II (Figure 4.2 C).  The optimal incubation time for HUVEC with 
0.1μM angiotensin II to elicit upregulation of NOX isoform/subunit mRNA was confirmed by a time 
course experiment.  Tumour-necrosis factor-alpha was selected for use as a positive control in this 
investigation, based upon a review of 12 research reports (Appendix Table 9.2.5).  Cultured HUVEC 
were incubated for one, two, three, four or five hours with 0.1μM angiotensin II, or 20ng/ml TNF-α; 
prior to RNA extraction and first strand cDNA synthesis.  The additional time points of one hour to 
four hours were chosen based on reported upregulation of NOX4 and p22phox mRNA by ~1.4-fold and 
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3-fold respectively following incubation of HUVECs for only four hours with 0.1µM angiotensin II 
(Yamagishi et al., 2005). 
Figure 4.4 Determination of optimal number of reference genes (geNorm V graph) for untreated 
HUVEC and following 5h incubation with 0.1μM angiotensin II and 10μM vanillic acid. 
 
geNorm V graph determining optimal number of reference genes.  ‘V2/3’ denotes comparison between 2 genes and 3 
genes, ‘V3/4’ compares 3 genes versus 4 genes etc. across untreated (basal) and treated (0.1μM angiotensin II & 10μM 
vanillic acid) samples.  Where the geNorm V value is below 0.15 (ie below dashed line), no additional benefit is derived 
from using a further reference gene. 
Expression of NOX4 and p22phox, in addition to six reference genes (Table 4.2), was compared against 
unstimulated (basal) cells by real-time PCR.  Owing to the inclusion of a positive control (TNF-α), a 
geNorm analysis was performed to identify the optimal reference genes across treatments used in 
this time course experiment (data not shown).  UBE2D2 and PRDM4 were identified as the optimum 
reference genes, and their geometric mean was used as the normalisation factor in this assay.  Based 
on fold change in NOX4 mRNA levels versus basal [1.86 fold ± 0.98; mean ± SD (Figure 4.5 A)], a four 
hour incubation was identified as the optimum time point for subsequent assays.  Endothelial mRNA 
levels for p22phox (Figure 4.5 B) showed the greatest fold change versus basal following five hours 
incubation with angiotensin II (1.80 ± 0.14); however, as upregulation was also indicated at the four 
hour time point (1.63 ± 1.10), four hours was selected as the optimum incubation period for 
upregulation of both NOX4 and p22phox mRNA levels in the final assay. 
Following stimulation of HUVEC with TNF-α (positive control), significant upregulation of NOX4 
mRNA was detected at the three hour time point (1.63 ± 0.39; Figure 4.6 A) as compared with the 
one hour time point (0.75 ± 0.19), and significantly elevated levels of p22phox mRNA were observed 
after two hours incubation with TNF-α (1.32 ± 0.11; Figure 4.6 B) relative to all other time points. 
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Figure 4.5 Modulation of endothelial NOX4 (A) and p22
phox
 (B) mRNA levels 
following stimulation of HUVEC with 0.1μM angiotensin II for 1-5 
hours. 
 
Fold change in HUVEC NOX4 (A) and p22
phox
 (B) mRNA levels versus unstimulated cells (basal) 
following incubation with 0.1μM angiotensin II for 1, 2, 3, 4 or 5 hours.  Relative quantification was 
performed using the comparative Ct method, incorporating the geometric mean of reference genes 
PRDM4 and UBE2D2 as the normalisation factor.  Data are graphed as mean ± SD (n=3); no 
significant differences between time points (p > 0.05). 
Figure 4.6 Modulation of endothelial NOX4 (A) and p22
phox
 (B) mRNA levels 
following stimulation of HUVEC with 20ng/ml TNF-α for 1-5 
hours. 
 
Fold change in HUVEC NOX4 (A) and p22
phox
 (B) mRNA levels versus basal (unstimulated) cells 
following incubation with 20ng/ml TNF-α for 1, 2, 3, 4 or 5 hours.  Relative quantification was 
performed using the comparative Ct method, incorporating the geometric mean of reference genes 
PRDM4 and UBE2D2 as the normalisation factor.  Data are graphed as mean ± SD (n=3); columns 
with different superscript letters are significantly different (p < 0.05). 
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Alternate cell stimulant (Figure 4.2 D).  Upregulation of gene expression levels following cell 
stimulation was less than two-fold of basal values (Figure 4.5 & Figure 4.6), therefore an alternate 
cell stimulant was investigated to increase upregulation of NOX isoform/subunit mRNA, and improve 
assay sensitivity.  TGF-β1 was selected for use in this experiment, following a review of potential 
positive controls for NOX expression (Appendix Table 9.2.5).  Cultured HUVEC were incubated for 
four hours with TGF-β1 at a concentration of 10ng/ml, prior to RNA extraction and cDNA synthesis.  
Real-time PCR analysis indicated modest fold changes in gene expression versus basal with decreased 
levels of NOX4 mRNA (NOX4 mRNA, 0.80 ± 0.14; p22phox mRNA, 1.14 ± 0.19), and therefore 
angiotensin II was retained as the cell stimulant. 
4.2.2 Final methodology 
Stimulated NOX isoform/subunit gene expression assay: optimised parameters.  The angiotensin II 
stimulated NOX gene expression assay utilised 24-well plates (SPL Life Sciences) coated with 
fibronectin (0.25µg/cm2), which were seeded with HUVEC at a density of ~30,000 cells/well, and the 
cells grown to confluence (~48 hours at 37°C and 5% CO2).  Culture medium was then aspirated, and 
the cells incubated for 16 - 18 hours in Medium 199 (M199) supplemented with 2% FBS (at 37°C and 
5% CO2).  Thereafter, the cells were incubated for four hours in supplemented M199 alone (basal), or 
media with 0.1µM angiotensin II in the presence or absence of 0.1, 1 or 10µM vanillic acid.  After 
incubation, media was aspirated from all wells, and the plates were either frozen at -80°C or utilised 
for RNA extraction. 
RNA extraction and mRNA reverse transcription.  RNA was extracted from cultured cells by phenol-
based organic extraction.  Briefly, cells were homogenised using TRIzol reagent (500μl per well), and 
homogenates incubated for five minutes at room temperature.  Following addition of 100μl 
chloroform, samples were agitated vigorously and subject to centrifugation at 12,000g for 15 
minutes at 4°C.  Two hundred microlitres of the aqueous phase was removed and mixed with 250μl 
isopropanol, prior to a ten minute incubation at room temperature.  Cellular RNA was pelleted by 
centrifugation at 12,000g for 10 minutes at 4°C, and washed with 500μl of 75% ethanol by 
centrifugation at 7500g for 5 minutes at 4°C.  After removal of supernatants, pellets were partially 
dried and resuspended in 20μl RNase-free water, prior to a 15 minute incubation at 57.5°C.  
Quantification of RNA was performed using a NanoDrop 2000 (Thermo Fisher Scientific). 
One microgram of each RNA sample was utilised in a 20μl reverse transcription reaction with oligo 
(dT) primers.  Prior to reverse transcription, RNA was incubated for 30 minutes at 37°C with DNase I 
and RiboLock RNase inhibitor, to remove any residual genomic DNA from extracted RNA.  Following 
addition of EDTA, oligo (dT) primers (final concentration 5μM), and dNTP PCR mix, DNase was 
inactivated by a 10 minute incubation at 65°C.  First strand buffer, RiboLock, and DTT were then 
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added to each sample, prior to a two minute incubation at 42°C to allow annealing of primers.  After 
the addition of SuperScript® II (or RNase-free water for a no reverse-transcriptase control), samples 
were incubated at 42°C for 50 minutes for first strand cDNA synthesis, followed by a 15 minute 
incubation at 70°C to inactivate the reverse transcriptase enzyme. 
Real-time PCR.  Analysis of gene expression was performed using the Applied Biosystems 7500 Real 
time PCR System (Life Technologies; 7500 software version 2.0) with SYBR®Green detection.  
Typically, 25ng cDNA (or RNase-free water for a ‘no template’ control) was amplified with 300nM of 
the appropriate primer set (Table 4.1 & Table 4.2), and 8.33μl Precision 2x real-time PCR MasterMix 
with SYBR®Green (Primer Design Ltd) in a total volume of 20μl.  Following enzyme activation at 95°C 
for 10 minutes, 50 cycles of denaturation (15 seconds at 95°C) and data collection (60 seconds at 
60°C) were performed, prior to melt curve analysis to confirm specificity of amplification.  Relative 
changes in gene expression following cell treatment were quantified using the comparative Ct 
method (Dorak, 2006, Schmittgen and Livak, 2008), incorporating the geometric mean of the 
reference genes UBE4A and VIPAR (as identified during method development; refer to section 4.2.1) 
as the normalisation factor. 
Statistical analysis.  Analysis of variance (ANOVA) with Tukey post-hoc test was performed using 
SPSS software (IBM, New York, USA) version 18 for Windows.  Significance was determined at the 5% 
level, and expressed relative to angiotensin II treatment.  Three biological replicates for each 
control/treatment were used for analysis unless otherwise noted. 
4.3 Results 
Following incubation of HUVECs with 0.1μM angiotensin II for four hours, NOX4 mRNA levels showed 
little change relative to unstimulated cells (1.04 ± 0.03 fold change; mean ± SD).  Co-incubation of 
angiotensin II with vanillic acid at concentrations of 0.1, 1 and 10μM elicited little alteration in NOX4 
mRNA, with no significant differences compared to angiotensin II alone (p > 0.05, Figure 4.7). 
A reduction in HUVEC p22phox mRNA levels, relative to basal cells (fold change 0.63 ± 0.44), was 
observed following a four hour incubation with angiotensin II.  However, co-incubation of 
angiotensin II with vanillic acid at 0.1μM and 1μM increased p22phox mRNA levels relative to 
angiotensin II [fold changes 2.19 ± 0.81, p = 0.2 and 2.30 ± 0.33, p = 0.1 (respectively) versus 
angiotensin II control] (Figure 4.8).  No changes were significant relative to angiotensin II control (p > 
0.05). 
  
95/185 
Figure 4.7 Modulation of endothelial NOX4 mRNA levels by vanillic acid 
following stimulation of HUVEC with 0.1μM angiotensin II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fold change in HUVEC NOX4 mRNA levels relative to angiotensin II following 4 hour 
incubation with 0.1μM angiotensin II control (Ang II), or Ang II with 0.1μM, 1μM or 10μM 
vanillic acid.  Relative quantification was performed using the comparative Ct method, 
incorporating the geometric mean of reference genes UBE4A and VIPAR as the 
normalisation factor.  Data are graphed as mean ± SD (n=3). 
Figure 4.8 Modulation of endothelial p22
phox
 mRNA levels by vanillic acid 
following stimulation of HUVEC with 0.1μM angiotensin II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fold change in HUVEC p22
phox
 mRNA levels relative to angiotensin II following 4 hour 
incubation with 0.1μM angiotensin II control (Ang II), or Ang II with 0.1μM, 1μM or 10μM 
vanillic acid.  Relative quantification was performed using the comparative Ct method, 
incorporating the geometric mean of reference genes UBE4A and VIPAR as the 
normalisation factor.  Data are graphed as mean ± SD (n=3). 
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4.4 Discussion 
The present study aimed to investigate potential mechanisms of NOX inhibition, and thus regulation 
of vascular endothelial ROS production, by the anthocyanin degradant vanillic acid (Figure 4.1); 
through examining the effects of vanillic acid on endothelial NOX isoform/subunit mRNA levels 
following cell stimulation.  NADPH oxidase or NOX enzymes are generally identified as the 
predominant source of ROS in the vasculature (Cai et al., 2003, Sumimoto et al., 2005, Leopold and 
Loscalzo, 2009), and NOX activity in response to stimulation by the hormone angiotensin II is a major 
source of ROS in atherosclerosis (Cai et al., 2003, Higashi et al., 2009).  In a prior investigation 
(Chapter 2), vanillic acid appeared to reduce endothelial superoxide levels following activation of 
NOX by angiotensin II; suggesting vanillic acid might enhance vascular function by reducing 
inactivation of NO by superoxide, as previously proposed for certain dietary flavonoids (Schewe et 
al., 2008).  Therefore the current study examined angiotensin II-stimulated NOX expression in HUVEC 
as a model of NOX activity, in the context of endothelial dysfunction preceding atherosclerotic 
development, to elucidate cellular mechanisms potentially underlying the observed activity of vanillic 
acid. 
Following incubation of cultured HUVECs with 0.1μM angiotensin II, observed changes in NOX4 and 
p22phox mRNA ranged from 0.95 - 1.86-fold increase relative to basal for NOX4 (Figure 4.5 A), and 
0.49 - 1.80-fold for p22phox (Figure 4.5 B), with the greatest fold increases detected after four and five 
hours incubation with angiotensin II respectively.  Previous reports have described upregulation of 
endothelial NOX4 mRNA by ~1.2 - 1.6-fold, and p22phox mRNA by ~1.1 - 3-fold, after stimulation of 
HUVEC with 0.1μM angiotensin II for four to seven hours (Rueckschloss et al., 2002, Yamagishi et al., 
2005, Alvarez et al., 2010), and incubation of human aortic endothelial cells (HAEC) with 1μM 
angiotensin II for six hours (Richard et al., 2009).  Therefore the maximal transcriptional response to 
angiotensin II stimulation in the current investigation was comparable to previous reports, suggesting 
adequate sensitivity of the HUVEC model used in the present study to the effects of a known 
vasoactive stimulant. 
Co-incubation of angiotensin II with 0.1, 1 or 10μM of the anthocyanin degradant vanillic acid elicited 
no significant changes in NOX4 or p22phox mRNA levels relative to angiotensin II alone.  NOX4 mRNA 
levels showed minimal change (Figure 4.7), whereas increased p22phox mRNA levels were observed 
when HUVEC were co-incubated with angiotensin II and 0.1 or 1μM vanillic acid (Figure 4.8).  
Interestingly, the apparent upregulation of p22phox mRNA did not display a linear dose - response 
relationship across the range of concentrations of vanillic acid tested, which reflects previous reports 
suggesting differential bioactivity of flavonoids across dose ranges (Chirumbolo et al., 2010, Kay et 
al., 2012).  However, vanillic acid demonstrated no statistically significant modulation of angiotensin 
II-stimulated gene expression for NOX4 and p22phox, thereby appearing to preclude an effect of this 
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degradant upon NOX4 activity at the transcriptional level.  These data reflect previous findings 
(Chapter 2) where vanillic acid (at 0.1 - 10μM) did not significantly alter angiotensin II-stimulated 
NOX4 protein expression in cultured HUVEC, and suggest vanillic acid does not modulate the function 
of the predominant vascular endothelial NOX isoform, which produces mainly hydrogen peroxide 
(Brown and Griendling, 2009).  Whilst NOX4-derived hydrogen peroxide would not act to limit NO 
bioavailability (Brandes et al., 2011), it may induce vasodilation through hyperpolarisation 
independently of NO activity (Ray et al., 2011); however the current study indicates that the 
anthocyanin phenolic degradant vanillic acid is unlikely to enhance vascular function in vivo by this 
mechanism. 
A limitation of the current investigation was the poor specificity of amplification observed with 
custom primer sets for NOX2, p47phox and p67phox (Appendix Figure 9.4.1), which could not be 
resolved by redesigning primers or gene-specific reverse-transcription; and thus prevented 
determination of relative changes in gene expression for the superoxide-generating NOX2 isoform, 
and the cytosolic ‘organiser’ and ‘activator’ proteins p47phox and p67phox respectively.  This is of 
particular consequence given the observed reduction in stimulated endothelial superoxide 
production elicited by vanillic acid (Chapter 2).  Previously reported studies have suggested low or no 
endothelial expression of NOX2 mRNA (Ago et al., 2004, Jiang et al., 2006, Xu et al., 2008, Alvarez et 
al., 2010), and low expression of p47phox and p67phox mRNA in HUVEC (Ago et al., 2004); therefore the 
poor specificity of amplification in the current investigation is likely to reflect low mRNA copy 
number, which might be addressed by the use of hydrolysis probe detection chemistry for real time 
PCR in future studies.  In contrast, specific amplification of NOX4 and p22phox amplicons (Appendix 
Figure 9.4.2) permitted relative quantification of transcript levels, reflecting the ~100-fold higher 
expression of NOX4 in HUVEC (Xu et al., 2008). 
In the current investigation, variation was noted in the stimulatory effect of angiotensin II after a four 
hour incubation, although time course experiments conducted during method development 
identified this time point as optimal for upregulation of NOX4 and p22phox mRNA levels (Figure 4.5).  
Moreover, the use of TGF-β1 to enhance upregulation of HUVEC NOX isoform/subunit mRNA was 
without effect, yet TGF-β1 is known to elicit NOX4 expression in vascular smooth muscle and 
endothelial cells (Montezano et al., 2011); and approximately six-fold upregulation of NOX4 mRNA in 
response to a four hour incubation with TGF-β1 has been reported in human cardiac fibroblasts 
(Cucoranu et al., 2005).  Therefore, data generated during the current investigation may indicate a 
relative lack of NOX transcriptional response in HUVEC following acute cell stimulation.  Whilst 
HUVEC are widely used for research concerning general properties of endothelial cells (Baudin et al., 
2007), an arterial endothelial cell type may be more appropriate for future studies investigating the 
potential modulation of NOX activity in relation to endothelial dysfunction preceding atherosclerosis; 
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the lesions of which occur primarily in medium to large-sized muscular and elastic arteries (Ross, 
1999).  As such, an alternative cell type, namely human arterial endothelial cells, should be used for 
subsequent in vitro studies investigating modulation of NOX subunit expression (as explored in 
Chapter 5).  A strength of the current investigation was the selection of optimal endogenous 
reference genes for relative quantification of mRNA levels (Figure 4.3 & Figure 4.4), ensuring their 
suitability for normalising qPCR data to account for non-treatment related sources of variation 
between samples (Bustin et al., 2009). 
The current study represents the first stage in elucidating possible mechanisms of action for vanillic 
acid, and suggests this phenolic acid degradant does not alter stimulated expression of the 
constitutively active NOX4 isoform at the transcriptional level; thus vanillic acid is unlikely to 
modulate vascular endothelial function through effects on NOX4 activity.  However, the vasoactive 
compound apocynin, which in common with vanillic acid (Figure 4.1) incorporates a mono-
methylated catechol group, has previously been reported to inhibit NOX function by inhibiting p47phox 
association with membrane components (Stolk et al., 1994, Drummond et al., 2011); indicating a 
possible mechanism by which vanillic acid could inhibit NOX2-mediated endothelial superoxide 
production (Chapters 2 & 3).  Inhibition of NOX-mediated superoxide production by anthocyanin 
degradants or metabolites in vivo, resulting in elevated vascular NO bioavailability and enhanced 
endothelial function, could explain at least part of the reported vasoprotective activity of ingested 
anthocyanins (Mink et al., 2007, Zhu et al., 2011, Cassidy et al., 2013). 
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5 Modulation of stimulated endothelial p47phox expression and 
activation by the anthocyanin B-ring degradant vanillic acid 
5.1 Background 
Dietary consumption of anthocyanins has been associated with reduced risk of cardiovascular 
disease (CVD) (Wallace, 2011) according to data from several epidemiological studies [for example 
(Mink et al., 2007, McCullough et al., 2012, Cassidy et al., 2013)].  Anthocyanins could enhance 
vascular endothelial function by modulating levels of the vasodilator nitric oxide (NO), through 
upregulation of the endothelial NO synthase (eNOS) enzyme or activation of eNOS; based on studies 
using cultured bovine (Xu et al., 2004a, Xu et al., 2004b, Paixão et al., 2012) and human (Lazze et al., 
2006, Edirisinghe et al., 2011, Quintieri et al., 2013) endothelial cells, and excised porcine (Bell and 
Gochenaur, 2006) and rat (Ziberna et al., 2013) arterial rings.  Reduced NO bioavailability may 
underlie the development of endothelial dysfunction and subsequent atherothrombotic 
cardiovascular disease (Kawashima and Yokoyama, 2004, Leopold and Loscalzo, 2009, Higashi et al., 
2009, Drummond et al., 2011), and loss of NO in many vascular pathologies is thought to be 
mediated by reaction with the reactive oxygen species (ROS) superoxide.  A major source of ROS in 
the vasculature is the NADPH oxidase (NOX) family of transmembrane enzymes (Bonomini et al., 
2008, Brandes et al., 2010), of which the superoxide-generating NOX2 isoform is the prototype and 
best characterised member (Lassegue and Clempus, 2003, Sumimoto et al., 2005, Bedard and Krause, 
2007, Brown and Griendling, 2009).  Vascular expression of NOX2 has been reported in endothelial 
cells, smooth muscle, and adventitial fibroblasts (Takac et al., 2011, Schramm et al., 2012), and NOX2 
function may contribute to the limitation of NO availability in the vasculature (Brandes and Schröder, 
2008, Violi et al., 2009, Schroder, 2010); whereas the predominant endothelial isoform NOX4 (Ago et 
al., 2004) produces mainly hydrogen peroxide (Brown and Griendling, 2009), and therefore vascular 
NOX4 activity is unlikely to result in scavenging of NO (Brandes et al., 2011). 
Formation of a functional NOX2 enzyme complex requires the association of NOX2 with a second 
transmembrane protein, p22phox (forming the cytochrome b558 complex), and recruitment of 
additional cytosolic subunits upon enzyme activation; specifically p47phox (‘organiser’ subunit), p67phox 
(‘activator’ subunit), p40phox, and the small G-protein Rac1/2 (Sumimoto et al., 2005, Bedard and 
Krause, 2007, Brandes and Schröder, 2008, Drummond et al., 2011).  Following cell stimulation by 
agonists such as angiotensin II (Cai et al., 2003), the p47phox subunit is subject to serine 
phosphorylation mediated by kinases including protein kinase C (PKC), Akt, or c-Src (el Benna et al., 
1994, Cai et al., 2003, Drummond et al., 2011).  Phosphorylation of p47phox results in membrane 
translocation and association of p47phox, p67phox and p40phox with the NOX2/p22phox complex 
(Sumimoto et al., 2005, Drummond et al., 2011, El-Benna et al., 2012).  The vasoactive compound 
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apocynin, which is structurally similar to certain anthocyanins and anthocyanin degradants or 
metabolites (as it incorporates a mono-methylated catechol functional group), has been reported to 
decrease NOX activity by inhibiting the association of p47phox with transmembrane components (Stolk 
et al., 1994, Drummond et al., 2011). 
Recent research reports suggest that p47phox may represent a target of flavonoid bioactivity in 
decreasing NOX activity and improving endothelial function (Sanchez et al., 2006, Sanchez et al., 
2007, Romero et al., 2009, Davalos et al., 2009).  For example, in a spontaneously hypertensive rat 
model, the flavonol quercetin (which contains a catechol B-ring) enhanced endothelium-dependent 
vasorelaxation and decreased NOX activity, in conjunction with downregulation of p47phox protein 
(Sanchez et al., 2006).  Moreover, quercetin and its metabolite isorhamnetin (containing a mono-
methylated catechol B-ring) decreased angiotensin II- and endothelin-1-stimulated p47phox expression 
in rat aortic rings (Sanchez et al., 2007, Romero et al., 2009).  In a prior investigation (Chapter 2), 
anthocyanins (namely peonidin-, petunidin-, and malvidin-3-glucoside) and anthocyanin phenolic 
acid degradants (protocatechuic, vanillic, and syringic acid) significantly decreased stimulated 
endothelial superoxide production, possibly through inhibition of NOX activity.  However, as low 
human bioavailability of parent anthocyanins suggests bioactivity in vivo is likely to be mediated by 
their degradation products or metabolites (Vitaglione et al., 2007, Azzini et al., 2010, Czank et al., 
2013), an anthocyanin phenolic degradant was selected to investigate cellular pathways potentially 
underlying the observed reductions in superoxide levels (Chapters 2 & 3). The B-ring degradant 
vanillic acid has been chosen for this study, as it significantly reduced endothelial superoxide levels 
(Chapter 2) at a physiologically relevant concentration [1µM; (Czank et al., 2013)], and in common 
with isorhamnetin and apocynin vanillic acid incorporates a mono-methylated catechol group (Figure 
5.1).  Therefore in the current investigation the effect of vanillic acid on endothelial p47phox 
expression and activation was explored, as a possible mechanism to explain at least part of the 
vasoprotective effects of anthocyanins described in epidemiological (Mink et al., 2007, Jennings et 
al., 2012, Cassidy et al., 2013), human (Zhu et al., 2011, Zhu et al., 2012) and animal (Fitzpatrick et al., 
1993, Andriambeloson et al., 1997) studies. 
Figure 5.1 Chemical structures of the anthocyanin degradant vanillic acid (A), the quercetin metabolite 
isorhamnetin (B), and the reported NOX inhibitor apocynin (C). 
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Experiments were conducted using human umbilical vein endothelial cells (HUVEC), which represent 
a widely-used model for research on general properties of endothelial cells (Baudin et al., 2007); and 
human coronary artery endothelial cells (HCAEC) as a more physiologically representative model of 
endothelial function in the context of atherosclerotic development, which is a disease of medium and 
large-sized arteries (Bonomini et al., 2008). 
5.2 Materials and methods 
Standards and reagents.  Vanillic acid was purchased from Sigma-Aldrich [Poole, United Kingdom 
(UK)], and a 200mM standard solution prepared in 100% dimethylsulphoxide (DMSO; Sigma-Aldrich 
molecular biology grade).  IGEPAL (octylphenoxy polyethoxyethanol, CA-630), fibronectin, & Medium 
199 were purchased from Sigma-Aldrich, and recombinant human tumour necrosis factor-α (TNF-α) 
from Invitrogen (Paisley, UK).  Foetal bovine serum (FBS; heat-inactivated) was purchased from 
Biosera (Ringmer, UK), safe-lock microcentrifuge tubes from Qiagen (Crawley, UK), acid-washed glass 
beads (~0.5mm diameter) from Sigma-Aldrich, and polycarbonate ultracentrifuge tubes (230µl) from 
Beckman Coulter (High Wycombe, UK).  Complete Protease Inhibitor Cocktail Tablets and PhosSTOP 
Phosphatase Cocktail Inhibitor Tablets were obtained from Roche Applied Science (Burgess Hill, UK).  
All water utilised was of Milli-Q grade (18.2 MΩ cm-1). 
NuPAGE sample reducing agent and LDS sample buffer were purchased from Invitrogen, and 
Precision Plus Protein Dual Colour standards from Bio-Rad Laboratories, Inc (Hemel Hempstead, UK).  
Protein-Free T20 (TBS) blocking buffer was obtained from Fisher Scientific (Loughborough, UK); 
Immobilon-FL PVDF membrane from Millipore, and InstantBlue protein gel stain from Expedeon 
Protein Solutions (Harston, UK).  Tween® 20 was purchased from Sigma-Aldrich.  Chicken polyclonal 
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; AB2302) was obtained from Millipore 
(Watford, UK); rabbit polyclonal anti-p47phox was purchased from Santa Cruz Biotechnology, Inc. 
(California, USA) and Abcam (Cambridge, UK) (sc-14015 and ab63361 respectively), and rabbit 
polyclonal anti-phospho (S304) p47phox from Abcam (ab63554).  Donkey anti-chicken IgG (IR dye 680 
LT) and goat anti-rabbit IgG (IR dye 800 CW) were supplied by Li-Cor (Cambridge, UK).  Antibodies 
were prepared in a diluent of 50% T20 blocking buffer:50% phosphate-buffered saline (PBS) with 
0.5% Tween® 20; and including 0.02% sodium dodecyl sulphate for solutions of IR dye 680 LT anti-IgG 
antibodies. 
Cell culture.  Cryo-preserved, early passage, HUVEC were purchased from TCS CellWorks 
(Buckingham, UK) and used between passages two to four.  Cells were routinely cultured in 75cm2 
flasks (SPL Life Sciences) coated with fibronectin (0.27µg/cm2), using large vessel endothelial cell 
growth medium [TCS CellWorks; proprietary basal medium formulation supplemented with growth 
factor and antibiotic (gentamicin & amphotericin B) supplements, final concentration of 2% v/v foetal 
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bovine serum] at 37°C and 5% CO2.  HUVECs were sub-cultured using 0.025% trypsin and 0.01% EDTA 
(TCS CellWorks). 
Cryo-preserved, second passage, single donor HCAEC were purchased from PromoCell GmbH 
(Heidelberg, Germany) and used between passages three to six (Figure 5.2).  Cells were routinely 
cultured in 75cm2 flasks (SPL Life Sciences) coated with fibronectin (0.27µg/cm2), using endothelial 
cell medium MV (PromoCell GmbH; proprietary basal medium formulation supplemented with foetal 
calf serum, endothelial cell growth supplement, recombinant human epidermal growth factor, 
heparin, and hydrocortisone, final concentration of 5% v/v foetal calf serum) at 37°C and 5% CO2.  
HCAEC were sub-cultured using 0.04% trypsin and 0.03% EDTA (PromoCell GmbH). 
 
Figure 5.2 Light microscopy image of sub-confluent HCAEC at sixth passage (cultured on fibronectin 
coating). 
 
 
 
5.2.1 Method development – HUVEC p47phox activation 
Stimulated p47phox activation in HUVEC: method development (Figure 5.3).  Method development 
was conducted to optimise cell fractionation methodology (Figure 5.3 A & Appendix Table 9.2.6), 
including buffer composition (Figure 5.3 B), as a means of assessing movement of endothelial p47phox 
from cytosolic to membrane fractions following stimulation of HUVEC with TNF-α (Appendix Table 
9.2.7).  The optimal cell stimulation time for detection of activated p47phox using an anti-phospho 
p47phox antibody was subsequently investigated (Figure 5.3 C). 
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Figure 5.3 Stimulated p47
phox
 activation in HUVEC: method development flow chart. 
 
 
 
 
 
 
 
 
Cell fractionation (Figure 5.3 A).  Immunodetection of p47phox was assessed in cytosolic and 
membrane fractions prepared by ultracentrifugation following HUVEC stimulation.  Cultured HUVEC 
were seeded in fibronectin-coated 6-well plates at a density of 100,000 cells/well and cells grown to 
confluence, prior to a 16 - 18 hour incubation in Medium 199 (supplemented with 2% FBS) at 37°C 
and 5% CO2.  Confluent cells were then incubated for a further five hours in supplemented Medium 
199, in the presence or absence of 20ng/ml TNF-α.  Prior NOX bioactivity and/or expression studies 
(Appendix Table 9.2.7) described incubation periods with TNF-α ranging from five minutes to 24 
hours; therefore five hours was selected for the current study, as comparable to the six hour period 
used in the previously reported stimulated superoxide production assay (Chapter 2).  Cells were 
subsequently lysed in 1% IGEPAL® CA-630, 150mM NaCl, 20mM Tris and 10% glycerol (pH 8.0), 
supplemented with protease inhibitors (Complete Protease Inhibitor Cocktail), and recovered 
solutions homogenised by probe sonication on ice (3 x 10 seconds) before centrifugation at 3000g at 
4°C for ten minutes to pellet nuclei and unbroken cells/debris.  The resulting supernatants were then 
subject to ultracentrifugation at 100,000g for 60 minutes at 4°C, using a Beckman Coulter Optima TLX 
with rotor TLA-100 (Beckman Coulter).  Supernatants were subsequently removed and designated as 
the cytosolic fraction, whilst pellets were resuspended in 125µl cell lysis buffer and ultracentrifuged 
as noted above.  Supernatants from the second ultracentrifugation were designated as the 
membrane-enriched fraction; and the protein content of both fractions quantified prior to gel 
electrophoresis and immunoblotting (section 5.2.2). 
A weak immunoreactive band for p47phox was observed in cytosolic fractions (Figure 5.4 A), whereas 
no p47phox could be detected in membrane fractions (Figure 5.4 B), and GAPDH loading control was 
present in both fractions (Figure 5.4 A & B).  Owing to low protein content of membrane-enriched 
fractions, the effect of lysis buffer composition upon protein recovery was investigated (Figure 5.3 B). 
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Figure 5.4 Immunodetection of endothelial p47
phox
 in cytosolic (A) and membrane (B) fractions 
following stimulation of HUVEC with 20ng/ml TNF-α. 
 
 
 
 
 
 
 
Detection of p47
phox
 protein (with GAPDH loading control) in cytosolic (A) and membrane-enriched (B) fractions 
prepared from unstimulated HUVEC (basal) and following a 5 hour incubation with TNF-α. 
Buffer composition for cell fractionation (Figure 5.3 B).  The effect of buffer composition on protein 
content of cellular fractions was explored using the HUVEC stimulation assay outlined above.  
Following cell treatment, HUVEC were harvested in a 20mM Tris-HCl buffer without IGEPAL [pH 7.5, 
supplemented with protease inhibitors; (Deng et al., 2012)], and cytosolic fractions prepared as 
described previously.  Pellets were then resuspended in Tris-HCl buffer with 1% IGEPAL prior to 
ultracentrifugation and collection of supernatants as membrane-enriched fractions (refer to 
Appendix Table 9.2.6). 
Low protein content (<1mg/ml) was measured for all fractions, and no immunoreactive bands for 
p47phox were detected after gel electrophoresis/immunoblotting of membrane fractions (data not 
shown).  An alternative methodology was therefore identified to detect p47phox activation following 
HUVEC stimulation (Figure 5.3 C). 
Anti-phospho-p47phox antibody: TNF-α time course (Figure 5.3 C).  Activation of p47phox occurs 
through phosphorylation of serine (S) residues (Sumimoto et al., 2005, Drummond et al., 2011), 
including S304 (el Benna et al., 1994), and detection of phospho-(S304) p47phox following cell 
stimulation has been described recently (Leverence et al., 2011).  As such, p47phox activation in the 
current study was investigated by immunoblotting of HUVEC lysates with a rabbit polyclonal anti-
phospho-(S304) p47phox antibody.  Previous scientific reports have described peak phosphorylation of 
p47phox following stimulation with TNF-α for five minutes in human pulmonary artery endothelial cells 
(Frey et al., 2002) and 30 minutes in human dermal microvascular endothelial cells (Li et al., 2005); 
therefore method optimisation was conducted to establish the optimal incubation time with TNF-α. 
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A time course experiment was performed to assess p47phox phosphorylation following incubation of 
cultured HUVEC with TNF-α for 0, 5, 15, 30, and 60 minutes; based on the HUVEC stimulation assay 
described above.  Incubation with TNF-α for 5 - 30 minutes appeared to elicit a minimal increase in 
phosphorylated p47phox relative to basal (0 minutes exposure), although after 60 minutes incubation 
with TNF-α phospho-p47phox decreased below basal levels (Figure 5.5).  As p47phox phosphorylation 
was sustained between the 5 and 30 minute time points, the mid-point (15 minutes) was selected as 
the optimal incubation time with TNF-α. 
Figure 5.5 Immunodetection of phospho-p47
phox
 protein following stimulation of HUVEC with 20ng/ml 
TNF-α for 5-60 minutes. 
 
 
 
 
 
Levels of phospho-p47
phox
 protein (with GAPDH loading control) in cell lysates from unstimulated HUVEC (0 minutes) 
and following incubation with 20ng/ml TNF-α for 5, 15, 30, or 60 minutes.  Inset graph shows fold change in phospho-
p47
phox
 levels relative to basal (designated as 1), after quantification by densitometry and normalisation to loading 
control (mean ± SD, n=4).  No significant differences in fold change were observed between time points (p > 0.05). 
5.2.2 Final methodology 
Stimulated p47phox activation: optimised parameters.  Cell lysates for immunoblotting were 
generated from cultured HUVEC pre-incubated with vanillic acid for five hours prior to stimulation 
with TNF-α.  Briefly, 6-well plates (SPL Life Sciences) coated with fibronectin (0.25µg/cm2) were 
seeded with HUVEC at a density of 100,000 cells/well and cells grown to confluence, prior to a 16 - 18 
hour incubation in Medium 199 (2% FBS) at 37°C and 5% CO2.  Thereafter, cells were pre-incubated 
for five hours with 0.1, 1, or 10µM vanillic acid and subsequently stimulated with TNF-α for 15 
minutes.  Cells were harvested and lysed in 1% IGEPAL® CA-630, 150mM NaCl, 20mM Tris and 10% 
glycerol (pH 8.0), supplemented with protease inhibitors (Complete Protease Inhibitor Cocktail), and 
phosphatase inhibitors (PhosSTOP Phosphatase Cocktail Inhibitor).  Six-well plates were incubated 
with lysis buffer (120µl/well) for 30 minutes at 4°C, prior to removal of cells by scraping.  Recovered 
solutions were subject to cell disruption by rapid agitation (50Hz for 5 minutes with Qiagen 
TissueLyser LT) with acid-washed glass beads in safe-lock microcentrifuge tubes.  After centrifugation 
at 13,000 rpm (15 minutes at 4°C), the protein content of the supernatants was assayed using the 
Pierce BCA Protein Assay Kit according to manufacturer’s instructions. 
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Stimulated p47phox expression.  Cell lysates for immunoblotting were generated from cultured 
HUVEC or HCAEC co-incubated with TNF-α and vanillic acid for five hours.  Briefly, 6-well plates (SPL 
Life Sciences) coated with fibronectin (0.25µg/cm2) were seeded with HUVEC or HCAEC at a density 
of 100,000 cells/well and cells grown to confluence, prior to a 16 - 18 hour incubation in Medium 199 
(2% FBS) at 37°C and 5% CO2 (HUVEC only).  Thereafter, cells were incubated for five hours in 
Medium 199 (2% FBS) with 0.1, 1, or 10µM vanillic acid and 20ng/ml TNFα.  Cells were harvested and 
lysed in 1% IGEPAL® CA-630, 150mM NaCl, 20mM Tris and 10% glycerol (pH 8.0), supplemented with 
protease inhibitors (Complete Protease Inhibitor Cocktail), as described for the p47phox activation 
assay. 
Immunoblot analysis.  For gel electrophoresis, samples were reduced using NuPAGE sample reducing 
agent (50mM dithiothreitol) prior to gel loading in NuPAGE LDS sample buffer.  Precision Plus Protein 
Dual Colour standards were loaded as comparative molecular weight markers.  Normally 20 - 25µg of 
protein was loaded onto a 4% polyacrylamide stacking gel, and separated across a 10% resolving gel 
(at 25mA for approximately one hour) prior to semi-dry transfer to Immobilon-FL PVDF membrane 
(at 200mA for approximately 90 minutes).  Equal protein transfer was confirmed by InstantBlue 
staining of the gels.  Membranes were blocked with T20 blocking buffer for one hour at room 
temperature, and incubated overnight (at 4°C) in the appropriate concentration of primary and 
loading control antibody (anti-GAPDH, 1 in 10,000; anti-p47phox; 1 in 200 to 1 in 500, anti-phospho 
p47phox, 1 in 500).  Membranes were washed using PBS with 0.1% Tween® 20 (PBST 0.1%), after 
which secondary antibody incubations were performed for one hour at room temperature, using IR 
dye-conjugated (680 and 800) secondary antibodies at a concentration of 1 in 10,000.  Membranes 
were washed with PBST 0.1%, and subsequently imaged using an Odyssey Infrared Imaging System 
(Li-Cor).  Immunoblots were quantified by densitometry using Odyssey Infrared Imaging System 
Application Software (Li-Cor, version 3.0.21). 
Statistical analysis.  Analysis of variance (ANOVA) with Tukey post-hoc test was performed using 
SPSS software (IBM, New York, USA) version 18 for Windows.  Significance was determined at the 5% 
level and expressed relative to TNF-α treatment.  Four biological replicates for each 
control/treatment were utilised for analysis unless otherwise noted. 
5.3 Results 
Minimal upregulation of p47phox was detected following stimulation of cultured HUVEC with TNF-α 
for five hours, as compared with unstimulated (basal) cells (1.04 ± 0.32 fold increase from basal, 
mean ± SD; Figure 5.6).  Co-incubation of cells with TNF-α and increasing concentrations of vanillic 
acid (0.1, 1, or 10µM) resulted in a trend towards decreased p47phox expression relative to TNF-α 
alone (with a maximal response of 0.57 ± 0.41 fold of basal expression at 1µM and 10µM vanillic 
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acid), although these changes were not statistically significant (p = 0.2 at 1µM and 10µM vanillic acid; 
Figure 5.6). 
Figure 5.6 Modulation of HUVEC p47
phox
 protein expression by vanillic acid following stimulation with 
20ng/ml TNF-α. 
 
 
 
 
 
Expression of p47
phox
 protein (with GAPDH loading control) in cell lysates from unstimulated HUVEC (basal) and 
following incubation with 20ng/ml TNF-α in the presence or absence of 0.1, 1, or 10µM vanillic acid (VA) for 5 hours.  
Inset graph shows fold change in p47
phox
 expression relative to basal (designated as 1 and marked by dashed line), 
after quantification by densitometry and normalisation to loading control (mean ± SD, n=5).  No significant differences 
in fold change were observed between treatments (p > 0.05). 
A weak immunoreactive band was detected for phospho-p47phox following stimulation of cultured 
HUVECs with TNF-α for 15 minutes (Figure 5.7).  Pre-incubation of HUVECs with 0.1, 1, or 10µM 
vanillic acid for five hours prior to cell stimulation elicited no discernible effect on phospho-p47phox 
protein levels; however densitometric quantification of detected bands, and statistical analysis of 
densitometric data from replicate immunoblots, were precluded by poor immunodetection of 
phospho-p47phox (Figure 5.7). 
Figure 5.7 Modulation of HUVEC phospho-p47
phox
 protein levels by pre-incubation with vanillic acid 
prior to stimulation with 20ng/ml TNF-α. 
 
  
  
 
 
Levels of phospho-p47
phox
 protein (with GAPDH loading control) in cell lysates from unstimulated HUVEC (basal) and 
following stimulation with 20ng/ml TNF-α for 15 minutes, with or without 5 hours pre-incubation in the presence of 
0.1, 1, or 10µM vanillic acid (VA). 
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In order to characterise the effect of vanillic acid on p47phox expression in a more physiologically 
representative cell line, a study was conducted using cultured HCAEC.  Here, no significant 
modulation of p47phox expression was detected after cells were co-incubated with 20ng/ml TNF-α in 
the presence of increasing concentrations (0.1, 1, or 10µM) of vanillic acid (p > 0.05; Figure 5.8), 
although incubation of HCAEC with TNF-α alone again elicited minimal increases in p47phox protein 
levels relative to unstimulated cells (Figure 5.8). 
Figure 5.8 Modulation of HCAEC p47
phox
 protein expression by vanillic acid following stimulation 
with 20ng/ml TNF-α. 
  
Expression of p47
phox
 protein (with GAPDH loading control) in cell lysates from unstimulated HCAEC (basal) and 
following 5h incubation with 20ng/ml tumour necrosis factor-alpha (TNF-α), or TNF-α with 0.1, 1, or 10μM vanillic acid.  
Inset graph shows fold change in p47
phox
 expression relative to basal (designated as 1 and marked by dashed line), after 
quantification by densitometry and normalisation to loading control (n=4; mean ± SD).  No significant differences from 
TNF-α were observed (p > 0.05). 
5.4 Discussion 
The current study aimed to explore modulation of stimulated endothelial p47phox expression, or 
activation, by the anthocyanin degradant vanillic acid, as a mechanism potentially underlying 
observed bioactivity of anthocyanins and their phenolic degradants in reducing stimulated 
endothelial superoxide production (Chapter 2).  Translocation of p47phox protein between cellular 
fractions was examined to assess NOX activation, based upon previous reports (Li et al., 2005, Deng 
et al., 2012), although in the present investigation low protein content of membrane-enriched 
fractions precluded immunodetection of p47phox protein (Figure 5.4).  Activation of p47phox was 
therefore detected by immunoblotting for serine-phosphorylated protein (Figure 5.5), as 
phosphorylation of p47phox precedes membrane translocation of this subunit and NOX-mediated 
superoxide production (el Benna et al., 1994). 
A trend was observed towards decreased p47phox protein levels after co-incubation of HUVEC for five 
hours with TNF-α and increasing concentrations of the anthocyanin B-ring degradant vanillic acid 
(Figure 5.6).  Following ingestion of 13C-labelled cyanidin-3-glucoside, low micromolar levels of phase 
II conjugates of the B-ring degradant protocatechuic acid, including vanillic acid, have been reported 
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in human serum within six hours [~0.8µM (Czank et al., 2013)]; therefore both the concentrations of 
vanillic acid (0.1 - 10µM) and duration of exposure (five hours) used in the current investigation were 
of physiological relevance.  Whilst the observed reductions in p47phox protein were not statistically 
significant (p ≥ 0.2), they reflect previously published reports detailing downregulation of p47phox 
mRNA and/or protein by quercetin and its metabolite isorhamnetin, which contain a catechol and a 
mono-methylated catechol B-ring respectively (Sanchez et al., 2006, Sanchez et al., 2007, Romero et 
al., 2009, Davalos et al., 2009).  In contrast, no effect of vanillic acid was detected on levels of 
phospho-p47phox protein following a five hour pre-incubation of HUVECs with vanillic acid prior to 
acute stimulation by TNF-α (Figure 5.7); suggesting that vanillic acid does not modulate 
phosphorylation status of p47phox following cell stimulation and thus inhibit NOX activity by this 
mechanism. 
Given the absence of statistically significant effects on p47phox protein expression, the activity of 
vanillic acid was further explored in an alternative primary human endothelial cell model; as 
atherosclerosis is principally a disease of medium and large-sized arteries (Ross, 1999, Bonomini et 
al., 2008), and thus umbilical vein endothelial cells may not represent the most physiologically 
representative model for examining altered endothelial function preceding development of 
atherosclerotic lesions (Baudin et al., 2007).  Several previous research reports have investigated 
stimulated p47phox expression in cultured HCAEC (Yun et al., 2006, Dandapat et al., 2007, Yoshida and 
Tsunawaki, 2008, Chen et al., 2011b), therefore this cell type was selected for a confirmatory study of 
vanillic acid bioactivity.  Here, no significant modulation of TNF-α stimulated p47phox expression was 
detected after co-incubation of HCAEC with 0.1 - 10µM vanillic acid (Figure 5.8), and in contrast to 
HUVEC data (Figure 5.6) there was no trend towards downregulation of this protein; indicating 
HUVEC may not be an appropriate model for investigating modulation of p47phox levels in the context 
of arterial endothelial function. 
The current investigation therefore suggests vanillic acid is unlikely to affect activity of the 
superoxide-generating NOX2 isoform by decreasing protein expression of the key p47phox subunit, 
and apparent reductions in stimulated endothelial superoxide production elicited by anthocyanins 
and their degradants (Chapter 2) may not be attributable to this mechanism of action.  However, it is 
interesting to note that the anthocyanidin delphinidin has recently been reported to inhibit p47phox 
translocation and NOX activity in human dermal fibroblasts (Lim et al., 2013), suggesting that 
anthocyanins and/or their degradation products at cellular pH might modulate NOX function by this 
mechanism.  Moreover, vanillic acid is structurally similar to the vasoactive compound apocynin, 
which is reported to inhibit association of p47phox with membrane-bound components of the NOX 
complex (Drummond et al., 2011).  Activity of the NOX2 isoform may limit bioavailability of the key 
vascular mediator NO (Schroder, 2010), resulting in disruption of vascular homeostasis and 
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endothelial dysfunction; therefore decreasing NOX-generated superoxide production by preventing 
enzyme assembly could enhance NO levels and preserve vascular endothelial function in vivo. 
A limitation of the present investigation was the minimal change detected in both total p47phox 
expression (Figure 5.6 & Figure 5.8) and levels of phosphorylated p47phox (Figure 5.7) relative to 
unstimulated cells following stimulation of cultured endothelial cells with 20ng/ml TNF-α; although a 
time course experiment was conducted to identify the optimal incubation period with TNF-α for 
immunodetection of phospho-p47phox in HUVEC (Figure 5.5).  Previously published reports have 
described elevations in membrane-associated p47phox (Massaro et al., 2006, Carluccio et al., 2007, 
Deng et al., 2012), p47phox protein levels (Yoshida and Tsunawaki, 2008, Chen et al., 2011b), or 
phospho-p47phox levels (Frey et al., 2002, Li et al., 2005) following stimulation of human endothelial 
cells.  This may be partly attributable to the use of alternative cell types, for example pulmonary 
artery endothelial cells (Frey et al., 2002) or saphenous vein endothelial cells (Massaro et al., 2006).  
Equally, prior studies have used alternative cell stimulants, such as homocysteine (Carluccio et al., 
2007), or treatment conditions, for instance 40ng/ml TNF-α for 24 hours (Deng et al., 2012); which 
might also explain the limited response to cell stimulation observed in the current study relative to 
previous reports.  Furthermore, low expression of p47phox mRNA has been reported in HUVEC (Jones 
et al., 1996, Ago et al., 2004), which may contribute to poor immunodetection of the expressed 
protein; as observed previously for NOX2 following angiotensin II stimulation of cultured HUVEC 
(Chapters 2 & 4).  Another potential limitation of the current study was that the ratio of 
phosphorylated p47phox to total p47phox protein in HUVEC was not examined, although levels of total 
protein may not represent an appropriate reference as these were apparently affected by vanillic 
acid; and any changes in phosphorylated protein were compared to baseline or basal values (Figure 
5.5 & Figure 5.7). 
In summary, the current study has indicated that the anthocyanin degradant vanillic acid does not 
inhibit stimulated endothelial superoxide production by downregulating a key component of the 
NOX2 enzyme complex.  Both anthocyanin glucosides and their phenolic acid degradants appeared to 
decrease endothelial superoxide levels in a prior investigation (Chapter 2); suggesting a mechanism 
for reducing NO scavenging by superoxide anion and enhancing vascular function in vivo following 
ingestion of anthocyanins, where phenolic degradants and metabolites are likely to constitute the 
major circulating forms (Czank et al., 2013).  By contrast, direct upregulation and/or activation of 
endothelial nitric oxide synthase (eNOS) previously described for parent anthocyanins in vitro 
[Chapter 3, also (Xu et al., 2004b, Xu et al., 2004a, Sorrenti et al., 2007, Edirisinghe et al., 2011)] may 
not contribute to elevated NO levels in vivo; given the low human bioavailability reported for parent 
anthocyanins relative to their degradant products/metabolites (Vitaglione et al., 2007, Azzini et al., 
2010).  However, data from the present investigation and prior studies (Chapter 2) do not indicate a 
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direct inhibition of NOX2 function by vanillic acid, suggesting an indirect effect on stimulated 
superoxide production; potentially through upregulation of the cytoprotective haem oxygenase-1 
(HO-1) enzyme, which has been reported to inhibit NOX function in human microvascular endothelial 
cells (Jiang et al., 2006) and apolipoprotein E-deficient mice (Datla et al., 2007); and should form a 
focus of future research (as detailed in Chapter 6). 
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6 Effect of the anthocyanin phenolic degradant vanillic acid on 
endothelial haem oxygenase-1 expression 
6.1 Background 
Increased dietary intake of anthocyanins has been associated with decreased risk of cardiovascular 
disease (CVD) (Mink et al., 2007, Cassidy et al., 2013), which might in part reflect improved vascular 
endothelial function (Wallace, 2011) owing to enhanced availability of the key mediator nitric oxide 
(NO) (Xu et al., 2004b, Xu et al., 2004a, Bell and Gochenaur, 2006, Edirisinghe et al., 2011, Zhu et al., 
2011).  However, the molecular mechanisms underlying potential cardioprotective activity of 
anthocyanin degradation products and/or metabolites, which are likely to mediate anthocyanin 
bioactivity in vivo (Azzini et al., 2010, Czank et al., 2013), are not yet fully elucidated with regard to 
effects on the vascular endothelium.  Vascular endothelial dysfunction, and particularly reduced NO 
activity, forms an initial stage of atherosclerotic development (Landmesser et al., 2004, Kawashima 
and Yokoyama, 2004, Higashi et al., 2009), and loss of NO can arise through scavenging by superoxide 
anion, generating the potent oxidant peroxynitrite (Wever et al., 1998, Naseem, 2005).  The NADPH 
oxidase (NOX) transmembrane enzyme family constitutes a major source of reactive oxygen species 
in the vasculature (Bedard and Krause, 2007, Bonomini et al., 2008), moreover activity of the 
superoxide-generating NOX2 isoform could contribute to reduced vascular availability of NO 
(Brandes and Schröder, 2008, Violi et al., 2009, Schroder, 2010).  However, bilirubin derived from 
haem degradation by the haem oxygenase-1 (HO-1) enzyme may inhibit NOX activity (Jiang et al., 
2006, Datla et al., 2007), and bilirubin has also been reported to preserve expression of eNOS in 
stimulated endothelial cells (Kawamura et al., 2005).   
Haem oxygenase (HO) enzymes catalyse the oxidative degradation of cellular haem, yielding carbon 
monoxide (CO) gas, free ferrous (Fe2+) iron, and the bile pigment biliverdin IXα (subsequently 
reduced to bilirubin IXα by biliverdin reductase) (Ryter et al., 2002, Ryter et al., 2006).  Two 
isoenzymes of HO have been characterised, an inducible form (HO-1, molecular mass ~32,000 Da) 
and a constitutively expressed form (HO-2, molecular mass ~34,000 Da) (Abraham and Kappas, 
2008); localised to subcellular compartments such as the rough endoplasmic reticulum and plasma 
membrane caveolae (Ryter et al., 2006).  Upregulation of HO-1 can be induced in both tissues and 
cultured cells by a range of chemical or physical agents, including nitric oxide (NO), pro-inflammatory 
cytokines, heavy metals, oxidised low-density lipoprotein (LDL), ultraviolet A radiation, and both 
hypo- and hyperoxia (Siow et al., 1999, Ryter et al., 2002, Ryter et al., 2006, Abraham and Kappas, 
2008).  In the absence of cellular stress, HO-1 is normally present at low or undetectable levels in 
most cell types or tissues (Ryter et al., 2002, Ryter et al., 2006), and upregulation of HO-1 confers 
protection against oxidative stress in vivo and in vitro (Ryter et al., 2002).  Carbon monoxide 
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produced by HO displays anti-inflammatory (Ryter et al., 2002) and vasodilatory (Siow et al., 1999) 
activity; and HO-1-derived bilirubin can scavenge reactive oxygen species in vitro, inhibit NOX 
function, and enhance vascular reactivity (Abraham and Kappas, 2008).  Indeed, upregulation of HO-
1 with subsequent inhibition of NOX activity has been described in human microvascular endothelial 
cells (Jiang et al., 2006) and apolipoprotein-E deficient mice (Datla et al., 2007). 
Anthocyanins and/or their metabolites (in ex vivo serum incubation) have previously been reported 
to upregulate expression of HO-1 in human vascular endothelial cells (Sorrenti et al., 2007, Cimino et 
al., 2013), and thus could potentially decrease endothelial NOX activity through induction of HO-1.  
Inhibition of NOX may represent a mechanism by which certain flavonoids enhance vascular function 
by increasing NO bioavailability (Schewe et al., 2008); and elevated CO production through 
upregulation of HO-1 might also mediate a vasodilatory effect (Chan et al., 2011).  Based upon earlier 
investigations (Chapters 2 & 3) the anthocyanin B-ring degradant vanillic acid (Figure 6.1) was 
selected to elucidate cellular mechanisms potentially underlying the reductions in superoxide levels 
observed previously with anthocyanins and their degradants (Chapter 2). 
Figure 6.1 Anthocyanin degradant (vanillic acid) selected for investigation of potential mechanisms of 
NOX inhibition. 
   
 
In the current study, the effect of vanillic acid (at 0.1 - 10μM) on endothelial mRNA and protein levels 
of HO-1 was examined by reverse transcription – quantitative polymerase chain reaction (RT-qPCR) 
and immunoblotting respectively; to assess whether basal HO-1 expression was modulated by vanillic 
acid, as a potential indirect mechanism of NOX inhibition.  Experiments were conducted using human 
umbilical vein endothelial cells (HUVEC), which represent an experimental model of endothelial cells 
(Baudin et al., 2007); and human coronary artery endothelial cells (HCAEC) as a more physiologically 
representative model of endothelial function in the context of atherosclerotic development within 
medium and large-sized arteries (Bonomini et al., 2008). 
6.2 Materials and methods 
Standards and reagents.  Vanillic acid was purchased from Sigma-Aldrich [Poole, United Kingdom 
(UK)] and a 200mM standard solution was prepared in 100% dimethylsulphoxide (DMSO; Sigma-
Aldrich molecular biology grade).  All water utilised was of Milli-Q grade (18.2 MΩ cm-1). 
OH O
OH
OCH3
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Tumour necrosis factor-alpha (TNF-α), TRIzol® reagent, RNase-free water, oligo (dT) primer (50μM), 
SuperScript® II Reverse Transcriptase (with 5x first strand buffer and 100mM dithiothreitol/DTT), and 
MicroAmp™ optical microplates were obtained from Life Technologies (Paisley, UK).  RiboLock RNase 
inhibitor, DNase I (with 10x reaction buffer with MgCl2, and 50mM EDTA), dNTP PCR mix (10mM), 
oligo (dT) primer (100μM), chloroform (molecular biology grade), and isopropanol were purchased 
from Thermo Fisher Scientific (Fisher Scientific, Loughborough, UK); and ethanol (molecular biology 
grade), (octylphenoxy)polyethoxyethanol (CA-630), phorbol 12-myristate 13-acetate (PMA), and 
fibronectin from Sigma-Aldrich.  Precision 2x real-time PCR MasterMix with SYBR®Green was 
obtained from PrimerDesign Ltd (Southampton, UK), and custom primers for human HO-1 (HMOX-1, 
accession number NM_002133.2) were supplied by Life Technologies.  The primer sequences (5’ to 
3’) used were ATGGCCTCCCTGTACCACATC (forward) and TGTTGCGCTCAATCTCCTCCT (reverse). 
Safe-lock microcentrifuge tubes were purchased from Qiagen (Crawley, UK), acid-washed glass beads 
(~0.5mm diameter) from Sigma-Aldrich, and Complete Protease Inhibitor Cocktail Tablets were 
obtained from Roche Applied Science (Burgess Hill, UK).  NuPAGE sample reducing agent and LDS 
sample buffer were purchased from Invitrogen, and Precision Plus Protein Dual Colour standards 
from Bio-Rad Laboratories, Inc (Hemel Hempstead, UK).  Protein-Free T20 (TBS) blocking buffer was 
obtained from Fisher Scientific (Loughborough, UK); Immobilon-FL PVDF membrane from Millipore, 
and InstantBlue protein gel stain from Expedeon Protein Solutions (Harston, UK).  Tween® 20 was 
purchased from Sigma-Aldrich.  Chicken polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH; AB2302) was obtained from Millipore (Watford, UK) and rabbit polyclonal anti-HO-1 
(ab13243) from Abcam (Cambridge, UK).  Donkey anti-chicken IgG (IR dye 680 LT) and goat anti-
rabbit IgG (IR dye 800 CW) were supplied by Li-Cor (Cambridge, UK).  Antibodies were prepared in a 
diluent of 50% T20 blocking buffer:50% phosphate-buffered saline (PBS) with 0.5% Tween® 20; and 
including 0.02% sodium dodecyl sulphate for solutions of IR dye 680 LT anti-IgG antibodies. 
Cell culture.  Cryo-preserved, early passage, pooled HUVEC were purchased from TCS CellWorks 
(Buckingham, UK) and used between passages two to four.  Cells were routinely cultured in 75cm2 
flasks (SPL Life Sciences) coated with fibronectin (0.27µg/cm2), using large vessel endothelial cell 
growth medium [TCS CellWorks; proprietary basal medium formulation supplemented with growth 
factor and antibiotic (gentamicin & amphotericin B) supplements, final concentration of 2% v/v foetal 
bovine serum] at 37°C and 5% CO2.  HUVECs were sub-cultured using 0.025% trypsin and 0.01% EDTA 
(TCS CellWorks). 
Cryo-preserved, second passage, single donor HCAEC were purchased from PromoCell GmbH 
(Heidelberg, Germany) and used between passages three to six (Figure 6.2).  Cells were routinely 
cultured in 75cm2 flasks (SPL Life Sciences) coated with fibronectin (0.27µg/cm2), using endothelial 
cell medium MV (PromoCell GmbH; proprietary basal medium formulation supplemented with foetal 
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calf serum, endothelial cell growth supplement, recombinant human epidermal growth factor, 
heparin, and hydrocortisone, final concentration of 5% v/v foetal calf serum) at 37°C and 5% CO2.  
HCAEC were sub-cultured using 0.04% trypsin and 0.03% EDTA (PromoCell GmbH). 
Figure 6.2 Light microscopy image of sub-confluent HCAEC at sixth passage (cultured on fibronectin 
coating). 
 
 
 
6.2.1 Method development – HUVEC RT-qPCR 
Reverse-transcription – quantitative polymerase chain reaction: method development for HUVEC 
model (Figure 6.3 & Appendix Table 9.2.8).  Method development was conducted to identify a 
positive control for upregulation of HO-1 expression (Figure 6.3 A); and to select endogenous 
reference genes for normalisation of Ct data for genes of interest (Figure 6.3 B). 
Figure 6.3 Analysis of HUVEC HO-1 expression: RT-qPCR method development flow chart. 
 
 
 
 
 
 
 
Cell stimulant (Figure 6.3 A).  A positive control for induction of HO-1 expression was identified using 
20ng/ml TNF-α with or without serum starvation (Terry et al., 1998, Terry et al., 1999), and 10ng/ml 
PMA.  Cultured HUVEC (~70 - 80% confluent) were incubated for five or six hours with TNF-α or PMA 
respectively, as comparable to the six hour period used in the previously reported stimulated 
superoxide production assay (Chapters 2 & 5); prior to RNA extraction and first strand cDNA 
synthesis.  For the serum-starved condition, HUVEC were pre-incubated for three hours in basal 
(non-supplemented) endothelial cell growth medium, prior to incubation with TNF-α in the same 
PMA TYW1, 
PPIA 
A. Positive control 
TNF-α, PMA 
 
B. Reference genes 
PPIA, PRDM4, UBE2D2, 
UBE4A, TYW1, 
C14orf133/VIPAR 
 
116/185 
medium.  Expression of HO-1, in addition to six reference genes (Table 6.1), was compared against 
unstimulated (basal) cells by real-time PCR.  PMA elicited optimal upregulation of HO-1 expression, 
and was used as the positive control. 
Reference/housekeeping genes (Figure 6.3 B).  Reference genes for normalisation of Ct data were 
selected using a geNormPLUS kit (PrimerDesign Ltd).  Primer sets for six stably expressed human 
reference genes (Table 6.1) were designed, pre-validated and supplied by PrimerDesign Ltd, and used 
to evaluate expression of these genes in both unstimulated and stimulated HUVEC.  Real-time PCR 
data were analysed using the geNorm function in qbasePLUS software (version 2.3, Biogazelle NV, 
Zwijnaarde, Belgium) to assess reference gene stability across samples, and optimal number of 
reference genes (Vandesompele et al., 2002). 
Table 6.1 Reference/housekeeping genes evaluated during method development. 
Gene Description 
PPIA Peptidylprolyl isomerase A (cyclophilin A) 
PRDM4 PR domain containing 4 
UBE2D2 Ubiquitin-conjugating enzyme E2D 2 
UBE4A Ubiquitination factor E4A 
TYW1 tRNA-yW synthesizing protein 1 homologue (S. cerevisiae) 
VIPAR/C14orf133/VIPAS39 VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 
homologue 
Cultured HUVEC were incubated for six hours with culture medium only (basal), 10ng/ml PMA, 
vehicle control (0.005% DMSO), or 10μM vanillic acid.  Following RNA extraction and first strand 
cDNA synthesis, reference gene expression was assessed by real-time PCR, and the generated Ct data 
were analysed using qbasePLUS.  The average expression stability of reference targets across 
treatment conditions (geNorm M value) was investigated by geNorm analysis (Figure 6.4; targets 
plotted in order of increasing stability from left to right); and optimal number of targets was also 
confirmed (Figure 6.5).  TYW1 and PPIA were identified as the optimum reference genes, and their 
geometric mean used as the normalisation factor in the final assay. 
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Figure 6.4 Average reference gene expression stability (geNorm M graph) for untreated HUVEC and 
following 6h incubation with 10ng/ml PMA, vehicle control (0.005% DMSO), or 10μM 
vanillic acid. 
 
geNorm M graph demonstrating average reference gene expression stability (geNorm M value, y-axis) across 
experimental conditions (ie untreated, PMA, vehicle control, or 10μM vanillic acid).  Reference genes (x-axis) are 
arranged in order of increasing stability from left to right (refer to Table 6.1 for gene descriptions). 
 
Figure 6.5 Determination of optimal number of reference genes (geNorm V graph) for untreated 
HUVEC and following 6h incubation with 10ng/ml PMA, vehicle control (0.005% DMSO), or 
10μM vanillic acid. 
 
geNorm V graph determining optimal number of reference genes.  ‘V2/3’ denotes comparison between 2 genes and 3 
genes, ‘V3/4’ compares 3 genes versus 4 genes etc. across untreated (basal) and treated (PMA, vehicle control, or 10μM 
vanillic acid) samples.  Where the geNorm V value is below 0.15 (ie below dashed line), no additional benefit is derived 
using a further reference gene. 
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6.2.2 Final methodology 
HO-1 gene expression assay: optimised parameters.  The optimised HO-1 gene expression assay 
used 6-well plates (SPL Life Sciences) coated with fibronectin (0.25µg/cm2), which were seeded with 
HUVEC at a density of ~100,000 cells/well, and the cells grown to ~70% confluence (~24 hours at 
37°C and 5% CO2).  Culture medium was then aspirated, and the cells were incubated for six hours in 
supplemented culture medium alone (basal), or media with 10ng/ml PMA, 0.005% DMSO, or 0.1, 1 or 
10µM vanillic acid.  After incubation, media was aspirated from all wells, and the plates were either 
frozen at -80°C or utilised for RNA extraction. 
RNA extraction and mRNA reverse transcription.  RNA was extracted from cultured cells by phenol-
based organic extraction.  Briefly, cells were homogenised using TRIzol reagent (1ml per well), and 
homogenates incubated for ten minutes at room temperature.  Following addition of 200μl 
chloroform, samples were agitated vigorously, incubated for ten minutes at room temperature, and 
then subject to centrifugation at 12,000g for 20 minutes at 4°C.  Four hundred microlitres of the 
aqueous phase was removed and mixed with 500μl isopropanol, prior to a ten minute incubation at 
room temperature.  Cellular RNA was pelleted by centrifugation at 12,000g for 15 minutes at 4°C, 
and washed with 1000μl of 75% ethanol by centrifugation at 12,000g for ten minutes at 4°C.  After 
removal of supernatants, pellets were partially dried and resuspended in 20μl RNase-free water, 
prior to a 15 minute incubation at 57.5°C.  Quantification of RNA was performed using a NanoDrop 
2000 (Thermo Fisher Scientific). 
One microgram of each RNA sample was utilised in a 20μl reverse transcription reaction with oligo 
(dT) primers.  Prior to reverse transcription, RNA was incubated for 30 minutes at 37°C with DNase I 
and RiboLock RNase inhibitor, to remove any residual genomic DNA from extracted RNA.  Following 
addition of EDTA, oligo (dT) primers (final concentration 5μM), and dNTP PCR mix, DNase was 
inactivated by a 10 minute incubation at 65°C.  First strand buffer, RiboLock, and DTT were then 
added to each sample, prior to a two minute incubation at 42°C to allow annealing of primers.  After 
the addition of SuperScript® II (or RNase-free water for a no reverse-transcriptase control), samples 
were incubated at 42°C for 50 minutes for first strand cDNA synthesis, followed by a 15 minute 
incubation at 70°C to inactivate the reverse transcriptase enzyme. 
Real-time PCR.  Analysis of gene expression was performed using the Applied Biosystems 7500 Real 
time PCR System (Life Technologies; 7500 software version 2.0) with SYBR®Green detection.  
Typically, 25ng cDNA (or RNase-free water for a ‘no template’ control) was amplified with 300nM of 
the appropriate primer set, and 8.33μl Precision 2x real-time PCR MasterMix with SYBR®Green 
(Primer Design Ltd) in a total volume of 20μl.  Following enzyme activation at 95°C for 10 minutes, 50 
cycles of denaturation (15 seconds at 95°C) and data collection (60 seconds at 60°C) were performed, 
119/185 
prior to melt curve analysis to confirm specificity of amplification.  Relative changes in gene 
expression following cell treatment, as compared with basal (unstimulated) cells, were quantified 
using the comparative Ct method (Dorak, 2006, Schmittgen and Livak, 2008), incorporating the 
geometric mean of reference genes TYW1 and PPIA as the normalisation factor. 
Immunoblot analysis of HO-1 protein.  Cell lysates for immunoblotting were generated from 
cultured HUVEC or HCAEC incubated with culture medium only (basal), or PMA, vehicle control 
(HUVEC only), or vanillic acid (0.1 - 10µM).  Briefly, 6-well plates (SPL Life Sciences) coated with 
fibronectin (0.25µg/cm2) were seeded with HUVEC or HCAEC at a density of 100,000 cells/well, and 
cells were grown to ~70% confluence.  Thereafter, cells were incubated for six hours in 
supplemented culture medium only, or media with 10ng/ml PMA, 0.005% DMSO (HUVEC only), or 
0.1, 1, or 10μM vanillic acid (in ≤ 0.005% DMSO for HUVEC, or without DMSO for HCAEC).  Cells were 
harvested and lysed in 1% (octylphenoxy)polyethoxyethanol (CA-630), 150mM NaCl, 20mM Tris and 
10% glycerol (pH 8.0), supplemented with protease inhibitors (Complete Protease Inhibitor Cocktail).  
Six-well plates were incubated with lysis buffer (120µl/well) for 30 minutes at 4°C, prior to removal of 
cells by scraping.  Recovered solutions were subject to cell disruption by rapid agitation (50Hz for 5 
minutes with Qiagen TissueLyser LT) with acid-washed glass beads in safe-lock microcentrifuge tubes.  
After centrifugation at 13,000 rpm (15 minutes at 4°C), the protein content of the supernatants was 
assayed using the Pierce BCA Protein Assay Kit according to manufacturer’s instructions. 
For gel electrophoresis, samples were reduced using NuPAGE sample reducing agent (50mM 
dithiothreitol) prior to gel loading in NuPAGE LDS sample buffer.  Precision Plus Protein Dual Colour 
standards were loaded as comparative molecular weight markers.  Normally 15µg (HUVEC) or 20μg 
(HCAEC) of protein was loaded onto a 4% polyacrylamide stacking gel, and separated across a 10% 
resolving gel (at 25mA for approximately one hour) prior to semi-dry transfer to Immobilon-FL PVDF 
membrane (at 25V for 60 minutes).  Equal protein transfer was confirmed by InstantBlue staining of 
the gels.  Membranes were blocked with T20 blocking buffer for one hour at room temperature, and 
incubated overnight (at 4°C) in the appropriate concentration of primary and loading control 
antibody (anti-GAPDH, 1 in 10,000; anti-HO-1; 1 in 2000).  Membranes were washed using PBS with 
0.1% Tween® 20 (PBST 0.1%), after which secondary antibody incubations were performed for one 
hour at room temperature, using IR dye-conjugated (680 and 800) secondary antibodies at a 
concentration of 1 in 10,000.  Membranes were washed with PBST 0.1%, and subsequently imaged 
using an Odyssey Infrared Imaging System (Li-Cor).  Immunoblots were quantified by densitometry 
using Odyssey Infrared Imaging System Application Software (Li-Cor, version 3.0.21). 
Statistical analysis.  Analysis of variance (ANOVA) with Tukey post-hoc test was performed using 
SPSS software (IBM, New York, USA) version 18 for Windows.  Significance was determined at the 5% 
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level and expressed relative to DMSO (vehicle control) or PMA (positive control).  Three biological 
replicates for each control/treatment were used for analysis unless otherwise noted. 
6.3 Results 
Following incubation of HUVEC with 10ng/ml PMA for six hours, HO-1 mRNA levels were significantly 
elevated (6.42 ± 1.63 fold increase from basal; mean ± SD), as compared with the vehicle control 
0.001% DMSO (0.62 ± 0.12 fold change from basal).  Exposure to vanillic acid at concentrations of 
0.1μM, 1μM, and 10μM appeared to elicit a concentration-dependent increase in endothelial HO-1 
mRNA, with fold changes from basal of 0.53 ± 0.12, 1.03 ± 0.21, and 1.59 ± 0.29 respectively; 
although there were no significant differences compared to vehicle control (p = 1.0 for 0.1µM vanillic 
acid, p = 1.0 for 1µM vanillic acid, and p = 0.5 for 10µM vanillic acid; Figure 6.6). 
Figure 6.6 Modulation of HUVEC HO-1 mRNA levels following six hour 
incubation with 0.1 - 10μM vanillic acid. 
 
Fold change in HUVEC HO-1 mRNA levels versus unstimulated cells (basal; denoted by 
dashed line) following 6 hour incubation with vehicle control (VC, 0.005% DMSO), 
10ng/ml phorbol 12-myristate 13-acetate (PMA), or 0.1μM, 1μM or 10μM vanillic acid.  
Relative quantification was performed using the comparative Ct method, incorporating 
the geometric mean of reference genes TYW1 and PPIA as the normalisation factor.  Data 
are graphed as mean ± SD (n=3). *Significant difference versus vehicle control (*p < 0.01). 
An apparent upregulation of HO-1 protein in HUVEC following a six hour incubation with vanillic acid 
was observed at all concentrations of vanillic acid tested, with a maximal response at 1µM (mean 
1.83 ± 0.34 fold increase over basal), although the response was variable between biological 
replicates and no changes were significant relative to the vehicle control (p = 0.6 at 1μM vanillic acid, 
Figure 6.7).  A non-significant increase in HO-1 protein was observed following treatment with the 
positive control PMA (mean 1.92 ± 0.36 fold increase) relative to the vehicle control (p = 0.3); 
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however, the vehicle control (0.005% DMSO) also increased levels of HO-1 protein from basal (Figure 
6.7). 
Figure 6.7 Modulation of HUVEC HO-1 protein expression following six hour incubation with 0.1 - 
10μM vanillic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of HO-1 protein (with GAPDH loading control) in cell lysates from unstimulated HUVEC (basal) and following 
6h incubation with 10ng/ml phorbol 12-myristate 13-acetate (PMA), vehicle control (VC, 0.005% DMSO) or 0.1μM, 
1μM or 10μM vanillic acid.  Graph shows fold increase in HO-1 expression relative to basal (designated as 1 and 
marked by dashed line), after quantification by densitometry and normalisation to loading control (n=4; mean ± SD).  
No significant differences from vehicle control were observed (p > 0.05). 
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In order to characterise the observed effects of vanillic acid in a more physiologically relevant 
vascular endothelial cell model, a study was conducted using cultured HCAEC, with vanillic acid 
prepared directly in aqueous solution to exclude vehicle-related activity.  Here, HO-1 protein 
appeared to be upregulated at all concentrations of vanillic acid tested, with a maximal effect at 1µM 
(mean 1.81 ± 0.63 fold increase over basal; Figure 6.8); although again, responses were variable 
between biological replicates and no changes were significant relative to unstimulated cells (p ≥ 0.3). 
Figure 6.8 Modulation of HCAEC HO-1 protein expression following six hour incubation with 0.1 - 
10μM vanillic acid. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of HO-1 protein (with GAPDH loading control) in cell lysates from unstimulated HCAEC (basal) and following 
6h incubation with 10ng/ml phorbol 12-myristate 13-acetate (PMA), or 0.1μM, 1μM or 10μM vanillic acid.  Graph 
shows fold increase in HO-1 expression relative to basal (designated as 1 and marked by dashed line), after 
quantification by densitometry and normalisation to loading control (n=4; mean ± SD).  No significant differences from 
basal were observed (p > 0.05). 
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Given the limited induction of HO-1 protein by PMA in HCAEC (Figure 6.8), cultured HCAEC were 
incubated with 10ng/ml PMA for six hours and 24 hours, to assess whether an extended incubation 
period resulted in elevated upregulation of HO-1 from basal levels.  However, the fold increase in 
HO-1 protein over basal following PMA stimulation was comparable at both time points (~1.5-fold 
increase; Figure 6.9). 
Figure 6.9 Expression of HO-1 protein in HCAEC lysates following six hour or 24 hour incubation 
with PMA. 
 
Expression of HO-1 protein (with GAPDH loading control) in lysates prepared from unstimulated HCAEC (basal) and 
following either a six hour (6h) or 24 hour (24h) incubation with 10ng/ml phorbol 12-myristate 13-acetate (PMA).  
Inset graph shows fold increase in HO-1 expression relative to basal (designated as 1 and marked by dashed line), 
after quantification by densitometry and normalisation to loading control (n=1). 
6.4 Discussion 
The current investigation aimed to explore a potential mechanism by which the anthocyanin 
degradant vanillic acid could indirectly inhibit NOX activity in vascular endothelium, specifically 
through upregulating the inducible isoform of haem oxygenase/HO-1 (Jiang et al., 2006, Wolin and 
Abraham, 2006, Datla et al., 2007).  Inhibition of NOX-generated superoxide production may 
preserve bioavailability of the key meditator NO, with beneficial effects on vascular endothelial 
function, as suggested for certain flavonoids and their metabolites (Steffen et al., 2007b, Steffen et 
al., 2008, Schewe et al., 2008); as opposed to direct effects on endothelial NO synthase observed for 
parent anthocyanins but not phenolic acid degradation products including vanillic acid (Chapter 2).  
In a previous study, vanillic acid appeared to reduce endothelial superoxide levels following 
stimulation of NOX activity (Chapter 2); however, no significant modulation of endothelial expression 
of NOX2, NOX4, p22phox and p47phox mRNA and/or protein could be discerned following exposure to 
0.1 - 10µM vanillic acid (Chapters 2, 4 & 5), nor was it possible to detect any effect of vanillic acid 
upon p47phox activation following cell stimulation (Chapter 5).  These data therefore suggested an 
indirect effect of vanillic acid on NOX activity, which forms the basis of the present study examining 
endothelial HO-1 expression as a possible indirect mechanism of regulating NOX-mediated 
superoxide production and thereby enhancing NO levels in the vasculature. 
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Here, stimulation of cultured HUVEC with the positive control PMA [a protein kinase C activator 
(Terry et al., 1999)] elicited a six-fold increase in HO-1 mRNA from basal levels (Figure 6.6).  This 
elevation was comparable to a reported four- to five-fold increase in HO-1 mRNA levels following 
incubation of HUVEC with 0.1µg/ml PMA for four hours (Terry et al., 1999), indicating that the cells 
used in the current study were sufficiently responsive to a known stimulant of HO-1 expression.  
Moreover, expression of HO-1 protein by HUVEC was apparently increased following PMA 
stimulation as compared with unstimulated cells (Figure 6.7), by an average of two-fold, and Li et al 
(2004) have described a similar response in perfused rat kidneys after a two hour exposure to 0.2µM 
PMA (Li et al., 2004).  In the present study, the vehicle control (0.005% DMSO) slightly increased HO-
1 protein relative to basal (1.49-fold increase), potentially reducing the sensitivity of the assay; 
however, this reflects previously reported induction of HO-1 protein in HUVECs by low 
concentrations of DMSO (Liang et al., 2011).  Liang et al (2011) observed upregulation of HUVEC HO-
1 mRNA and protein expression following a four hour incubation with 0.05% DMSO, in a time- and 
concentration-dependent response mediated partly through activity of c-Jun-N-terminal kinases 
(JNKs) and NF-E2-related factor 2 (Nrf2) (Liang et al., 2011); although interestingly no effect of DMSO 
on HUVEC HO-1 mRNA levels was observed in the current investigation (0.62-fold change versus 
basal; Figure 6.6). 
Elevated endothelial HO-1 mRNA expression was observed following a six hour incubation of cultured 
HUVEC with 1µM and 10µM vanillic acid (1.03-fold and 1.59-fold increase versus basal respectively; 
Figure 6.6), in what appeared to be a concentration-dependent response, although the maximal 
response at 10μM vanillic acid was not significantly different from the vehicle control (p = 0.5).  An 
apparent increase in protein levels of HO-1 was also detected following exposure of HUVEC to vanillic 
acid, where the maximal response at 1µM vanillic acid (1.83-fold increase versus basal, Figure 6.7) 
was similar to that elicited by the positive control PMA (1.92-fold increase); although the observed 
changes were variable across replicates and not significant as compared with the vehicle control (p = 
0.6 and p = 0.3 respectively).  However, vanillic acid appeared to induce endothelial HO-1 expression, 
which could potentially inhibit NOX activity thus preserving NO levels and ultimately vascular 
homeostasis.  The induction of HO-1 protein elicited by both 1μM vanillic acid and PMA is of 
particular interest, given the significant elevation in HO-1 mRNA induced by PMA over the same 
period (Figure 6.6); suggesting no direct correlation between the magnitude of observed stimulatory 
effects on HO-1 mRNA relative to those on protein, and perhaps indicating an effect of vanillic acid at 
the translational/post-translational level as opposed to activation of gene transcription. 
In order to characterise further the activity of vanillic acid on endothelial HO-1 expression, an 
additional study was conducted using a more physiologically relevant vascular endothelial cell type; 
specifically human coronary artery endothelial cells.  Whilst HUVEC represent a widely used model 
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for research concerning general properties of endothelial cells (Baudin et al., 2007), a human arterial 
endothelial cell type may be more appropriate for studies investigating the potential modulation of 
NOX activity in relation to endothelial dysfunction preceding atherosclerosis, which is principally a 
disease of medium and large-sized arteries (Ross, 1999, Vita, 2005).  A number of previously 
published research reports have employed HCAEC to assess the effect of treatment compounds on 
HO-1 expression (Kaga et al., 2005, Vidavalur et al., 2006, Ungvari et al., 2010, Khoo et al., 2010, Wu 
et al., 2012, Donovan et al., 2012), and as such the effect of vanillic acid at 0.1 - 10µM on HO-1 
protein expression was investigated in cultured HCAEC.  For this study, vanillic acid was prepared 
directly in cell culture medium to exclude any vehicle-related effects on HO-1 expression, owing to 
induction of HO-1 observed with low concentrations of DMSO as discussed above. 
In the HCAEC model, an apparent upregulation of HO-1 protein was observed following exposure to 
increasing concentrations of vanillic acid (Figure 6.8), with a maximal increase of ~1.81-fold over 
basal at 1μM vanillic acid (p = 0.3), although again, the detected changes were variable between 
biological replicates.  Similar observations suggesting elevated endothelial HO-1 protein levels (Figure 
6.7 & Figure 6.8) were noted in both the HUVEC and HCAEC models following exposure to vanillic 
acid, as opposed to disparate effects between models on p47phox protein expression as described in 
Chapter 5; indicating HUVEC may represent an appropriate model for investigating modulation of 
HO-1 expression by anthocyanin phenolic degradants in the context of vascular endothelial cell 
function.  Interestingly, no linear concentration-response relationship was observed for the effects of 
vanillic acid on HO-1 expression in either cell model, in accordance with previous reports describing 
differential bioactivity of flavonoids across a concentration range (Chirumbolo et al., 2010, Kay et al., 
2012).  Upregulation of HO-1 may indirectly inhibit endothelial NOX activity (Wolin and Abraham, 
2006), and therefore reduce scavenging of the key vascular mediator NO by NOX-derived superoxide 
(Brandes et al., 2010), indicating a potential mechanism by which anthocyanin degradants or 
metabolites formed in vivo following anthocyanin intake (such as vanillic acid) (Czank et al., 2013) 
might act to enhance vascular function.  Indeed, Cimino et al (2013) have reported Nrf2 nuclear 
translocation and HO-1 expression in cultured HUVEC elicited by serum samples obtained from 
healthy subjects following ingestion of 160mg purified anthocyanins; which may reflect activity of 
anthocyanin metabolites as opposed to parent compounds (Cimino et al., 2013).  Increased HO-1 
expression could also result in elevated levels of generated CO and subsequent vasodilatory activity 
(Siow et al., 1999), although CO is considerably less potent as a vasodilator relative to NO (Chan et 
al., 2011). 
A limitation of the current investigation was the minimal increase detected in HO-1 protein following 
stimulation of HCAEC with the positive control PMA, as previous reports (Appendix Table 9.2.8) have 
described 2- to- 8-fold increases in HO-1 protein levels following stimulation of HCAEC with agents 
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such as haemin chloride, sildenafil, niacin, and Protandim (a marketed phytochemical dietary 
supplement).  (Vidavalur et al., 2006, Zieger and Gupta, 2009, Wu et al., 2012, Donovan et al., 2012).  
Upregulation of HO-1 protein elicited by PMA in the current study ranged from ~1.2 - 1.5-fold (Figure 
6.8 & Figure 6.9), and was not enhanced by an extended incubation period with PMA (Figure 6.9).  
These data suggest considerable variation in the response of cultured HCAEC to cell stimulation, 
which may constitute an inherent limitation of an endothelial cell culture model, as also reflected by 
the variability in response to vanillic acid observed between biological replicates in both models 
(Figure 6.7 & Figure 6.8).  Equally, the limited effect of PMA in the current study could also reflect the 
use of a lower concentration (10ng/ml, ~16.2nM) to stimulate HCAEC as compared with studies 
using, for example, 100ng/ml (Zhao et al., 2004) or 100nM (Meyer et al., 2005) PMA.  A strength of 
the HCAEC confirmatory study was the exclusion of any vehicle (DMSO)-related effects on HO-1 
induction (Liang et al., 2011), as observed in the HUVEC model, by preparing vanillic acid in aqueous 
solution and therefore ensuring observed effects reflected the activity of vanillic acid alone.  
Moreover, and as described in a previous investigation (Chapter 4), optimal endogenous reference 
genes were identified for relative quantification of HUVEC HO-1 mRNA levels (Figure 6.4 & Figure 
6.5); as selection of multiple reference genes stably expressed across experimental conditions 
ensures accurate normalisation of qPCR data to account for non-treatment related sources of 
variation between samples, such as RNA extraction and reverse transcription yields (Bustin et al., 
2009). 
In summary, the current study has indicated that the anthocyanin degradant vanillic acid might act to 
upregulate vascular endothelial expression of HO-1, as reported for cyanidin-3-glucoside (Sorrenti et 
al., 2007).  A previous investigation (Chapter 3) has demonstrated that bioactivity of anthocyanin 
glycosides may not necessarily correspond to activity of phenolic degradation products or 
metabolites, but to date no studies have sought to characterise the vascular bioactivity in vitro of 
these compounds at physiologically relevant concentrations.  Indeed, low human bioavailability of 
anthocyanin glycosides (Vitaglione et al., 2007, Azzini et al., 2010, Czank et al., 2013) suggests 
anthocyanin bioactivity in vivo is likely to be mediated by their degradants or metabolites present at 
levels in excess of the parent compound – for example Czank et al (2013) have reported a 42-fold 
greater abundance of metabolites in human serum relative to the administered parent anthocyanin 
cyanidin-3-glucoside, based on maximal serum concentrations (Czank et al., 2013).  Moreover, 
anthocyanin degradants and metabolites may act by mechanisms different to those reported for the 
parent compounds, such as upregulation of eNOS expression observed with anthocyanin-3-
glucosides (Chapter 3) and described by other studies (Xu et al., 2004b, Sorrenti et al., 2007, Paixão 
et al., 2012).  In contrast, anthocyanin phenolic degradants/metabolites could indirectly elevate NO 
levels through HO-1-mediated NOX inhibition, with enhanced vascular function resulting from 
improved NO bioavailability.  This should be explored further in an endothelial model by examining 
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modulation of HO-1 protein expression, and/or activity as assessed by bilirubin production (Datla et 
al., 2007); relative to NO levels [using reductive chemiluminescence methodology (MacArthur et al., 
2007, Brossette et al., 2011)] and NOX-derived superoxide production quantified by, for example, 
electron spin resonance spectroscopy (Maghzal et al., 2012) in cell supernatants.  Dysfunction of the 
vascular endothelium, and in particular reduced bioavailability of NO from eNOS with impaired 
endothelium dependent relaxation, is an initial process in the development of atherosclerosis 
(Landmesser et al., 2004, Kawashima and Yokoyama, 2004, Higashi et al., 2009); thus the current 
investigation suggests a mechanism by which anthocyanin degradants or metabolites may enhance 
vascular function in vivo, and thereby explain at least part of the reported cardioprotective activity of 
dietary anthocyanins observed following habitual intake in prospective studies (Mink et al., 2007, 
Cassidy et al., 2013). 
  
128/185 
7 Overview and future perspectives 
7.1 General discussion 
Consumption of anthocyanins may have beneficial effects on human vascular function, based upon 
data from both epidemiological studies (Mink et al., 2007, Cassidy et al., 2010, McCullough et al., 
2012, Jennings et al., 2012, Cassidy et al., 2013) and randomised controlled trials (Qin et al., 2009, 
Broncel et al., 2010, Zhu et al., 2011, Zhu et al., 2012, Hassellund et al., 2013).  For example, dietary 
anthocyanin intake has been inversely associated with risk of cardiovascular disease (CVD) morbidity 
or mortality (Mink et al., 2007, Cassidy et al., 2013), whilst daily ingestion of an anthocyanin 
supplement by hypercholesterolaemic subjects for up to 24 weeks improved blood lipid profile and 
endothelial function (Zhu et al., 2011, Zhu et al., 2012).  However, the low human bioavailability 
reported for anthocyanin glycosides (Manach et al., 2005, McGhie and Walton, 2007), and presence 
of degradation products and/or metabolites in the systemic circulation at levels greatly exceeding 
those of ingested anthocyanins (Vitaglione et al., 2007, Azzini et al., 2010, Czank et al., 2013), 
suggests anthocyanin bioactivity in vivo is likely to be mediated by lower molecular weight 
derivatives of parent compounds.  This is of particular relevance to in vitro or ex vivo investigations 
which seek to elucidate the cellular and molecular mechanisms underlying the observed bioactivity 
of anthocyanins, as for such studies to be physiologically relevant they must utilise compounds 
present in vivo, and at appropriate concentrations. 
Modulation of vascular endothelial function by anthocyanins has been the subject of many studies, 
for example initial observations include endothelium-dependent vasorelaxation of rat thoracic aortic 
rings elicited by red wine polyphenolic compounds (Andriambeloson et al., 1997), and anthocyanin-
enriched fractions of red wine (Andriambeloson et al., 1998).  More recently, the effects of 
anthocyanin glucosides or anthocyanidins on expression and activity of the key vascular enzyme 
endothelial nitric oxide synthase (eNOS) have been characterised in vitro using cultured endothelial 
cells (Xu et al., 2004a, Xu et al., 2004b, Lazze et al., 2006, Edirisinghe et al., 2011, Paixão et al., 2012, 
Quintieri et al., 2013), yet as noted such compounds are unlikely to represent the bioactive forms of 
anthocyanins present in vivo (Williamson and Clifford, 2010, Del Rio et al., 2013).  Therefore, whilst 
assessment of the vascular bioactivity of anthocyanins is essential to understanding potential 
cardioprotective effects of this important sub-class of flavonoids, there is a paucity of in vitro 
investigations examining biologically relevant compounds and doses on potential targets within the 
vasculature. 
The current thesis has sought to address at least part of these deficiencies in the scientific literature, 
by investigating relative vascular bioactivity of both parent anthocyanins and phenolic acid 
degradants in vitro, and at physiologically relevant concentrations [0.1, 1, 10μM (Czank et al., 2013)] 
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(Figure 7.1).  Moreover, two combination treatments of an anthocyanin, or its phenolic acid 
degradant, and additional bioactive dietary constituents (namely other sub-classes of flavonoids and 
vitamin C) commonly found in flavonoid-rich foods were screened for vascular activity, to explore the 
potential for interactions between bioactive compounds which may be consumed as part of a healthy 
diet.  Selection of treatment compounds was based upon the presence of a 3’, 4’-catechol B-ring, or 
methylated B-ring structure (Figure 7.1, ‘Treatment compounds’), as these structural features may 
confer inhibitory activity towards NADPH oxidase (NOX) enzymes (Steffen et al., 2007b, Steffen et al., 
2008) which represent predominant sources of reactive oxygen species (ROS) in the vasculature (Cai 
et al., 2003).  Vascular function may therefore be enhanced by reducing the production of NOX-
derived superoxide, and subsequent scavenging of the key vascular mediator nitric oxide (NO) 
(Schewe et al., 2008, Cassidy et al., 2010).  Treatment compounds and combinations were initially 
confirmed to be non-cytotoxic (Figure 7.1 (1); experimental flow diagram); then screened for 
inhibition of stimulated superoxide production by endothelial NOX, and direct effects on eNOS and 
NO production, in primary human vascular endothelial cells (Figure 7.1 (2)). 
Vascular bioactivity screening of anthocyanin-3-glucosides and their phenolic acid degradants 
indicated differential bioactivity of degradants relative to parent compounds (Chapters 2 & 3).  Both 
anthocyanins - with the exception of cyanidin-3-glucoside - and phenolic acid degradants appeared 
to reduce stimulated endothelial superoxide production (Chapter 2), in a modified form of a 
previously reported assay (Steffen et al., 2007b, Steffen et al., 2008); as did a combination treatment 
of the anthocyanin degradant protocatechuic acid with quercetin, epicatechin, and ascorbic acid.  In 
contrast, three anthocyanins (cyanidin-, peonidin-, and petunidin-3-glucoside) upregulated 
endothelial expression of eNOS (Chapter 3), reflecting previous reports (Xu et al., 2004b, Paixão et 
al., 2012), yet the more physiologically relevant phenolic acid degradants were without effect on 
eNOS.  Moreover, no treatments or combinations significantly modulated NO production (Chapter 3), 
although this may reflect insufficient sensitivity of the modified Griess reaction used to detect NO 
degradation products at submicromolar concentrations (Granger et al., 1996).  However, data from 
the current study suggest that anthocyanin derivatives in vivo are unlikely to enhance vascular 
function by direct activity upon eNOS, which should be further investigated and confirmed across 
multiple time points (for example 0, 6, 12, 18, 24, 30 hours) in a human endothelial cell model using 
alternative NO detection methodology (MacArthur et al., 2007).  Anthocyanins and their phenolic 
degradants might therefore indirectly elevate endothelial NO levels by reducing NOX-mediated 
generation of superoxide anion, and enhance vascular function through a similar mechanism as 
described previously for flavan-3-ols (Schewe et al., 2008).   
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Figure 7.1 Experimental scheme for assessment of vascular bioactivity in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Work scheme for investigation of vascular bioactivity in vitro, in primary human endothelial cell model, of selected treatment compounds (1-2), and exploration of mechanisms potentially underlying observed bioactivity with 
identified lead compound (3-5).  ‘X’ denotes possible bioactivity mechanism not selected for further investigation owing to lack of activity of anthocyanin degradants in previous experiments.  eNOS, endothelial nitric oxide 
synthase; HO-1, inducible haem oxygenase; HCAEC, human coronary artery endothelial cell; HUVEC, human umbilical vein endothelial cell; NO, nitric oxide; NOX2/NOX4, NADPH oxidase isoform 2 or 4; O2˙
-, superoxide. 
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Whilst the cytochrome c reduction assay used in the current investigation may be subject to 
interference by direct radical scavenging activity of polyphenols, the doses of the treatment 
compounds and combinations examined were in the high nanomolar to low micromolar range, as 
compared with concentrations of ~40 - 100μM used in previous reports describing superoxide 
scavenging activity of flavonoids (Taubert et al., 2003) or direct reduction of cytochrome c by 
anthocyanins (Skemiene et al., 2012).  Indeed, vanillic acid has been reported to have no effect on 
superoxide levels generated by xanthine oxidase activity in a cell-free system (Steffen et al., 2008, 
Woodward, 2010).  Moreover, a NOX-selective inhibitor (Stielow et al., 2006) was employed in the 
current study to ascertain the involvement of endothelial NOX in the production of superoxide 
(Chapter 2).  Ideally, data from the stimulated superoxide production assay should be confirmed 
using an alternative detection methodology for reactive oxygen species (ROS), for example electron 
spin resonance spectroscopy (Maghzal et al., 2012).  In addition, catalase controls could be 
incorporated into the cytochrome c assay to address possible interference by hydrogen peroxide 
(Nauseef, 2013).  Interestingly, a combination of protocatechuic acid with two other flavonoids and 
ascorbic acid, but not the parent anthocyanin cyanidin-3-glucoside, appeared to reduce superoxide 
production at 10μM, but this decrease was smaller than that observed for protocatechuic acid alone.  
These data could reflect the lower individual concentrations of each component within an equimolar 
mixture, or may suggest the absence of additive effects (or potentially indicate antagonistic effects) 
between dietary bioactive compounds.  Again, this supposition warrants further investigation, 
perhaps using all constituents at the same concentration (ie 10μM of each individual compound), 
and testing all constituents singly as well as in combination. 
For the purposes of the current study, one treatment compound of those screened (cyanidin-, 
peonidin-, petunidin- & malvidin-3-glucoside; and protocatechuic, vanillic, & syringic acid), namely 
vanillic acid, was selected (Figure 7.1) to explore mechanisms potentially underlying the apparent 
reductions in stimulated superoxide production; and in particular effects on endothelial expression of 
NOX isoforms (Figure 7.1 (3)).  NOX4 has been described as the major vascular endothelial isoform 
(Ago et al., 2004) producing predominantly hydrogen peroxide which may have vasodilatory activity 
(Ray et al., 2011), whereas NOX2 generates superoxide and could have an important role in 
regulation of vascular function (Violi et al., 2009, Schroder, 2010).  Both NOX2 and NOX4 associate 
with the integral membrane protein p22phox, although NOX2 activation requires recruitment of 
cytosolic proteins including p47phox and p67phox (Drummond et al., 2011); thus in the present study 
gene expression of NOX2, NOX4, p22phox, p47phox, and p67phox was examined in a primary human 
vascular endothelial cell model.  Vanillic acid, the phenolic acid degradant of peonidin-3-glucoside, 
was chosen for this investigation (Figure 7.1); as vanillic acid elicited a significant reduction in 
endothelial superoxide levels (at 1μM; Chapter 2), and contains a mono-O-methylated catechol 
functional group which has been previously associated with NOX inhibitory activity (Steffen et al., 
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2008, Cassidy et al., 2010).  Moreover, vanillic acid has recently been described in human serum 
following ingestion of 13C-labelled cyanidin-3-glucoside (Czank et al., 2013), where isotope-labelled 
phase II conjugates (including vanillic acid) of the degradant protocatechuic acid reached a collective 
Cmax of 2.35μM; suggesting the presence of vanillic acid in vivo at concentrations similar to those 
associated with bioactivity in vitro in the current investigation (Chapter 2). 
Vanillic acid (at 0.1 - 10μM) did not significantly modulate angiotensin II-stimulated gene expression 
of NOX4 and p22phox (Chapter 4), in accordance with immunoblotting data indicating no effect of this 
degradant on NOX4 endothelial protein levels following cell stimulation (Chapter 2).  However, gene 
expression analysis for NOX2, p47phox and p67phox was precluded by poor specificity of real time 
polymerase chain reaction (PCR) amplification (Chapter 4); which may reflect reported low or no 
endothelial expression of mRNA for this NOX isoform and subunits (Jones et al., 1996, Ago et al., 
2004, Jiang et al., 2006, Xu et al., 2008, Alvarez et al., 2010) as manifested in poor immunodetection 
of NOX2 protein (Chapter 2).  Another limitation of the current study was the relative lack of NOX 
transcriptional response to acute stimulation in the human umbilical vein endothelial cell (HUVEC) 
model used (Chapter 4), even in response to the more potent stimulus transforming growth factor-
beta 1 (TGF-β1) (Cucoranu et al., 2005); thus a more physiologically representative cell type (namely 
human coronary artery endothelial cells/HCAEC) was used to confirm vanillic acid bioactivity on 
subsequent targets explored in a HUVEC model (Chapters 5 & 6; Figure 7.1 (4) & (5)).  As vanillic acid 
appeared to be without effect on NOX4 activity at the level of transcription or translation, the next 
stage of the current research examined potential translational/post-translational mechanisms of NOX 
inhibition; specifically modulation of expression and activation of the cytosolic p47phox subunit (Figure 
7.1 (4)), as described for structurally similar compounds such as isorhamnetin and apocynin (Romero 
et al., 2009, Drummond et al., 2011). 
The vasoactive compound apocynin, which in common with vanillic acid incorporates a mono-
methylated catechol group, has been reported to inhibit p47phox association with membrane 
components of the NOX complex (Stolk et al., 1994, Drummond et al., 2011), and both quercetin 
(containing a catechol B-ring) and its mono-methylated metabolite inhibited endothelin-1-stimulated 
p47phox gene expression in rat aortic rings (Romero et al., 2009).  Therefore the effect of vanillic acid 
on both total p47phox expression, and activation of p47phox [as assessed by levels of phosphorylated 
protein (Leverence et al., 2011)], was examined in a HUVEC model.  Here, vanillic acid did not 
significantly modulate TNF-α stimulated p47phox expression, although a trend towards decreased 
protein levels with increasing concentration of vanillic acid was observed (Chapter 5); but no effect 
was discerned upon levels of phosphorylated p47phox.  However, and as noted above, HUVEC were 
relatively unresponsive to acute cell stimulation, perhaps reflecting low p47phox expression (Jones et 
al., 1996, Ago et al., 2004).  Interestingly, a confirmatory study conducted as part of this investigation 
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using a more physiologically relevant HCAEC model (Figure 7.1 (4)) (Baudin et al., 2007) suggested 
vanillic acid was without effect on total p47phox protein expression (Chapter 5); although TNF-α again 
elicited minimal upregulation of p47phox.  Previously reported studies using HCAEC have described up 
regulation of p47phox by ~1.5-fold (Yoshida and Tsunawaki, 2008) and 5-fold (Chen et al., 2011b) 
following cell stimulation, and it is possible the observed variation in response to stimulation 
represents an inherent limitation of a static cell culture model.  Indeed, the effect of vanillic acid on 
p47phox mRNA and protein expression may be better studied using an excised tissue model as 
reported for other flavonoids (Sanchez et al., 2006, Sanchez et al., 2007, Romero et al., 2009), and 
should be a focus of future investigations. 
The final part of the current thesis examined upregulation of the cytoprotective enzyme haem 
oxygenase-1 (HO-1) as a possible indirect mechanism of NOX inhibition, resulting in decreased 
superoxide production (Figure 7.1 (5)).  Induction of HO-1 has been reported to decrease NOX 
activity in studies using human microvascular endothelial cells (Jiang et al., 2006) and apolipoprotein-
E deficient mice (Datla et al., 2007); and anthocyanins are reported to upregulate expression of HO-1 
in human vascular endothelial cells (Sorrenti et al., 2007, Cimino et al., 2013) and murine 
hepatocytes (Inoue et al., 2012).  The effect of the anthocyanin degradant vanillic acid on levels of 
HO-1 mRNA and protein was therefore examined in a HUVEC model (Chapter 6), using phorbol 12-
myristate 13-acetate (PMA) as a positive control for HO-1 induction (Terry et al., 1999).  In the 
current investigation, vanillic acid appeared to upregulate endothelial HO-1 mRNA (~1.6-fold increase 
at 10μM) and protein (~1.8-fold increase at 1μM); although these changes were not significant 
relative to the vehicle control (0.005% DMSO) which also upregulated HO-1 protein, but not mRNA 
(Chapter 6).  Induction of HO-1 in HUVEC by low concentrations of DMSO has been described 
previously (Liang et al., 2011); and thus a confirmatory study was conducted to confirm the effect of 
vanillic acid, prepared in aqueous solution without vehicle, on HO-1 protein expression in cultured 
HCAEC (Figure 7.1 (5)).  Here, a possible upregulation of HO-1 by vanillic acid was observed (~1.8-fold 
increase at 1μM), although this was not significant relative to PMA; and the response to cell 
treatments was variable between biological replicates in both HUVEC and HCAEC models (Chapter 6).  
Whilst limitations on time and available resources have precluded further investigation of these 
observations as part of the current thesis, the activity of vanillic acid on HO-1 expression could be 
further characterised in the HCAEC model.  Such a study might incorporate an extended incubation 
period with PMA and include a time course experiment (for example protein levels at 0, 6, 12, 18, 24 
hours) to establish the maximal response elicited by vanillic acid, or examine modulation of bilirubin 
production as a marker of HO-1 enzyme activity (Datla et al., 2007) and therefore potential NOX 
inhibition. 
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In summary, data presented in the current thesis suggest anthocyanin phenolic acid degradants 
might act to enhance vascular function by decreasing NOX-mediated endothelial superoxide 
production, and therefore reduce scavenging of the key vascular mediator NO in vivo; as opposed to 
direct stimulatory activity on eNOS described for parent anthocyanins.  Vanillic acid, which contains a 
structural configuration previously associated with NOX inhibitory activity, could in theory elicit this 
effect by downregulating endothelial p47phox and/or upregulating HO-1.  Although no statistically 
significant changes were observed in studies of these target proteins conducted using primary 
human vascular endothelial cells, immunoblotting data from HUVEC and HCAEC models suggest a 
possible induction of HO-1 expression by vanillic acid; which could potentially result in NOX inhibition 
and enhanced NO bioavailability, with beneficial effects on vascular regulation.  However, the 
differential bioactivity observed for parent anthocyanins and their derivatives re-emphasises the 
need to conduct in vitro investigations of cellular activity using compounds likely to mediate in vivo 
bioactivity, and at physiologically relevant concentrations, in order to elucidate molecular 
mechanisms underlying cardioprotective activity associated with dietary anthocyanin intake 
(Jennings et al., 2012, Cassidy et al., 2013). 
7.2 Future perspectives 
Characterising the mechanisms by which anthocyanin derivatives in vivo may act to enhance vascular 
function is key to understanding reported vasoprotective effects of this sub-class of flavonoids, and 
therefore improvements in cardiovascular health associated with consumption of anthocyanin-rich 
dietary components.  A major limitation of in vitro studies conducted using static cultures of 
endothelial cell monolayers is the absence of physiological fluid shear stress upon vascular cells, and 
concomitant effects on eNOS and NOX expression according to the type of stress applied (Boo and 
Jo, 2003, Hwang et al., 2003, Hsiai et al., 2007).  Therefore the effect of anthocyanin degradants or 
metabolites on the activity of these important vascular enzymes should be investigated in 
endothelial cultures subjected to laminar or oscillatory shear stress, using equipment such as the 
ibidi Pump System1 where cells can be cultured in flow chambers and subject to differential medium 
flow (for example unidirectional or oscillatory).  Equally, effects of target compounds on vascular 
biomarkers could be examined in systems mimicking anatomical structure in vivo as a more 
representative model of the vascular endothelial environment, such as excised arterial rings (Bell and 
Gochenaur, 2006, Sanchez et al., 2006, Sanchez et al., 2007, Romero et al., 2009) or potentially co-
culture models of endothelial and smooth muscle cells.  The biomarkers to be targeted also require 
consideration, as prior in vitro investigations conducted using supraphysiological doses of parent 
anthocyanins may not necessarily reflect activity of in vivo derivatives (for example expression 
                                                          
1
 http://ibidi.com/xtproducts/en/Instruments-Accessories/Pump-Systems/ibidi-Pump-System; accessed 3
rd
 July 
2013. 
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and/or activation of eNOS); and therefore are unlikely to elucidate mechanisms underlying 
bioactivity in vivo mediated by anthocyanin degradation products and metabolites. 
NOX2 represents an important putative target of anthocyanin bioactivity, given the reported inverse 
relationship between NOX2 and endothelial function (Violi et al., 2009, Loffredo et al., 2013), and 
previous studies of flavonoids targeting NOX activity (Steffen et al., 2007b, Sanchez et al., 2007, 
Steffen et al., 2008, Romero et al., 2009).  However, and as described in the current thesis, low 
endothelial expression of NOX2 (Ago et al., 2004) may hinder assessment of treatment-induced 
modulations in mRNA and/or protein levels; although the effect of exposing endothelial cells to 
oscillatory shear stress (Leopold and Loscalzo, 2009) should be explored as noted above.  Inhibition 
of NOX could be elicited by direct (for example reduced p47phox expression, activation, or 
translocation) or indirect (induction of HO-1) mechanisms; and modulation of HO-1 activity, relative 
to NOX function and ROS generation, should be investigated in a suitable endothelial cell model such 
as HCAEC, or if feasible excised human vascular tissue (for example from cardiovascular surgical 
procedures).  As described in Chapter 1, HO-1 expression is regulated by the transcription factor Nrf2 
(nuclear factor-erythroid 2-related factor 2) and nuclear localisation of Nrf2 in HUVEC, with increased 
expression of HO-1 mRNA, was enhanced by human serum derived from healthy subjects who had 
ingested 160mg purified anthocyanins (Cimino et al., 2013).  Thus the effects of anthocyanin 
degradants and metabolites on both Nrf2 activity [possibly in a reporter gene assay system, for 
example (Kropat et al., 2013)], and endothelial expression of genes containing antioxidant response 
elements (AREs) in their promoter regions such as HO-1 and catalase (Pi et al., 2010), must be 
explored.  Equally, given previous reports of inhibition of activity of the pro-inflammatory 
transcription factor NF-κB (nuclear factor kappa B) (Bremner and Heinrich, 2002) by anthocyanins 
(Karlsen et al., 2007, Haseeb et al., 2013), anthocyanin derivatives should also screened for 
modulation of NF-κB function and therefore transcription of regulated genes, such as NOX2 
(Anrather et al., 2006) and NOX4 (Manea et al., 2010). 
In addition to characterising bioactivity of anthocyanin degradants or metabolites at the cellular 
level, the activity of these compounds could be assessed in human intervention studies, to correlate 
identified mechanisms with effects on vascular function and ultimately disease outcomes.  Several 
randomised controlled trials with anthocyanin supplements have described improved blood lipid 
profile (Qin et al., 2009, Zhu et al., 2011, Zhu et al., 2012, Hassellund et al., 2013), endothelial 
function (Zhu et al., 2011), and decreased levels of inflammatory cytokines (Zhu et al., 2012) 
compared to placebo; thus similar interventions could be performed using anthocyanin degradation 
products or metabolites, such as vanillic acid, as opposed to parent compounds.  Vascular endothelial 
function, as determined by endothelial-dependent vasodilatation (Zhu et al., 2011, Riso et al., 2013, 
Del Bo et al., 2013, Rodriguez-Mateos et al., 2013), could be assessed as part of such an intervention, 
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in addition to measuring circulating levels of soluble NOX2 derived peptide (Pignatelli et al., 2009, 
Rodriguez-Mateos et al., 2013) as a marker of NOX2 activation (Loffredo et al., 2011). 
In conclusion, this thesis has contributed to the current literature on the vascular biological activity of 
anthocyanins, by providing novel insights into potential mechanisms responsible for the 
vasoprotective activity of anthocyanin metabolites at physiologically relevant levels.  However, 
further investigation of these mechanisms is required to explain fully the observed cardioprotective 
effects of anthocyanins in epidemiological and clinical studies.  Increased dietary intake of 
anthocyanins, through consumption of grapes and berries or derived juices, could represent a simple 
measure to reduce the relative risk of cardiovascular disease (CVD); which is of particular relevance 
to public health as it is estimated that approximately 23.3 million people will die owing to CVD by 
2030 (WHO, 2013). 
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9 Appendices 
9.1 Cytotoxicity assay (WST-1 reagent): method optimisation 
Method development.  Initial cytotoxicity assays were conducted using HUVECs seeded at densities 
of 1,600–2,560 cells/well, and grown to confluence, in 96-well microplates.  However, these 
experiments generated inconsistent results across the concentration range utilised, and between 
repeat experiments.  Reduced cell viability was observed with the vehicle control treatment (0.05% 
DMSO in Medium 199 with 2% FBS) relative to the control, yet this effect was not uniform across all 
concentrations of treatment compounds (at 0.05% DMSO in the same medium). 
In order to address these discrepancies, published scientific literature was reviewed for previous 
reports of cytotoxicity assessment in HUVECs using WST-1 reagent, to optimise the method for key 
parameters.  Several manufacturers’ protocols for this reagent were also examined, to compare 
recommended assay procedures.  Overall, eleven research papers and three protocols were selected 
and analysed, and data extracted for nine method parameters; including cell seeding density, 
incubation time with treatment compound(s), incubation time with WST-1 reagent, and volume of 
WST-1 reagent (Appendix Table 9.2.1). 
Cytotoxicity assay method development was conducted using cell seeding densities of 2,000, 3,500, 
5,000, 10,000 and 12,000 cells/well; to determine the optimum seeding density.  In addition, 
absorbance measurements were recorded after 2.0, 2.5, 3.0, 3.5 and 4.0 hours incubation with WST-
1 reagent, such that incubation time could be optimised.  Finally, assays were performed using 
control, vehicle control, 0.1 and 100µM protocatechuic acid treatments, to confirm the suitability of 
the selected maximum dose of treatment compound.  Figure 9.1.1 summarises this method 
development process, and optimised parameters identified at each stage. 
Figure 9.1.1 Cytotoxicity assay method development flow chart. 
 
 
 
 
 
Cell seeding density (Figure 9.1.1 A).  The effect of HUVEC seeding density (Figure 9.1.1 A) upon 
absorbance at 440nm was measured for the control (Medium 199 with 2% FBS) and vehicle control 
(Medium 199 with 2% FBS and 0.05% DMSO) following a four hour incubation with WST-1 reagent 
(Figure 9.1.2).  No absorbance was detected for cells seeded at 2,000 cells/well, irrespective of 
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treatment or time point.  The mean absorbance at all other seeding densities demonstrated a clear 
trend for increased absorbance at elevated cell densities.  Moreover, the difference between mean 
absorbance measured at the higher (10,000 and 12,000 cells/well) and the lower (≤ 5,000 cells/well) 
densities was statistically significant for the control (at 5,000 cells/well or fewer) and vehicle control 
(at 3,500 cells/well or fewer).  Differences between mean absorbance for the control and vehicle 
control were not significant at any seeding density; nor was there a significant difference between 
mean absorbance at the two highest seeding densities.  Therefore, elevated cell seeding densities (≥ 
10,000 cells/well) resulted in improved assay sensitivity (as evidenced by increased mean 
absorbance) and were utilised in subsequent stages of method development. 
Figure 9.1.2 Effect of HUVEC seeding density on mean absorbance at 440nm with control (A) or vehicle 
control (B) treatment. 
 
Mean absorbance for HUVECs seeded at varying densities in 96-well plate, following 24h incubation with either control 
(A; Medium 199 with 2% FBS) or vehicle control (B; control with 0.05% DMSO) and after 4h incubation with WST-1 
reagent.  Data are shown as mean ± SD (n=3); columns with different superscript letters are significantly different (p < 
0.05). 
 
Incubation time with WST-1 reagent (Figure 9.1.1 B).  In order to establish whether increased 
incubation time with WST-1 reagent resulted in increased assay sensitivity, absorbance at 440nm 
was measured at multiple time points (Figure 9.1.1 B).  No statistically significant differences in mean 
absorbance between the control and vehicle control were observed at any time point with a seeding 
density of 10,000 cells/well (Figure 9.1.3).  However, the control mean absorbance at four hours was 
significantly different from that for the two hour time point.  A significant difference was also 
observed between mean absorbance for the vehicle control after four hours incubation with WST-1 
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reagent, as compared with the two hour time point, at a seeding density of 12,000 cells/well.  
Therefore, an extended incubation with WST-1 reagent increased mean absorbance at 440nm, 
thereby improving the assay sensitivity; and was used during subsequent stages of method 
development. 
Figure 9.1.3 Effect of incubation time with WST-1 reagent on mean absorbance at 440nm for HUVECs 
seeded at 10,000 cells/well. 
 
Mean absorbance following 24h incubation with either control (Medium 199 with 2% FBS) or vehicle control (control 
with 0.05% DMSO) treatments and after 2, 2.5, 3, 3.5 and 4h incubation with WST-1 reagent.  Data are shown as mean 
± SD (n=3).  *Significant difference relative to 2h time point with either control or vehicle control treatment (p < 0.05). 
 
Maximum treatment concentration (Figure 9.1.1 C).  The cytotoxicity of 0.1µM and 100µM 
protocatechuic acid (PCA) (Figure 9.1.1 C) was assessed during a 24 hour incubation at each HUVEC 
seeding density.  HUVEC viability was reduced following exposure to 100µM PCA at cell densities of 
10,000 cells/well (Table 9.1.1) or less, with a statistically significant difference from the control 
observed at 5,000 and 10,000 cells/well.  By contrast, 0.1µM PCA appeared to increase cell viability 
or respiration relative to control at all seeding densities, though this difference was not significant for 
3,500 cells/well.  Thus a maximum concentration of 100µM of treatment compound(s) was suitable 
for demonstrating cytotoxicity using the WST-1 reagent, and was utilised during subsequent stages of 
method development. 
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Table 9.1.1 Assessment of cytotoxicity of 0.1µM and 100µM protocatechuic acid/PCA following 24 hour 
incubation with HUVECs seeded at 10,000 cells/well. 
HUVEC seeding density 
(cells/well) 
Cell viability (percentage of control) 
0.1µM PCA 100µM PCA 
10,000 136.37 ± 16.10 * 62.24 ± 15.73 * 
Mean absorbance as percentage of mean control absorbance following 24h incubation with either 0.1µM or 100µM 
PCA (structure inset) after 4h incubation with WST-1 reagent.  Data are shown as mean ± SD (n=3).  *Significant 
difference relative to control (p < 0.05). 
Microplate coating (Figure 9.1.1 D).  Cytotoxicity screening conducted utilising the parameters 
identified above indicated all treatment compounds tested were cytotoxic, but no consistent dose-
response relationship was evident.  Therefore, fibronectin coating of microplates (Baudin et al., 
2007) was investigated in order to improve assay reliability and reproducibility (Figure 9.1.1 D). 
Microplates were washed with warm phosphate-buffered saline (PBS), and incubated with 25µl/well 
of 5µg/ml fibronectin (in PBS) for 60 minutes at room temperature.  Plates were then rinsed with 
PBS, dried, and stored at 4°C until use.  Treatment compounds were subsequently screened for 
endothelial cytotoxicity using HUVECs cultured on fibronectin-coated microplates, which yielded 
reproducible data.  Thus, the use of fibronectin-coated microplates enhanced cytotoxicity assay 
reliability, and was utilised in the optimised method. 
Optimised parameters.  The optimised cytotoxicity assay was conducted using 96-well microplates 
(BD Falcon®) coated with fibronectin (0.42µg/cm2), which were seeded with HUVECs at a density of 
~10,000 cells/well.  Cells were subsequently grown to confluence (~24 - 48 hours at 37°C and 5% 
CO2).  Culture medium was then aspirated, and solutions of the treatment compounds (0.5, 1, 10, 50 
or 100µM; maximum 0.25% DMSO) prepared in supplemented large vessel endothelial cell growth 
medium were added to relevant wells at a volume of 100µl/well.  The assay controls consisted of 
wells with media only (control), wells with DMSO in media (vehicle control), and blank wells (vehicle 
control only, no cells).  Four replicate wells were used for each control and treatment solution.  The 
microplates were incubated for 24 hours at 37°C and 5% CO2; after which 10µl WST-1 reagent was 
added to each well, and plates were incubated for a further four hours prior to brief agitation.  
Absorbance was then measured at 440-450nm using a microplate reader [Fluostar Omega or 
Polarstar Optima, BMG Labtech (Aylesbury, UK)]. 
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OH
OH
166/185 
9.2 Method optimisation tables 
Table 9.2.1 Method optimisation table for cytotoxicity assay (WST-1 reagent). 
Source Cell type & 
passage number 
Cell seeding 
density 
(cells/well) 
Culture after 
seeding & prior 
to assay 
Volume of 
WST-1 
reagent 
Incubation time 
with treatment 
compound(s) 
(hours) 
Incubation 
time with 
reagent 
(hours) 
Incubation 
conditions 
with reagent 
Detection 
λ (nm) 
Presentation of data 
Current internal 
protocol 
HUVEC, P2-4 1,600 – 2,560 Until cells 
confluent 
(2 – 4 days) 
10µl per 
100µl 
24 2 37°C / 5% CO2 440 Plot of mean absorbance for 
treatments normalised to control 
Roche WST-1 
protocol 
(October 2007)
2
 
N/A 1,000 – 50,000 Cells seeded 
with treatment 
compound in 
media in 
examples cited 
10µl per 
100µl 
24 – 96 0.5 – 4 37°C / 5% CO2 420-480 Plot of absorbance versus 
treatment concentration or cell 
number 
Clontech WST-1 
user manual 
(January 2007)
3
 
N/A 1,000 - 50,000 Cells seeded 
with treatment 
compound in 
media in 
examples cited 
10µl per 
100µl 
24 – 96 0.5 – 4 37°C / 5% CO2 420-480 Plot of absorbance versus 
treatment concentration 
Millipore Cell 
Proliferation 
Assay Kit 
datasheet 
(October 2005)
4
 
N/A 1,000 - 50,000 Cells seeded 
with treatment 
compound(s) in 
media 
10µl 24 – 96 0.5 – 4 Not specified 420-480 N/A 
(Kim et al., 
2011) 
HUVEC, P2-10 3,000 24 hours + 16 
hours serum-
starved 
10µl 24 2 37°C / 5% CO2 450 Plot of mean absorbance versus 
treatment 
(Schwarz et al., 
2010) 
HUVEC 4,000 16 hours + 5 
hours in basal 
medium 
 
10µl 72 2 37°C / 5% CO2 450 Plot of mean absorbance for 
treatments normalised to control 
                                                          
2
 https://www.roche-applied-science.com/pack-insert/1644807a.pdf 
3
 http://www.clontech.com/images/pt/PT3946-1.pdf 
4
 http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/bbb066008837e3f98525730600754a40/$FILE/2210.pdf 
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Source Cell type & 
passage number 
Cell seeding 
density 
(cells/well) 
Culture after 
seeding & prior 
to assay 
Volume of 
WST-1 
reagent 
Incubation time 
with treatment 
compound(s) 
(hours) 
Incubation 
time with 
reagent 
(hours) 
Incubation 
conditions 
with reagent 
Detection 
λ (nm) 
Presentation of data 
(Felice et al., 
2010) 
HUVEC, P4-5 Not specified Until sub-
confluent 
10µl 48 – 96 4 37°C / 5% CO2 450 Plot of mean absorbance versus 
treatment 
(Jeon et al., 
2010) 
HUVEC, P3-6 5,000 12 hours serum 
starved before 
treatment 
10µl 72 Not specified Not specified 450 Plot of mean proliferation (% of 
control) versus treatment 
(Potapova et 
al., 2009) 
HUVEC, P2-5 Not specified 
(confluent cells) 
Not specified 10µl per 
100µl 
4 4 37°C / 5% CO2 450 Plot of mean absorbance versus 
treatment 
(Schweppe et 
al., 2008) 
EA.hy 926 
(HUVEC-derived) 
30,000 24 hours 10µl 54 3 37°C / 5% CO2 450 Plot of viable cells (% of control) 
versus treatment concentration 
(Mundel et al., 
2008) 
 
HUVEC, P2-6 4,000 Cells seeded 
with treatment 
compound in 
media 
10µl 48 4 37°C / 5% CO2 450 Plot of mean absorbance versus 
treatment 
(Munoz et al., 
2007) 
 
Some method 
details from 
(Munoz et al., 
2001) 
HUVEC 3,000 24 hours Not specified 48 2 37°C / 5% CO2 450 Plot of cell viability (%) versus 
treatment concentration 
 
(Sakurai et al., 
2004) 
HUVEC, up to P7 20,000 N/A 10µl 24 4 37°C / 5% CO2 480
5
 Plot of cell proliferation versus 
treatment
6
 
(Otani et al., 
2000) 
 
HUVEC ~5,000 cells/cm
2
 
(1,600 cells/well 
assuming surface 
area of 0.32cm
2
) 
Until confluent Not specified 24 Not specified 37°C / 5% CO2 Not 
specified 
Plot of mean cell viability (%) 
versus treatment concentration
7
 
 
  
                                                          
5
 Supernatant solutions transferred to new 96-well plate 
6
 Proliferative activity calculated as mean ± SD of triplicate wells for each experiment divided by that of the controls 
7
 Cell viability expressed as a percentage of vehicle-treated control. 
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Table 9.2.2 Method optimisation table for stimulated superoxide production assay. 
Source Cell type & 
passage 
number 
Cell seeding 
density & type 
of culture dish 
(cells/well) 
Culture 
after 
seeding & 
before 
assay 
Assay medium used Percentage 
of serum in 
assay 
medium 
Pre-treatment Stress agent used Glucose 
present Y/N 
Incubation time with 
stress agent, +/- 
treatment (where 
relevant) 
Current 
internal 
protocol(s) 
HUVEC, P2-
4 
6-well plate: 
47,500 – 57,000 
24-well plate: 
10,000 – 16,000 
Until 
confluent 
Medium 199 (phenol-
red free) 
2% 24 hour equilibration in 
assay medium 
Angiotensin II 
(0.1µM) 
Y, in 
Medium 
199 
(5.56mM) 
6 hours 
(Rowlands et 
al., 2011)
8
 
HUVEC Not specified Confluent 
monolayer 
Krebs buffer None 
specified 
4 hour incubation in 
Medium 199 with 1% FCS, 
then 30 minute 
incubation in Krebs buffer 
+/- treatment 
compounds
9
 
Equol (0.1µM) Y, 10mM D-
glucose in 
Krebs buffer 
2 minutes (enhanced 
chemiluminescence 
measured over 40 
minutes) 
(He et al., 
2010)
10
 
Bovine 
aortic 
endothelial 
cells/BAEC 
Not specified Confluent 
cells 
DMEM (incubation) 
then Krebs buffer 
(measurement of 
ROS) 
1% 24 hour equilibration in 
DMEM (1% FCS) 
AGE (advanced 
glycation end 
products)-modified 
BSA (100μg/ml)
11
 
Present in 
DMEM 
(5.5mM) 
0-24 hours; then ROS 
generation measured 
immediately over 0-40 
minutes in Krebs buffer
12
 
(Steffen et al., 
2008) 
HUVEC, P2-
4 
~10
6
 cells/dish Confluent Hepes-buffered 
isotonic salt medium 
None Pre-incubation with 
treatment compounds (in 
serum-free medium) for 6 
or 24 hours 
Angiotensin II (1µM) Y, in 
medium 
(5.5mM) 
6 hours 
(Steffen et al., 
2007b) 
HUVEC, P2-
4 
~10
7
 cells; 
vessel not 
specified 
Confluent 
cells 
Hepes-buffered 
isotonic salt medium 
None Not specified Angiotensin II (1µM) Y, in 
medium 
(5.5mM) 
6 hours 
(Steffen et al., 
2007a) 
HUVEC, P2-
4 
~10
7
 cells; 
culture dish 
Not 
specified 
Not specified – cells 
cultured in 
supplemented 
Medium 199 
Not 
specified – 
20% FCS in 
culture 
medium 
2-deoxyglucose (10mM) 
or (–)-epicatechin (10μM) 
or apocynin (10 or 
100μM) for 30 minutes 
MPO/H2O2/nitrite-
oxLDL (100μg/ml), or 
angiotensin II (0.1µM) 
Present in 
Medium 
199 
24 hours 
(MPO/H2O2/nitrite-oxLDL) 
or 4 hours (angiotensin II) 
                                                          
8
 Chemiluminescent detection of ROS using lucigenin. 
9
 In absence or presence of SOD or other inhibitors. 
10
 Chemiluminescent detection of ROS using luminol analogue L-012. 
11
 In absence or presence of superoxide chelator or other inhibitors. 
12
 Cells incubated in Krebs buffer containing L-012 with/without stress agent and inhibitors. 
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Source Cell type & 
passage 
number 
Cell seeding 
density & type 
of culture dish 
(cells/well) 
Culture 
after 
seeding & 
before 
assay 
Assay medium used Percentage 
of serum in 
assay 
medium 
Pre-treatment Stress agent used Glucose 
present Y/N 
Incubation time with 
stress agent, +/- 
treatment (where 
relevant) 
(Afzal-Ahmed 
et al., 2007) 
HUVEC 
(primary 
culture) 
Density not 
specified
13
; 96-
well plate 
Not 
specified 
Not specified – cells 
cultured in 
supplemented 
Medium 199 
Not 
specified – 
10% FCS & 
10% 
newborn 
calf serum 
in culture 
medium 
Not specified Angiotensin II 
(0.1µM) or phorbol 
myristate acetate 
(PMA, 0.1µM) 
Experiments 
conducted 
in presence 
& absence 
of 5mM D-
glucose 
0-3 hours 
(Rueckschloss 
et al., 2002)
14
 
HUVEC 
(primary 
culture) 
Not specified Confluent 
culture 
Medium 199 (phenol-
red free) 
None 24 hour incubation in 
medium with 0.5% calf 
serum; then 6 hour pre-
incubation with/without 
angiotensin II +/- AT 
receptor inhibitors in 
same medium 
Angiotensin II (1nM – 
1µM) 
Present in 
Medium 
199 
1-24 hours 
(Rueckschloss 
et al., 2001)
14
 
HUVEC 
(primary 
culture) 
Not specified Not 
specified 
Medium 199 Not 
specified 
Not specified PMA (1µM) or oxLDL 
(100μg/ml) 
Present in 
Medium 
199 
~1-6 hours (PMA) or 2-4 
hours (oxLDL) 
(Sohn et al., 
2000) 
HUVEC Not specified Confluent 
culture 
Medium 199 
(incubation) then 
Hepes (20mM) – 
Tyrode buffer 
(measurement of 
superoxide) 
None 
specified 
Serum starved for 24 
hours, then 6 hour 
incubation with 
angiotensin II +/- AT 
receptor inhibitors 
Angiotensin II (0.1-
1µM) 
Present in 
Medium 
199 
6 hours (see pre-
treatment); then 30 
minutes in Hepes buffer 
(supernatant sampled for 
analysis) 
(Heinloth et 
al., 2000) 
HUVEC, P5 ~1 x 10
5
 cells; 
culture dish 
Not 
specified 
Supplemented 
endothelial basal 
medium 
2% 18 hour pre-incubation 
with stress agent, 
followed by transfection 
with sense or antisense 
oligo-nucleotide for 
p22
phox
 (4 hours) 
oxLDL (100µg/ml) or 
lysophosphatidyl-
choline/LPC (10µM) 
Not 
specified 
4 hours (22 hours in total 
– see pre-treatment) 
                                                          
13
 Superoxide production expressed as nmoles/min/10
6 
cells 
14
 NADPH oxidase-derived superoxide production estimated using flavin-containing enzyme inhibitor diphenylene iodonium. 
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Table 9.2.3 Method optimisation table for immunoblot analysis of endothelial NOX (and eNOS) expression. 
Source Cell type Protein 
loaded for 
SDS-PAGE 
Gel 
percentages 
for SDS-PAGE 
Primary NOS/NOX 
antibody (supplier) 
Primary immunogen Primary 
band size 
(kDa) 
Primary 
antibody 
concentrati
on 
Loading control 
antibody 
Loading band 
size (kDa) 
Loading 
control 
concentration 
Current 
internal 
protocol(s) 
HUVEC P2-4 Current 
maximum 
~10µg
15
 
per lane 
10% resolving, 
4% stacking 
Polyclonal rabbit anti-
NOX4 (Abcam)
16
 
 
C terminal residues 500-
578 of human NOX4 
 
67 
(predicted) 
1 in 500 Polyclonal 
chicken anti-
GAPDH 
(Millipore)
17
 
~ 36 1 in 2000 
(best result to 
date) 
(Rowlands et 
al., 2011) 
HUVEC P3 - - Monoclonal anti-
eNOS (Santa Cruz)
18
 
 
Monoclonal anti-p-
eNOS (Cell 
Signalling)
19
 
 
Human NOS3, amino 
acids 2-160 
 
 
Synthetic phosphor-
peptide; corresponds to 
residues surrounding 
Ser1177 of human eNOS 
140 
 
 
 
140 
- Mono-clonal 
anti-α-tubulin 
(Chemicon/ 
Millipore)
20
 
~ 50-60 - 
(Steffen et al., 
2007a) 
HUVEC P2-4 25µg per 
lane 
10% resolving Polyclonal rabbit anti-
iNOS (Cayman 
Chemical Co.)
21
 
 
Monoclonal mouse 
anti-eNOS 
(Transduction 
Laboratories)
22
 
Purified murine enzyme 
 
 
 
 
Human eNOS, amino 
acids. 1025-1203 
133 
 
 
 
 
144 
- Anti-GAPDH 39 - 
                                                          
15
 From maximum seeding density of 57,000 cells/well 
16
 http://www.abcam.com/NOX4-antibody-HRP-ab81967.html 
17
 http://www.millipore.com/catalogue/item/ab2302 
18
http://www.scbt.com/datasheet-136977-nos3-b-5-antibody.html 
19
 http://www.cellsignal.com/products/9570.html 
20
 http://www.millipore.com/search.do?q=Anti-%ce%b1-Tubulin&tabValue=PC&filterProductTypes=taxonomy%3a%5e73UUAR%2f73UUB8&show=10#0:0 
21
 http://www.caymanchem.com/app/template/Product.vm/catalog/160862 
22
 http://www.bdbiosciences.com/ptProduct.jsp?prodId=32086&key=eNOS&param=search&mterms=true 
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Source Cell type Protein 
loaded for 
SDS-PAGE 
Gel 
percentages 
for SDS-PAGE 
Primary NOS/NOX 
antibody (supplier) 
Primary immunogen Primary 
band size 
(kDa) 
Primary 
antibody 
concentrati
on 
Loading control 
antibody 
Loading band 
size (kDa) 
Loading 
control 
concentration 
(Jiang et al., 
2006) 
Human micro-
vascular 
endothelial cells 
(HMEC) P<25 
- 10% resolving Anti-NOX4
23
 
(Santa Cruz) 
 
 
Anti-NOX1
24
 (Santa 
Cruz) 
 
Anti-gp91phox 
(NOX2) (Upstate/ 
Millipore)
25
 
Peptide mapping at N-
terminus of human NOX4 
 
 
Amino acids 
121-195 of human NOX1 
 
Synthetic peptide; 
corresponds to amino 
acids 548-560 of human 
gp91-phox 
70 
 
 
 
~33 
 
 
~75 (band) 
75-91 
(smear) 
- Anti-β-actin ~ 43
26
 - 
(Hu et al., 
2005) 
 
HUVEC P2-6 40µg 10% resolving Polyclonal rabbit anti-
NOX4 (in-house) 
 
C-terminal amino acids 
320 - 428 of human NOX4 
(Mahadev et al., 2004) 
~65 1:1,500 - - - 
(Feng et al., 
2005) 
HUVEC 50µg per 
lane 
15% (NOX) or 
7% (eNOS) 
resolving 
Monoclonal anti-
p47
phox
 (from 
collaborator) 
 
Anti-eNOS (Cell 
Signalling 
Technology)
27
 
- 
 
 
 
Human eNOS (synthetic 
peptide/recombinant 
protein 
44 
 
 
 
140 
1:1000 
 
 
 
1:1000 
Anti-β-actin 42 1:5000 
(Steinert et 
al., 2002) 
HUVEC 20µg per 
lane 
8% resolving, 
3% stacking 
Monoclonal anti-
eNOS (Affiniti/Enzo) 
- ~133 1:2500 
 
 
Mono-clonal 
anti-α-tubulin 
(Chemicon/ 
Millipore)
28
 
~53 1:2000 
(Rueckschloss 
et al., 2002) 
HUVEC (primary 
culture) 
- - Monoclonal gp91
phox
-
specific (NOX2) 
- ~75 
(predicted) 
- - - - 
                                                          
23
 http://www.scbt.com/datasheet-21860-nox4-n-15-antibody.html 
24
 http://www.scbt.com/datasheet-25545-mox1-h-75-antibody.html 
25
 http://www.millipore.com/catalogue/item/07-024 
26
 From http://www.millipore.com/catalogue/item/04-1116 
27
 http://www.cellsignal.com/products/9586.html or http://www.cellsignal.com/products/5880.html 
28
 http://www.millipore.com/search.do?q=Anti-%ce%b1-Tubulin&tabValue=PC&filterProductTypes=taxonomy%3a%5e73UUAR%2f73UUB8&show=10#0:0 
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Table 9.2.4 Method optimisation table for stimulated expression of NOX isoforms/subunits (for RT-qPCR and/or immunoblotting). 
                                                          
29
 Inhibitors: rottlerin (PKC δ), CGP53353 (PKC β2), gp91ds-tat (NADPH oxidase), apocynin (NADPH oxidase) 
30
 Also translocation of p47
phox
 and p67
phox
 between membrane & cytosol 
31
 No PCR product detected for NOX1-3 in unstimulated cells 
32
 NO donor 
33
 No mRNA detected for NOX1 or NOX2 (but NOX2 detected by immunoblot)  
34
 Quantification of mRNA by multi-standard assisted competitive RT-PCR 
Source Cell type & 
passage 
number 
Cell seeding 
density & 
type of 
culture dish 
Culture 
after 
seeding 
Assay medium 
used 
Pre-treatment Stimulant Treatments/ 
controls 
Incubation 
time 
(hours) 
RT-qPCR and/or 
immunoblot (& 
reference 
gene/protein) 
Isoforms and/or 
subunits examined 
(Deng et al., 
2012) 
HUVEC 
(P2-4) 
2 x 10
5
 cells; 
flask 
Until 80% 
confluent 
Serum free media 
with 1% foetal 
bovine serum  
 
24h pre-
incubation in 
assay medium 
40ng/ml 
TNF-α 
Untreated, TNF-α, or 
TNF-α with 
inhibitors
29
 
24 RT-qPCR & 
immunoblot (β-
actin control for 
both) 
NOX2, NOX4, p22
phox
, 
p47
phox 30
, p67
phox
 
(Alvarez et 
al., 2010) 
HUVEC 
(P4-10) 
10,000 
cells/well in 
96-well 
plate 
- Supplemented 
endothelial cell 
growth medium 
 
12h serum/ 
supplement 
starvation 
Angiotensin 
II (100nM) 
Ang II, Ang II with 
pravastatin (NOX4, 
p22
phox
) 
6 RT-qPCR (β-actin 
control) 
NOX1-5
31
, p22
phox
 
(Kamiyama et 
al., 2009) 
HUVEC 
(≤ P6) 
- Confluent Endothelial cell 
growth medium 
- 50μg/ml 
oxLDL 
Equol Unclear - 
possibly 48 
RT-qPCR (36B4 
control) & 
immunoblot  
p22
phox
, p47
phox
, p67
phox
 
(RT-qPCR); Rac1 
(immunoblot) 
(Jiang et al., 
2006) 
Human 
micro-
vascular 
endothelial 
cells 
(HMEC) 
P<25 
6-well plate 
for RT-qPCR 
Confluent 
culture 
Supplemented 
MCDB-131 
medium 
24h incubation 
in low serum 
(0.1%) medium 
 
- NONOate
32
 (1mM) 6 RT-qPCR & 
immunoblot (β-
actin control for 
immunoblot) 
NOX1, NOX2 NOX4, 
p22
phox
, p47
phox
 (RT-
qPCR)
33
; NOX1, NOX2, 
NOX4 (immunoblot) 
(Feng et al., 
2005) 
HUVEC 10
5
  
cells ml
-1
 
Confluent 
culture 
Supplemented 
F12K medium 
- Endothelin-1 
(1nM) 
- 24 Immunoblot (β-
actin control) 
p47
phox
 
(Rueckschloss 
et al., 2002) 
HUVEC 
(primary 
culture) 
Not 
specified 
Confluent 
culture 
Supplemented 
Medium 199 
24 hour 
incubation in 
medium with 
0.5% calf serum 
Angiotensin 
II (10nM, 
100nM, 
1µM) 
AT1 receptor 
antagonist 
candesartan (NOX2 
RT-PCR only) 
7-8 RT-PCR
34
 & 
immunoblot 
NOX2, p22
phox
, p47
phox
, 
p67
phox
 (RT-PCR); NOX2 
(immunoblot) 
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Table 9.2.5 Method optimisation table for positive controls for stimulated expression of NOX 
isoforms/subunits. 
Source Cell type Mediator Concentration Incubation 
time 
Scope (NOX bioactivity and/or 
expression) 
(Deng et al., 
2012) 
HUVEC TNF-α 40ng/ml 24 hours Bioactivity and mRNA/protein 
expression 
(Kamizato et 
al., 2009) 
Human 
colonic 
epithelial cells 
TNF-α 20ng/ml 0-24 hours Used to upregulate ROS 
production and NOX1/NOXO1 
mRNA & protein 
(Yoshida and 
Tsunawaki, 
2008) 
Human 
coronary 
artery EC 
TNF-α 10ng/ml 6 & 21 hours 
(mRNA) 
Bioactivity and mRNA/protein 
expression 
Note:  no effect on NOX4/p22
phox
 
mRNA in this system 
(Yang et al., 
2007) 
Human retinal 
pigment 
epithelial cells 
TNF-α 0-50ng/ml 0-60 minutes Bioactivity 
(Li et al., 
2005) 
Human 
dermal 
microvascular 
EC 
TNF-α 100U/ml 0-60 minutes Bioactivity (p47
phox
 
phosphorylation/translocation/a
ssociation) 
(Muzaffar et 
al., 2004) 
Porcine 
pulmonary 
artery VSMC 
and EC 
TNF-α 10ng/ml 16 hours Bioactivity and protein 
expression 
(Frey et al., 
2002) 
Human 
pulmonary 
artery EC 
TNF-α 500U/ml 0-15 minutes Bioactivity (p47
phox
 
phosphorylation/translocation) 
 
(Kamizato et 
al., 2009) 
Human 
colonic 
epithelial cells 
IFN-γ 1000U/ml 0-12 hours Used to upregulate ROS 
production and NOX1/NOXO1 
mRNA & protein 
(Yang et al., 
2007) 
Human retinal 
pigment 
epithelial cells 
IFN-γ 0-20U/ml 0-60 minutes Bioactivity 
(Kuwano et 
al., 2006) 
Human 
colonic 
epithelial cells 
IFN-γ 0-10,000U/ml 0-24 hours ROS production & expression of 
NOX1/NOXO1/NOXA1 
Note:  no effect on NOX2/4 
mRNA in this system 
 
(Yang et al., 
2007) 
Human retinal 
pigment 
epithelial cells 
IL-1β 0-40ng/ml 0-60 minutes Bioactivity 
(Kaur et al., 
2004) 
Human 
coronary 
artery SMC 
IL-1β 25U/ml & 50U/ml 24 hours Bioactivity 
(Lo et al., 
1998) 
Bovine 
chondrocytes 
IL-1β 20ng/ml 20 minutes 
(ROS) 
Stimulation of ROS production 
 
(Muzaffar et 
al., 2004) 
Porcine 
pulmonary 
artery VSMC 
and EC 
IL-1α 10ng/ml 16 hours Bioactivity and protein 
expression 
 
(Sturrock et 
al., 2006) 
Human 
pulmonary 
artery SMC 
TGF-β1 1ng/ml 24 hours 
(mRNA) 
Bioactivity and mRNA/protein 
expression 
Note: no effect of IFN-γ at 
2000U/ml on NOX4 mRNA in this 
system 
(Cucoranu et 
al., 2005) 
Human 
cardiac 
fibroblast 
cells 
TGF-β1 10ng/ml 0-24 hours 
(mRNA) 
Bioactivity and mRNA/protein 
expression 
Note: Effect on NOX4/5 mRNA 
only, but upregulation of NOX4 
mRNA noted from 2h onwards 
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Table 9.2.6 Method optimisation table for stimulated p47
phox
 translocation: preparation of cytosolic & membrane fractions 
 
Source Cell type & 
passage 
number 
Cell 
seeding 
density & 
type of 
culture 
dish 
Stimulant Incubation 
time 
(minutes) 
Lysis/extraction 
buffer 
Homogenisation P1
35
/S1 P2
36
 (from S1) S3 (from P2) p47
phox
 
antibody 
(Deng et al., 
2012) 
HUVEC 
(P2-4) 
2 x 10
5
 
cells; size 
of vessel 
not 
specified 
40ng/ml 
TNF-α 
24 hours 10mM Tris HCl 
(pH 7.5), 5mM 
EDTA, 50μg/ml 
PMSF
37
 
- - 100,000g at 4°C 
for 60 minutes – 
supernatant 
designated as 
cytosolic fraction 
Pellet re-suspended in 
lysis buffer (with 1% 
Triton X-100), 
sonicated, & incubated 
at 4°C for 45 minutes.  
Lysate centrifuged at 
4°C & supernatant 
designated membrane 
fraction 
Millipore - 
polyclonal 
(Wang et 
al., 2010b) 
Rat VSMC 
(P5-12) 
- High glucose 
(25mM) or 
normal 
glucose 
(5mM) 
0-120 RIPA buffer
38
 with 
protease inhibitor 
mixture (Santa 
Cruz) 
- 3000g for 
10 minutes 
100,000g at 4°C 
for 90 minutes – 
supernatant 
defined as 
cytosolic fraction 
and pellet as 
membrane 
fraction
39
 
- Santa Cruz 
Biotechnology
40
 
                                                          
35
 Unbroken cells/debris, also pelleted nuclei 
36
 Crude membrane pellet 
37
 Phenylmethylsulfonylfluoride – serine protease inhibitor 
38
 Radio-immunoprecipitation assay buffer 
39
 Integrin-β1 used as marker of membrane fraction 
40
 Immunoprecipitation to detect phosphorylated p47
phox
 (using anti-phosphoserine) 
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Source Cell type & 
passage 
number 
Cell 
seeding 
density & 
type of 
culture 
dish 
Stimulant Incubation 
time 
(minutes) 
Lysis/extraction 
buffer 
Homogenisation P1
35
/S1 P2
36
 (from S1) S3 (from P2) p47
phox
 
antibody 
(Fortuño et 
al., 2009) 
PBMCs 
(peripheral 
blood 
mononuclear 
cells) 
5 x 10
6
 
cells 
3.2μM PMA 15 10mM Tris (pH 8), 
150mM NaCl with 
protease inhibitor 
cocktail (Roche 
Complete) 
- 2000g for 
10 minutes 
100,000g at 4°C 
for 60 minutes – 
supernatant used 
as cytosolic 
fraction 
P2 used as membrane 
fraction 
Santa Cruz 
Biotechnology 
(Carluccio et 
al., 2007) 
HUVEC 
(P1-3) 
- 100μM 
homocysteine 
0-30 
 
7.5mM Tris HCl 
(pH 7.5), 2mM 
EGTA,2mM EDTA, 
0.25M sucrose, 
1mM DTT, 1mM 
PMSF, 1mg/ml 
aprotinin, 1mg/ml 
leupeptin 
Sonication on ice, 
3 x 15s 
500g for 10 
minutes 
100,000g at 4°C 
for 60 minutes – 
supernatant 
saved as cytosolic 
fraction 
P2 re-suspended in 
extraction buffer with 
1% Triton X-100; 
centrifuged at 100,000g 
for 60 minutes - 
supernatant saved as 
membrane-enriched 
fraction 
Santa Cruz 
Biotechnology 
(Nishikawa 
et al., 2007) 
CM-MC 
(cutaneous 
mastocytoma 
cells) 
10
8
 cells 30μg/ml 
compound 
48/80 
0-10 10mM Tris HCl, 
5mM EGTA, 2mM 
PMSF, 10μg/ml 
aprotinin, 
10μg/ml 
leupeptin 
Sonication on ice 10,000g at 
4°C for 10 
minutes 
100,000g at 4°C 
for 60 minutes – 
separation into 
membrane and 
cytosolic fractions 
P2 dissolved in lysis 
buffer (plus 1% sodium 
deoxycholate & 1% NP-
40) with sonication 
Santa Cruz 
Biotechnology 
(Massaro et 
al., 2006) 
HSVEC 
(human 
saphenous 
vein EC; ≤ P5) 
- 10ng/ml IL-1α  20 7.5mM Tris HCl 
(pH 7.5), 2mM 
EGTA, 2mM 
EDTA, 0.25M 
sucrose, 1mM 
DTT, 1mM PMSF, 
1mg/ml aprotinin, 
1mg/ml leupeptin 
Sonication on ice, 
3 x 15s 
500g for 10 
minutes 
100,000g at 4°C 
for 60 minutes – 
supernatant 
saved as cytosolic 
fraction 
P2 re-suspended in 
extraction buffer with 
1% Triton X-100; 
centrifuged at 100,000g 
for 60 minutes – 
supernatant saved as 
membrane-enriched 
fraction 
Santa Cruz 
Biotechnology - 
monoclonal 
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Source Cell type & 
passage 
number 
Cell 
seeding 
density & 
type of 
culture 
dish 
Stimulant Incubation 
time 
(minutes) 
Lysis/extraction 
buffer 
Homogenisation P1
35
/S1 P2
36
 (from S1) S3 (from P2) p47
phox
 
antibody 
(Ushio-Fukai 
et al., 2002) 
HUVEC 
(P2-5) 
Gelatin-
coated 
plates 
20ng/ml 
human 
recombinant 
VEGF165 
0-60 Ice-cold 10mM 
Tris (pH 7.4), 
1.5mM MgCl2, 
5mM KCl, 1mM 
DTT, 0.2mM 
sodium vanadate, 
1mM PMSF, 
1μg/ml aprotinin, 
1μg/ml leupeptin 
(5 minute 
treatment) 
Lysate drawn 
through 1ml 
syringe (rapid 
stokes) 
2000g at 
4°C for 5 
minutes 
100,000g at 4°C 
for 90 minutes – 
supernatant 
saved as cytosolic 
fraction 
14,000rpm at 4°C for 20 
minutes – supernatant 
saved as membrane 
fraction 
N/A – 
examining Rac1 
translocation 
(Heyworth 
et al., 1991) 
Human 
neutrophils 
3 x 10
7
 
cells 
100ng/ml 
PMA 
5 100mM KCl, 3mM 
NaCl, 3.5mM 
MgCl2, 1.25mM 
EGTA, 10mM 
piperazine 
diethane sulfonic 
acid (pH 7.3) 
Sonication, 5s 
burst, at 4°C 
250g at 4°C 
for 5 
minutes 
115,000g at 4°C 
for 20 minutes – 
supernatant 
saved as cytosolic 
fraction 
P2 washed with 0.6ml 
buffer; centrifuged at 
115,000g at 4°C for 20 
minutes – pellet 
(membrane fraction) 
resuspended in buffer 
& subject to sonication 
(2-3s burst) 
Polyclonal 
antiserum 
binding p47
phox
 
and p67
phox
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Table 9.2.7 Method optimisation table for p47
phox
 immunoblotting: potential cell stimulants 
Source Cell type Mediator Concentration Incubation 
time 
Scope 
(NOX bioactivity and/or 
expression) 
 
(Deng et al., 
2012) 
HUVEC TNF-α 40ng/ml 24 hours Bioactivity, including p47
phox
 
translocation, and 
mRNA/protein expression 
(Li et al., 
2005) 
Human 
dermal 
microvascular 
EC 
TNF-α 100U/ml 0-60 minutes Bioactivity (p47
phox
 
phosphorylation/translocation/
association) 
(Muzaffar et 
al., 2004) 
Porcine 
pulmonary 
artery EC and 
VSMC 
TNF-α 10ng/ml 16 hours Bioactivity and protein 
expression 
(Frey et al., 
2002) 
Human 
pulmonary 
artery EC 
TNF-α 500U/ml 0-15 minutes Bioactivity (p47
phox
 
phosphorylation/translocation) 
(Li et al., 
2002) 
Murine 
coronary 
microvascular 
endothelial 
cells 
TNF-α 100U/ml 10 minutes 
(pre-
incubation) 
Role of p47
phox
 in NOX 
activity/ROS production 
 
(Li et al., 
2002) 
Murine 
coronary 
microvascular 
endothelial 
cells 
PMA 100ng/ml 10 minutes 
(pre-
incubation) 
Role of p47
phox
 in NOX 
activity/ROS production 
(Görlach et 
al., 2000) 
HUVEC 
(also SMC) 
PMA 0.01 -1μM ~20-40 
minutes 
ROS production, NOX2 isoform 
& subunit expression 
 
(Ushio-Fukai 
et al., 2002) 
HUVEC Human 
recombinant 
VEGF165 
20ng/ml 0-60 minutes Bioactivity 
 
(Massaro et 
al., 2006) 
Human 
saphenous 
vein EC 
IL-1α 10ng/ml 20 & 60 
minutes 
(NOX) 
p47
phox
 translocation, NOX 
activity (as part of wider study) 
(Muzaffar et 
al., 2004) 
Porcine 
pulmonary 
artery EC and 
VSMC 
IL-1α 10ng/ml 16 hours Bioactivity and protein 
expression 
 
(Carluccio et 
al., 2007) 
HUVEC Homo-
cysteine 
100μM 0-30 minutes 
(p47
phox
 
translocation) 
p47
phox
 translocation, NOX 
activity (as part of wider study) 
 
(Chen et al., 
2009) 
HUVEC oxLDL 150μg/ml 60 minutes 
(ROS 
production) 
ROS production, mRNA levels 
(Rueckschloss 
et al., 2001) 
HUVEC oxLDL 100μg/ml 1 – 7 hours ROS production, NOX2 
expression 
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Table 9.2.8 Method optimisation table for endothelial expression of HO-1 (for mRNA/protein quantification) 
Source Cell type & 
passage 
number 
Cell seeding 
density & type 
of culture dish 
Culture 
after 
seeding 
Assay medium 
used 
Pre-
treatment 
Stimulant Treatments/ 
controls 
Incubation 
time 
(hours) 
Quantification 
of HO-1 
mRNA/protein 
Concentration and/or time 
for maximal effect 
(Zheng et 
al., 2012) 
Porcine 
aortic 
endothelial 
cells 
Not specified Not 
specified 
Supplemented 
Medium 199 
(5% foetal 
bovine serum) 
Transfection 
with control 
or caveolin-1 
siRNA 
- Epigallocatechin-3-
gallate (EGCG) at 
30µM 
6 Immunoblotting - 
(Wu et al., 
2012) 
HCAEC 6-well plate: 2 x 
10
5
 cells 
Until 
confluent 
Serum-free 
DMEM
41
 
12h 
incubation in 
assay medium 
- 0.25-1mM niacin  0-24 RT-qPCR & 
immunoblotting 
mRNA: ~3-fold (1mM niacin, 
6 hours) 
Protein: ~5-6-fold 
(1mM niacin, 6 hours; 
detectable basal signal) 
(Donovan 
et al., 
2012) 
HCAEC, P3-
12 
65mm dish Until 
≥80% 
confluent 
- - None for 
immunoblot 
analysis 
1-50μg/ml 
Protandim
42
 
12 Immunoblotting Protein: ~8-fold (20μg/ml 
Protandim; weak basal HO-1 
band) 
(Lee et al., 
2011) 
HUVEC 
(P4-9) 
Not specified ~80% 
confluent 
Supplemented 
Medium 199 
+/- siRNA or 
inhibitors 
H2O2 for cell 
death 
assays only 
Fisetin (5-25µM) 1-24 RT-PCR; 
immunoblotting  
mRNA: 25µM (1h) & 1h 
(10µM)
43
 
Protein: 25µM (16h) & 16h 
(10µM) 
(Zheng et 
al., 2010) 
Porcine 
aortic 
endothelial 
cells 
Not specified Confluent 
culture 
Supplemented 
Medium 199 
(5% foetal 
bovine serum) 
24h 
incubation in 
low serum 
(1%) 
conditions; 
+/- siRNA 
2ng/ml TNF-
α 
EGCG at 30µM  4 or 8
44
 RT-qPCR
45
; 
immunoblotting 
- 
                                                          
41
 Dulbecco’s modified Eagle’s medium 
42
 Marketed dietary supplement comprised of phytochemicals from five well-characterised medicinal plants 
43
 HO-1 mRNA/protein detected at time points up to & including 24h 
44
 4h co-incubation with stimulant; or 2h pre-incubation with EGCG followed by 6h exposure to TNF-α 
45
 Primers for HO-1 listed, but no data shown 
179/185 
Source Cell type & 
passage 
number 
Cell seeding 
density & type 
of culture dish 
Culture 
after 
seeding 
Assay medium 
used 
Pre-
treatment 
Stimulant Treatments/ 
controls 
Incubation 
time 
(hours) 
Quantification 
of HO-1 
mRNA/protein 
Concentration and/or time 
for maximal effect 
(Ungvari 
et al., 
2010) 
HCAEC - - - - None for 
RT-qPCR 
analysis 
0.1-100μM 
resveratrol 
Not stated – 
possibly 24 
RT-qPCR mRNA: ~3-fold at 50μM 
resveratrol 
(Khoo et 
al., 2010) 
HCAEC, P3-7 - Until 
confluent 
Complete 
medium with 
10% serum 
Serum-
deprived for 
16h 
- 2.5 & 5μM nitro-
oleic acid; also oleic 
acid (concentration 
not specified) 
16 (mRNA) 
24 (protein) 
RT-qPCR & 
immunoblotting 
mRNA: ~12-fold (5μM nitro-
oleic acid) 
Protein: blot only (weak basal 
HO-1 band) 
(Zieger 
and 
Gupta, 
2009) 
HCAEC, P5-
10 
T25 flasks: 
13,000 
cells/cm
2
 
Until 
confluent 
EGM2-MV - - 10μM haemin 
chloride 
1 (with 
treatment) 
+ 2 (EGM 
only) 
ELISA Protein: ~2-fold 
(Sorrenti 
et al., 
2007) 
Human iliac 
artery 
endothelial 
cells 
 
Not specified Until sub-
confluent 
Supplemented 
F12K medium 
(10% foetal 
bovine serum) 
24h 
incubation in 
low serum 
(0.5%) 
medium 
10% foetal 
bovine 
serum (ie 
assay 
medium) 
Cyanidin-3-
glucoside (6.25nM 
to 250µM) 
24 Immunoblotting - 
(Vidavalur 
et al., 
2006) 
HCAEC 100mm dishes Until 
confluent 
Supplemented 
EGM-2 
- - 10 & 20μM 
sildenafil 
24 Immunoblotting Protein: ~3-fold (20μM 
sildenafil; weak basal HO-1 
band) 
(Lazze et 
al., 2006) 
HUVEC Not specified Confluent 
culture 
Supplemented 
Medium 199 
- - Cyanidin, 
delphinidin (both at 
50 or 100µM) 
24 ELISA - 
(Wu et al., 
2006a) 
Bovine 
aortic 
endothelial 
cells 
 
Petri dish Confluent 
culture 
Not clear – 
serum-free 
DMEM 
12 hour 
incubation in 
serum-free 
DMEM 
- EGCG at 25-100µM 
(+/- inhibitors or 
antioxidants); also 
epicatechin-3-
gallate, 
epigallocatechin, or 
epicatechin (at 50 
or 100µM) 
3-24 Northern blot 
analysis; 
immunoblotting 
Protein: 100µM (6h) and 6-
12h (100µM) 
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Source Cell type & 
passage 
number 
Cell seeding 
density & type 
of culture dish 
Culture 
after 
seeding 
Assay medium 
used 
Pre-
treatment 
Stimulant Treatments/ 
controls 
Incubation 
time 
(hours) 
Quantification 
of HO-1 
mRNA/protein 
Concentration and/or time 
for maximal effect 
(Kaga et 
al., 2005) 
HCAEC, P3-5 - - - - - 1-50μM resveratrol, 
1–1000nM 
thioredoxin-1 
(with or without 
10μM SnPP
46
) 
12 Immunoblotting Protein: blot only, basal HO-1 
band visible 
(Nordskog 
et al., 
2003) 
HCAEC, P4-5 Flasks - EGM-2-MV - - Cigarette smoke 
condensate 
(30μg/ml total 
particulate matter) 
24 cDNA array 
analysis 
mRNA: ~3-fold 
Note: no HO-1 band detected 
for aortic endothelial cell 
lysates following exposure to 
0.7% DMSO 
(Terry et 
al., 1999) 
HUVEC 
(P1) 
Cells in 60mm 
dishes (1% 
gelatin coating) 
Until 
confluent 
Neuman Tytell 
media
47
 
3-4h 
incubation in 
Neuman 
Tytell medium 
500U/ml 
TNF-α
48
 
(or 50U/ml 
IL-1α) 
Agonists/ 
inhibitors including 
PMA
49
 
4 Northern blot 
analysis; 
immunoblotting 
- 
(Terry et 
al., 1998) 
HUVEC 
(P1) 
Cells in 60mm 
dishes (1% 
gelatin coating) 
Until 
confluent 
Endothelial cell 
growth media 
(≥ 12h 
treatment) or 
Neuman Tytell 
media (< 12h 
treatment) 
3-4h 
incubation in 
Neuman 
Tytell medium 
10-
1,000U/ml 
TNF-α 
(also 1-
500U/ml IL-
1α) 
Actinomycin 
D/cycloheximide/ 
curcumin
50
 
2-8 Northern blot 
analysis; 
immunoblotting 
mRNA: 4h incubation with 
500U/ml TNF-α or 50U/ml IL-
1α 
Protein: 6h incubation with 
500U/ml TNF-α or 50U/ml IL-
1α 
 
 
                                                          
46
 Tin-protoporphyrin IX 
47
 Serumless media 
48
 TNF-α used at 20ng/ml in current study (approximately 400-1000U/ml, based on manufacturer’s datasheet) 
49
 PMA: phorbol 12-myristate 13-acetate 
50
 Transcription inhibitor/protein synthesis inhibitor/inhibitor of AP-1, NF-κB activation respectively 
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9.3 Stimulated superoxide production assay: reduction of cytochrome c 
(mM) measured at 550nm 
 
Figure 9.3.1 Elevation of superoxide levels by angiotensin II (0.1μM) following 6h incubation in HUVEC 
model (reduction of cytochrome c at 550nm). 
 
Reduction of cytochrome c (mM) measured at 550nm (molar extinction coefficient/ɛ = 21.1mM
-1
 cm
-1
) for basal 
(unstimulated) cells, angiotensin II control (Ang II, 0.1μM) and Ang II with superoxide dismutase (SOD) in stimulated 
superoxide production assay (24-well plate format) at 0.1, 1 and 10µM.  Data are graphed as mean ± SD (n=8).  
*Significant difference versus basal (p < 0.05); †significant difference versus Ang II (p < 0.05). 
Figure 9.3.2 Modulation of angiotensin II-stimulated endothelial superoxide production by NOX 
inhibitor VAS2870 (reduction of cytochrome c at 550nm). 
 
Reduction of cytochrome c (mM) measured at 550nm (molar extinction coefficient/ɛ = 21.1mM
-1
 cm
-1
) with and without 
superoxide dismutase (SOD) correction (white & black bars respectively) for basal (unstimulated) cells, angiotensin II 
control (Ang II, 0.1μM), 5µM VAS2870 (NOX inhibitor) with 0.1µM Ang II (VAS2870 + Ang II), and 5µM VAS2870 in 
stimulated superoxide production assay (24-well plate format).  Data are graphed as mean ± SD (n=3).  *Significant 
difference versus Ang II (p < 0.05); †significant difference versus Ang II + SOD (p < 0.05). 
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Figure 9.3.3 Modulation of superoxide levels by cyanidin-3-glucoside (A), peonidin-3-glucoside (B), malvidin-3-glucoside (C), petunidin-3-glucoside (D), protocatechuic acid (E), 
vanillic acid (F), and syringic acid (G) following 6h incubation in angiotensin II-stimulated HUVEC model (reduction of cytochrome c at 550nm). 
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Reduction of cytochrome c (mM) measured at 
550nm (molar extinction coefficient/ɛ = 21.1mM
-1
 
cm
-1
) with and without superoxide dismutase 
(SOD) correction (white & black bars respectively) 
for angiotensin II control (Ang II, 0.1μM) and 
cyanidin-3-glucoside (A), peonidin-3-glucoside (B), 
malvidin-3-glucoside (C), petunidin-3-glucoside 
(D), protocatechuic acid (E), vanillic acid (F), and 
syringic acid (G; structures inset) screened in 
stimulated superoxide production assay (24-well 
plate format) at 0.1, 1 and 10µM.  Data are 
graphed as mean ± SD (n=3).  *Significant 
difference versus Ang II (p < 0.05); †significant 
difference versus Ang II + SOD (p < 0.05). 
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Figure 9.3.4 Modulation of superoxide levels by cyanidin-3-glucoside (A) or protocatechuic acid (B) in 
combination with epicatechin, quercetin and ascorbic acid following 6h incubation in 
angiotensin II-stimulated HUVEC model (reduction of cytochrome c at 550nm). 
 
Reduction of cytochrome c (mM) measured at 550nm (molar extinction coefficient/ɛ = 21.1mM
-1
 cm
-1
) with and without 
superoxide dismutase (SOD) correction (white & black bars respectively) for angiotensin II control (Ang II, 0.1μM) and 
equimolar ratio of cyanidin-3-glucoside (A) or protocatechuic acid (B) with epicatechin, quercetin and ascorbic acid, 
screened in stimulated superoxide production assay (24-well plate format) at 0.1, 1 and 10µM.  Data are graphed as mean ± 
SD (n=3).  *Significant difference versus Ang II (p < 0.05); †significant difference versus Ang II + SOD (p < 0.05). 
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9.4 Reverse transcription – quantitative polymerase chain reaction: melt 
curve data for NOX custom primer sets 
Figure 9.4.1 Specificity of real time PCR amplification for NOX2 (A), p47
phox
 (B), and p67
phox
 (C) primer 
sets (melt curve analysis). 
 
  
 
 
Melt curve analysis of real time PCR product following 50 cycles denaturation/data collection using primer sets for 
NOX2 (A), p47
phox
 (B), and p67
phox
 (C).  Real time PCR was conducted using 25ng cDNA generated from basal 
(unstimulated) HUVEC, and cells incubated with 0.1μM angiotensin II for 4 hours (n=4 per treatment group, n=8 
overall). 
A B 
C 
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Figure 9.4.2 Specificity of real time PCR amplification for NOX4 (A) and p22
phox
 (B) primer sets (melt 
curve analysis). 
 
 
Melt curve analysis of real time PCR product following 50 cycles denaturation/data collection using primer sets for 
NOX4 (A) and p22
phox
 (B).  Real time PCR was conducted using 25ng cDNA generated from basal (unstimulated) 
HUVEC, and cells incubated with 0.1μM angiotensin II for 4 hours (n=4 per treatment group, n=8 overall). 
 
 
A B 
